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“I've come loaded with 
statistics, for I've noticed that a 
man can't prove anything 
without statistics.” 
-Mark Twain  
(1835 - 1910) 
  
 “Not everything that can be 
counted counts; and not 
everything that counts can be 
counted.” 





“Whether epidemiology alone 
can, in strict logic, ever prove 
causality, even in this modern 
sense, may be questioned, but 
the same must also be said of 
laboratory experiments on 
animals.” 
-Sir Richard Doll 
(1912-2005) 
“It remains an astonishing, disturbing fact that in America – a 
nation where nearly every new drug is subjected to rigorous 
scrutiny as a potential carcinogen, and even the bare hint of a 
substance’s link to cancer ignites a firestorm of public hysteria and 
media anxiety – one of the most potent and common carcinogens 
known to humans can be freely bought and sold at every corner 
store for a few dollars.” 
-Siddharta Mukherjee  
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Interstitial lung disease (ILD) is a heterogeneous group of parenchymal lung 
disorders having varied histopathologies. Although histologically different, the ILDs 
have rather similar clinical presentations consisting of increasing dyspnea, a 
restrictive lung function, impaired gas exchange, and widespread shadowing on 
chest radiography. Approximately two-thirds of ILD cases have no known etiology. 
The remaining one-third is either associated with connective tissue disease (CTD) or 
caused by various environmental or occupational exposures including inhalation of 
asbestos or other inorganic particles, inhalation of inorganic agents, certain drugs 
and radiation therapy. It is widely accepted that prevention, improved prognosis and 
quality of healthcare are dependent on a better understanding of disease 
epidemiology, and it is to this end that the present research contributes.  
This doctoral research project makes use of a large and well-validated primary care 
database to investigate the frequency of ILD, the incidence of comorbidity after 
diagnosis, and characteristics of ILD patients at diagnosis compared to a general 
population control group. For many ILD subgroups an increase in incidence density 
and prevalence over time was observed, however it is uncertain to what extent 
secular trends played a role in these findings. Rates for all-cause mortality and 
comorbidities varied greatly across ILD subgroups, as did patient characteristics at 
diagnosis. This research project also delved deeper into specific epidemiological 
topics relating to certain ILD subgroups within the more broadly-classified, non-
idiopathic ILD disease category.  
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1.1 Burden of respiratory disease in the global context 
 
Respiratory disease is one of the leading causes of mortality worldwide. The number 
of deaths attributed to respiratory disease is expected to climb even further until 
2020, in particular from tuberculosis (TB), chronic obstructive pulmonary disease 
(COPD), and lung cancer. The predicted numbers are staggering: In 2020, of 68 
million deaths worldwide, 11.9 million will have been attributed to respiratory disease 
(4.7 million from COPD, 2.5 million from pneumonia, 2.4 million from TB and 2.3 from 
lung cancer). In terms of worldwide incidence, prevalence, mortality, and health care 
costs, respiratory disease ranks second after cardiovascular disease [Alberg AJ et al. 
2007, Loddenkemper R et al. 2003]. 
Respiratory disease imposes a tremendous burden on healthcare budgets. In the 
European Union alone, with annual direct costs (i.e. costs paid directly for healthcare 
services) totalling approximately €47.3 billion and assuming a total annual 
expenditure on healthcare of approximately €800 billion (estimated 9% of gross 
domestic product (GDP)), the direct cost of respiratory disease accounts for 
approximately 6% of the total healthcare budget [Rabe KF et al. 2007]. For the 
predominant respiratory diseases, namely, asthma, pneumonia, TB, and COPD total 
annual direct and indirect costs (i.e. the value of lost productivity from time off work 
due to illness) are estimated at €17.7, €10.1 and €2.1 €38.7 billion, respectively 
[Rees J 2005, Loddenkemper R et al. 2003]. 
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From the healthcare regulatory perspective, interstitial lung disese (ILD) is classified 
as an “orphan disease”, that is, a disease affecting less than one in 2,000 people 
worldwide [Loddenkemper R et al. 2003]. 
No precise data are available on the total cost of ILD at the population level, however 
individual costs are estimated to be high, since most patients will eventually become 
incapable of working (i.e. due to dyspnea on exertion), and require continued home 
oxygen therapy. Others will require lung transplantation or continued palliative care. 
[Loddenkemper R et al. 2003]. 
1.2 Evolving paradigms of ILD pathogenesis and disease 
classification 
 
ILD is also known as diffuse parenchymal lung disease (DPLD) and refers to a large 
group of acute and chronic pulmonary diseases characterized by damage to the lung 
parenchyma, with varying patterns of inflammation and/or fibrosis [ATS/ERS 2002, 
Leslie KO 2006]. Although the pulmonary interstitium (i.e. the space between the 
epithelial and basement membranes) is the primary site of the parenchymal damage, 
these diseases also frequently affect the airspaces, peripheral airways, vasculature, 
and corresponding epithelial and endothelial surfaces [Cushley MJ et al. 1999].  
Furthermore, despite being numerous and histopathologically diverse, the 
physiologic, radiographic, and clinical manifestations of the ILDs are often quite 
similar, that is, a restrictive (as opposed to obstructive) lung function and impaired 
gas exchange, widespread shadowing of the lungs on chest X-ray, and increasing 
shortness of breath or dyspnea, respectively.  
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The older model of pathogenesis was a universal one. It maintained that all ILDs are 
characterized by inflammation of the lung interstitium, and that chronic inflammation 
causes irreversible fibrosis [Crystal RG 1981]. Presence of inflammation was proven 
by research on alveolitis conducted during the mid-1970s and early 1980s following 
the introduction of a new medical procedure called bronchoalveolar lavage (BAL) 
[Chapman HA 2004]. Later, with the introduction of high resolution computed 
tomography (HRCT), the presence of ground glass opacities was found to be 
consistent with edema and/or inflammation, features viewed as ‘less fibrotic’ 
occurring in very stages of the disease. This was the rationale behind treating these 
patients with high-dose of anti-inflammatory drugs such as dexamethasone. 
However, as clinicians became confronted with the fact that many forms of ILD are 
recalcitrant to corticosteroid treatment, a new hypothesis of disease pathogenesis 
emerged, namely that fibrosis itself could arise and progress in the absence of 
inflammation. 
A visual description of the pathways (shown as A and B) from normal lung tissue to 
fibrosis progression is shown Figure 1.1 below. 
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Figure 1.1 Pathways from normal lung tissue to fibrosis [taken and adapted from 
Gauldie J. et al. 2002] 
 
Adapted from Gauldie J et al., Resp Res. 2001 Epub Sep26 
 
Some types of ILD are characterized by marked inflammation (e.g. bronchiolitis 
obliterans organising pneumonia (BOOP), or bacterial pneumonia) with presence of 
stimulated matrix synthesis, however, after treatment a return to normal lung tissue is 
observed. In this type of disease, lung matrix remodelling does not occur and lung 
function is restored to baseline levels (as exhibited at the left-hand side of figure 1.1). 
However, some forms of ILD are characterized by repeated injury (e.g. 
hypersensitivity pneumonitis) or continuous low-level-inflammation (e.g. chronic 
forms of bird-fancier’s disease), which can lead to scarring and progressive fibrosis 
with serious functional impairment (as exhibited by pathway A in Figure 1.1) [Gauldie 
J et al. 2002]. Treatment with corticosteroids can improve pulmonary function, but a 
return to normal lung function is not observed. And still other forms of ILD exhibit an 
abnormal, out-of-control repair process with progression to fibrosis. This progression 
to fibrosis is believed to be the underlying mechanism present in the idiopathic 
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interstitial pneumonias (IIPs) and is characterized by the absence of inflammation (as 
exhibited by pathway B in Figure 1.1)  (e.g. IPF, acute interstitial pneumonia (AIP), 
cryptogenic organising pneumonia (COP)) [Gauldie J et al. 2002].  Drugs with strong 
anti-inflammatory properties (e.g. dexamethasone) have minimal to no influence on 
progressive functional impairment which eventually leads to respiratory failure. In 
spite of their clinical distinctions (IPF, AIP, COP, etc.), these disorders are 
characteristic of  matrix remodelling and share a common paradigm of disease 
progression: Provisional matrices formed in the context of injury emitting signals to 
activate inflammatory response and epithelial cells, provoking ingrowth and/or 
expansion of connective tissue that lead to permanent matrix reordering [Chapman 
HA 2004, Kolb J & Gauldie J 2011]. 
With this addition to the paradigm of fibrosis pathogenesis – the possibility of 
progressive fibrosis in the absence of chronic inflammation – a new histological 
classification was proposed by Katzenstein et al. (see Figure 1.2), comprised of four 
distinct major forms of idiopathic interstitial pneumonia having well-defined 
histological patterns [Katzenstein AA & Myers JL 1998]. The failure to recognize 
these different patterns has often given rise to clinical diversity observed in patients 
with these conditions [Katzenstein AA & Myers JL 1998]. This classification scheme 
put forth the patterns usual interstitial pneumonia (UIP) and desquamative interstitial 
pneumonia (DIP) from Liebow’s original classification and included two ‘new’ entities, 
namely acute interstitial pneumonia (AIP) [Katzenstein AA et al. 1986] and non-
specific interstitial pneumonia (NSIP) [Katzenstein AA & Fiorelli RF 1994]. 
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Figure 1.2 Evolution of histological classification of ILD 
 
Liebow (1969) Katzenstein (1993) International Consensus (2002) 
UIP UIP UIP 
 AIP AIP (ARDS) 
DIP DIP DIP / RBILD 
BIP BOOP COP 
LIP LIP LIP 
GIP -- -- 
 NSIP NSIP 
Figure 1.2: comparison with the older (or Liebow’s) and newer (or Katzenstein’s) classification of idiopathic interstitial 
pneumonia. UIP: usual interstitial pneumonia, NSIP: non-specific interstitial pneumonia, DIP: desquamative interstitial 
pneumonia, RBILD: respiratory bronchiolitis interstitial pneumonia, AIP: acute interstitial pneumonia, BIP: bronchiolitis obliterans 
interstitial pneumonia, BOOP: bronchiolitis obliterans organising pneumonia, COP: cryptogenic organising pneumonia, LIP: 
lymphoid interstitial pneumonia, GIP: giant cell interstitial pneumonia, HP: interstitial pneumonia, IPF: idiopathic pulmonary 
fibrosis, HBV: Hepstein barr virus 
 
The next dilemma awaiting to be solved was whether or not the pathological 
characteristics of these different histological patterns could explain a pathway that 
leads to lung fibrosis. The diagnostic clue to UIP is the presence of a patchy, non-
uniform, and variable distribution of interstitial changes, the appearance of which can 
be readily appreciated at low magnification [Katzenstein AA & Myers JL 1998]. 
Histological variation from one low-magnification field to another is characteristic, with 
alternating zones of interstitial fibrosis, inflammation, honeycombing, and normal lung 
tissue. Honeycombing is a manifestation of scarring and architectural restructuring 
that follows lung injury of a variety of causes, and is not specific to UIP. Another facet 
of the histological variability of UIP is appreciated when the nature of the fibrosis is 
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examined. Although most of the fibrotic zones are composed of “old”, relatively 
acellular collagen bundles, small aggregates of actively proliferating myofibroblasts 
and fibroblasts are consistently identifiable [Katzenstein AA & Myers JL 1998]. These 
aggregates, termed “fibroblast foci”, are characterized by spindle-shaped cells (see 
Figure 1.3) which are usually arranged with their long axes parallel to the long axes 
of the alveolar septa. [Selman et al. 2001] Fibroblast foci are widely scattered and 
can be found in inflamed, fibrotic, and honeycombed areas. Although fibroblast foci 
are not pathognomonic of UIP, they are necessary for the diagnosis [Katzenstein AA 
& Myers JL 1998, Du Bois R & King TE 2007].  They indicate that the fibrotic process 
is active rather than representing the residue of a process that once occurred, but is 
now inactive. The presence of fibroblast foci in some places, and of scarring with 
collagen deposition or honeycomb changes in others, exhibits temporal 
heterogeneity, a feature that is central to diagnosing UIP and distinguishing it from 
other IIPs [Katzenstein AA & Myers JL 1998]. 
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Figure 1.3 Depiction of alveolar epithelial cell injury [taken and adapted from 
Selman et al. 2001] 
 
 
NSIP is characterised by the presence of varying degrees of inflammation and 
fibrosis within alveolar walls, but it lacks more specific changes that would indicate a 
diagnosis of UIP, DIP, or AIP. As further explained by Katzenstein & Fiorelli, NSIP 
comprises “…a fairly sizable group of idiopathic interstitial pneumonias (that) cannot 
be pigeon-holed into one of the three main groups, and we have termed these 
lesions nonspecific interstitial pneumonia or fibrosis.” [Katzenstein AA & Fiorelli RF 
1994]. The new hypothesis relating to the absence of inflammation in the progression 
of lung fibrosis and this new pathologic classification have been well-received by 
specialists because the histopathology of different types of lung fibrosis is clearly 
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defined and provides a basis for research on antifibrotic therapeutics, instead of anti-
inflammatory agents [Du Bois R & King TE 2007]. 
With the general acceptance of these distinct histological patterns together with the 
changing nature of the pathophysiologic model during the final three decades of the 
last millennium, the American Thoracic Society (ATS) and the European Respiratory 
Society (ERS) put forth in the years 2000-2002 joint consensus statements that 
defined classification, diagnosis, and management of ILD [ATS/ERS 2002, ATS 
2000]. These guidelines classify the ILDs based on clinical, radiologic, and pathologic 
findings into four main categories: (1) ILD of known cause (e.g. environmental 
exposure, drug exposure, association with a connective tissue disease (CTD), etc.), 
(2) granulomatous ILD (i.e. sarcoidosis, Wegener’s Granulomatosis), (3) extremely 
rare ILD with well-defined clinico-pathologic features (e.g. pulmonary alveolar 
proteinosis (PAP), eosinophilic pneumonia, lymphangioleiomyomatosis (LAM), etc.), 
and  (4) idiopathic interstitial pneumonia (IIP) (see Figure 1.4). The latter is further 
subdivided into seven distinct clinico-pathologic disease entities, the causes of which 
are unknown by definition. In the order of relative frequency, they are: idiopathic 
pulmonary fibrosis (IPF), non-specific interstitial pneumonitis (NSIP), cryptogenic 
organizing pneumonia (COP), acute interstitial pneumonitis (AIP), respiratory 
bronchiolitis-interstitial disease (RBILD), desquamative interstitial pneumonia (DIP), 
and lymphoid interstitial pneumonia (LIP) (Figure 1.4). 
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Figure 1.4 Classification of ILD, taken and adapted from ATS/ERS consensus 
statements [taken and adapted from ATS/ERS 2002] 
 
 
2 Aims of this dissertation 
Large-scale epidemiological investigations of the full spectrum of ILD are few and far 
between. In fact, until very recently, the only true population-based study, conducted 
over 20 years ago, encompassed a relatively small US population of approximately 
half a million inhabitants, and was restricted to a two-year study period [Coultas DB 
et al. 1994]. Over the last decade, however, there have been some population-based 
investigations, mainly in the form of questionnaires to chest specialists, specialty 
clinic registries or database studies exploring only the most commonly-occurring ILD 
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Updated, epidemiological data describing ILD disease frequency, natural history, and 
survivorship are essential for public health planning, such as the prediction of health 
care resource use and the justification for health education programs. Furthermore, 
current data would greatly enhance our understanding of presumed risk factors for 
ILD, disease classification, and the natural history and treatment of ILD. Most 
importantly, the careful evaluation of descriptive epidemiologic findings would better 
define the breadth and burden of ILD in the general population, may yield important 
clues about the etiology of the idiopathic subgroups, and would hopefully guide 
researchers and health care practitioners in their approaches to developing 
treatments and caring for ILD patients. 
Therefore, it is the aim of this dissertation to report the following epidemiological 
investigations of ILD using data from the general population: (1) To describe the 
demographic and clinical characteristics of patients with a first-time diagnosis of ILD, 
and to compare these characteristics to a cohort of non-ILD control subjects; (2) To 
calculate incidence and prevalence of ILD subgroups (to the extent possible) using 
the currently-accepted classification paradigm; (3) To determine absolute and relative 
rates of all-cause mortality in different ILD subgroups; (4) To determine the relative 
risk of certain comorbidities after a first-time diagnosis of ILD; (5) To explore in more 
depth certain epidemiological topics pertaining to the subgroup of ILD classified as 
being of known cause or associated with other conditions. These topics are are 
handled as manuscripts (either in press or submitted and under review by various 
biomendical journals) in Section 8 of this dissertation. 
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3.1 Data source 
This U.K. General Practice Research Database (GPRD) is a large and well-validated 
database that was established in June 1987.  It is the largest of its kind, and has 
been used for numerous disease epidemiology and drug safety studies [Wood L & 
Martinez C 2004, Jick H 1997, Garcia-Rodriguez L & Perez Gutthann 1998].   About 
450 general practices throughout the UK participate in the GPRD, which contains 
some 5 million active patients, and a total of approximately 13 million patients who 
are representative of the overall UK population with regard to age, sex, geographic 
distribution and annual turnover rate.  All patient information stored in the database is 
strictly anonymous.  The general practitioners (GPs) participating in the GPRD have 
been trained to record relevant medical information in a standardized and coded 
manner using office computers. Medical diagnoses are coded in the form of ‘Read’ 
codes. In addition, information on patient demographics, some laboratory data, and 
virtually all drug prescriptions are also recorded by the GPs. Prescriptions are 
generated directly on the computer, containing not only the name of the drug 
prescribed, but also the route of administration, dosage, and number of doses 
dispensed on each prescription, which are recorded as so-called ‘Multilex’ codes. 
Hospital discharge and referral letters, as well as death certificates, can be reviewed 
as a means of validating diagnoses recorded in the computer record. In addition, it is 
also possible to contact GPs and patients indirectly through the GPRD-group at 
MHRA to pose follow-up questions or submit questionnaires [Wood L & Martinez C 
2004, Jick H 1997, Garcia-Rodriguez L & Perez Gutthann 1998]. The recorded 
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information on drug exposure and on outpatient diagnoses in the GPRD has been 
validated in numerous publications and proven to be of high quality [Jick H et al. 
1991, Jick H et al. 1992, Jick SS et al. 2003]. The data for the present study was 
extracted from the large subset of GPRD data currently being used by the Boston 
Collaborative Drug Surveillance Program (BCDSP) and its associates (i.e. including 
the Basel Pharmacoepidemiology Unit directed by Prof. Christoph Meier). 
Figure 3.1 Study design 
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3.2 Timeframes and approval 
The analyses took place between January 2010 and December 2011 and included 
GPRD data between January 1995 and the end of 2009. This dissertation is based 
on two protocols (Protocol Nos. 10-021-R and 10-145) submitted to and approved by 
the Independent Scientific Advisory Committee (ISAC) of the U.K. Medicines and 
Healthcare products Regulatory Agency (MHRA). 
3.3 Study population 
The study population consisted of all patients with 3 or more years of recorded 
history in the GPRD who had a first-time diagnosis of an ILD (see diagnosis codes in 
Appendix 1) between January 1995 and the end of 2009. The date of first-time 
diagnosis of an ILD is subsequently referred to as ‘index date.’ A comparison/control 
group of ILD-free subjects was matched 1:1 to the ILD cohort on age (i.e. year of 
birth), gender, general practice, calendar time (i.e. index date assignment as per 
matched case), and number of years of recorded history in the database. The 
inclusion criterion of a minimum of 3 years of medical history was applied in order to 
increase the likelihood of including incident (rather than prevalent) ILD subjects in the 
study. Each ILD case and matched control was categorized by ILD subgroup (as per 
the ATS/ERS classification scheme Figure 1 above: ILD of known cause or 
associated w/other diseases, idiopathic interstitial pneumonia, granulomatous ILD, or 
other forms of ILD) based on diagnosis codes as well as an algorithm developed to 
handle cases having more than one ILD diagnosis code (see Figure 3.2 below). 
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Figure 3.2 ILD case-selection algorithm and resulting sample sizes 
 
 
BCDSP = Boston Collaborative Drug Surveillance Program 
Dx = diagnosis, NEC = not elsewhere classified, NOS = not otherwise specified 
 
3.4 Prevalence of ILD 
The prevalence of ILD was estimated for three 5-year periods (1995-1999, 2000-
2004, and 2005-2009). Prevalent cases in each period included existing cases (i.e. 
those diagnosed with ILD in a previous period and still alive and present in the 
database during the applicable period) and newly diagnosed ILD cases during the 
applicable period. The denominator was defined as the number of patients in the 
GPRD with any activity during the applicable period. Estimates for period prevalence 
were stratified by age group (in 10-yr bands) and gender, and a 95% confidence 
interval for each estimate was calculated. 
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3.5 Incidence of ILD 
The incidence rate of ILD was calculated for three 5-year periods (1995-1999, 2000-
2004, and 2005-2009). Incident cases were defined as newly diagnosed ILD patients 
during the applicable period. The denominator for each period was defined as the 
total person time (in years) of all GPRD subjects who had at least 3 years of recorded 
medical history. Rates of incidence density were stratified by age group (10-yr age 
bands) and gender, and a 95% confidence interval was calculated for each rate. 
3.6 All-cause mortality 
All-cause mortality rates were calculated for three 5-year periods (1995-1999, 2000-
2004, and 2005-2009) for the ILD cohorts. The numerators for these rates were the 
number of deaths in a given period divided by the total number of patients in the 
GPRD with any activity during the applicable period. Rates of all-cause mortality were 
stratified by age group (10-yr age bands) and gender, and 95% confidence intervals 
were calculated for all rates. 
3.7 Characteristics of ILD cases and controls 
The ILD and non-ILD cohorts are described statistically in terms of various 
characteristics at or prior to the index date. Variables include body mass index, 
smoking status, smoking amount, alcohol consumption status, quantity of alcohol 
consumption, no. of general practice visits, no. and type of drug prescriptions, and for 
a small proportion of subjects, level of blood glucose prior to index date. Odds ratios 
and 95% confidence intervals were determined using conditional logistic regression. 
University of Basel  Page 31 




3.8 Comorbidity after index date 
As per protocol, a variety of disease diagnoses were investigated post index date. 
For certain commonly occurring diagnoses, patients were not excluded from the 
analysis on the basis of having had such a diagnosis prior to index date. These 
diagnoses included pneumonia, respiratory (non-pneumonia) infections, 
pneumothorax, and bone fracture. For the cardiovascular disease diagnoses, in 
which greater interest was placed on whether or not they were truly incident after 
index date, patients having already had such a diagnosis in their medical history were 
excluded from the analysis. These outcomes included pulmonary embolism, deep 
vein thrombosis, myocardial infarction, congestive heart failure, ischemic heart 
disease, cerebrovascular events, and pulmonary hypertension. Survival time was 
calculated as the number of days from index date until either first diagnosis of an 
event (i.e. outcome of interest as aforementioned), recorded medical history 
terminates, death, or study period ends. In order to account for the matched design in 
the analysis, crude and adjusted hazard ratios (i.e. rate ratios) for the comparison of 
event rates in the ILD vs. non-ILD cohorts were determined using stratified Cox 
proportional hazards regression. 
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4.1 Prevalence of ILD 
4.1.1 Idiopathic Interstitial Pneumonia (IIP) 
4.1.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
The estimated prevalence of IPF more than doubled from the period 1995-1999 (7.2 
per 100’000 inhabitants) to the period 2000-2004 (15.2 per 100’000). No further 
increase was noted during the period 2005-2009. In all time periods, the overall 
gender-specific prevalence of IPF was approximately twice as high for males versus 
females. The highest overall age-specific estimates were observed in those 80-89 
years of age for the periods 2000-2004 and 2005-2009 (64.4 and 66.7 per 100’000 
inhabitants, respectively).  Table 4.1.1.1 below shows overall and age-/gender-
specific 5-year period prevalence estimates with 95% confidence limits. 
Table 4.1.1.1 IPF: 5-yr prevalence estimates* and 95% confidence limits, stratified 
by age band and gender 



















30 - 39 Male 1.6 0.2 3.1 4.0 2.0 5.9 3.5 1.8 5.2 
 Female 0.3 0.0 0.9 2.4 0.9 4.0 2.9 1.3 4.4 
 Overall 1.0 0.2 1.7 3.2 2.0 4.4 3.2 2.0 4.3 
40 - 49 Male 4.5 2.2 6.8 10.3 7.1 13.6 7.5 4.9 10.2 
 Female 0.3 0.0 0.8 4.0 2.0 5.9 6.2 3.9 8.6 
 Overall 2.2 1.1 3.3 7.0 5.2 8.9 6.9 5.1 8.6 
50 - 59 Male 16.3 12.2 20.5 30.9 25.7 36.1 41.4 35.2 47.6 
 Female 6.4 4.1 8.7 19.0 15.2 22.8 23.4 19.0 27.8 
 Overall 10.8 8.6 13.1 24.5 21.4 27.7 31.9 28.2 35.7 
60 - 69 Male 41.6 35.1 48.2 82.0 74.0 90.0 82.3 74.5 90.2 
 Female 17.0 13.2 20.8 32.6 27.9 37.2 38.9 33.8 44.0 
 Overall 28.1 24.5 31.7 55.5 51.1 60.0 59.4 54.8 64.0 
70 - 79 Male 57.2 49.3 65.0 97.2 88.5 105.9 81.5 74.1 88.8 
 Female 24.5 19.7 29.2 54.8 48.7 61.0 46.9 41.5 52.3 
 Overall 39.5 35.0 43.9 74.8 69.6 80.1 63.5 59.0 68.0 
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80 - 89 Male 18.8 14.4 23.2 48.1 41.7 54.5 45.9 40.2 51.5 
 Female 16.8 12.9 20.6 34.4 29.3 39.5 27.4 23.2 31.7 
 Overall 17.7 14.8 20.6 40.9 36.8 45.0 36.4 32.9 39.9 
90+ Male 1.9 0.5 3.2 1.7 0.5 2.9 1.6 0.5 2.7 
 Female 2.1 0.7 3.5 4.7 2.8 6.6 3.8 2.1 5.5 
 Overall 2.0 1.0 3.0 3.3 2.1 4.4 2.7 1.7 3.8 
OVERALL MALE 9.9 9.1 10.8 19.8 18.8 20.9 19.0 18.0 20.0 
 FEMALE 4.9 4.3 5.4 11.0 10.3 11.8 10.8 10.1 11.5 
 ---------- 7.2 6.7 7.7 15.2 14.5 15.8 14.7 14.1 15.4 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.1.2 Granulomatous ILD 
4.1.2.1 Sarcoidosis 
The estimated 5-year period prevalence of sarcoidosis increased more than 5-fold 
from the period 1995-1999 (1.4 per 100’000 inhabitants) to the period 2005-2009 (7.5 
per 100’000 inhabitants). No prevalent cases of sarcoidosis were found in those 
younger than 20 years of age. The highest overall age-specific estimates were found 
in those 50-59 years of age during the periods 2000-2004 and 2005-2009, 18.3 per 
100’000 during, and 37.5 per 100’000, respectively). In all age categories below 60 
years, the estimated prevalence of sarcoidosis was higher in males than in females. 
Thereafter, the prevalence is generally higher in females than in males. Table 4.1.2.1 
below shows overall and age-/gender-specific 5-year period prevalence estimates 
with 95% confidence limits. 
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Table 4.1.2.1 Sarcoidosis: 5-yr prevalence estimates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 8.5 5.2 11.7 11.1 7.9 14.4 5.2 3.1 7.3 
 Female 1.6 0.2 3.0 4.6 2.6 6.7 3.1 1.5 4.7 
 Overall 5.0 3.2 6.7 7.9 5.9 9.8 4.2 2.8 5.5 
40 - 49 Male 9.7 6.3 13.0 25.9 20.7 31.1 26.3 21.3 31.2 
 Female 2.3 0.8 3.8 9.5 6.5 12.5 18.3 14.2 22.3 
 Overall 5.7 3.9 7.4 17.3 14.4 20.2 22.2 19.0 25.3 
50 - 59 Male 4.6 2.4 6.8 23.2 18.7 27.7 51.1 44.2 58.0 
 Female 6.4 4.1 8.7 14.1 10.9 17.4 25.3 20.8 29.9 
 Overall 5.6 4.0 7.2 18.3 15.6 21.0 37.5 33.5 41.6 
60 - 69 Male 3.2 1.4 5.0 7.6 5.2 10.1 22.9 18.8 27.0 
 Female 3.1 1.5 4.7 12.2 9.3 15.0 23.9 19.9 27.9 
 Overall 3.2 1.9 4.4 10.1 8.2 12.0 23.4 20.5 26.3 
70 - 79 Male 0.0 0.0 0.0 4.3 2.4 6.1 13.7 10.7 16.8 
 Female 0.5 0.0 1.1 13.3 10.2 16.3 23.5 19.7 27.3 
 Overall 0.3 0.0 0.6 9.0 7.2 10.8 18.8 16.4 21.3 
80 - 89 Male 1.3 0.2 2.5 1.5 0.4 2.7 2.7 1.3 4.1 
 Female 0.0 0.0 0.0 4.0 2.2 5.8 10.6 7.9 13.2 
 Overall 0.6 0.1 1.2 2.8 1.8 3.9 6.7 5.2 8.3 
90+ Male 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.9 3.3 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.4 1.7 
OVERALL MALE 2.0 1.6 2.3 4.7 4.2 5.2 7.7 7.1 8.3 
 FEMALE 1.0 0.7 1.2 4.0 3.5 4.4 7.2 6.6 7.8 
 ---------- 1.4 1.2 1.7 4.3 4.0 4.7 7.5 7.0 7.9 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.1.2.2 Wegener’s Granulomatosis 
The estimated 5-year period prevalence of Wegener’s Granulomatosis increased 
more than 3-fold from the period 2000-2004 to 2005-2009 (from 1.7 to 5.8 per 
100’000 inhabitants, respectively). Overall gender-specific estimates indicate that 
prevalence is roughly equal in males and females. For all three time periods the 
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highest overall age-specific prevalence estimates were found in those 60-89 years of 
age. Table 4.1.2.2 below shows overall and age-/gender-specific 5-year period 
prevalence estimates with 95% confidence intervals. 
Table 4.1.2.2 WG: 5-yr prevalence estimates* and 95% confidence limits, stratified 
by age band and gender 



















10 - 19 Male 1.1 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.6 0.0 1.3 1.1 0.1 2.1 1.1 0.1 2.0 
 Overall 0.8 0.2 1.5 0.5 0.1 1.0 0.5 0.1 1.0 
20 - 29 Male 0.0 0.0 0.0 3.7 2.0 5.5 2.9 1.4 4.4 
 Female 3.5 1.5 5.6 5.4 3.2 7.5 3.0 1.5 4.5 
 Overall 1.8 0.8 2.8 4.5 3.1 5.9 3.0 1.9 4.0 
30 - 39 Male 0.0 0.0 0.0 1.5 0.3 2.7 3.1 1.5 4.7 
 Female 1.6 0.2 3.0 3.9 2.0 5.8 4.2 2.3 6.1 
 Overall 0.8 0.1 1.5 2.7 1.6 3.8 3.6 2.4 4.8 
40 - 49 Male 1.5 0.2 2.8 3.0 1.2 4.8 6.6 4.1 9.0 
 Female 2.8 1.2 4.5 4.2 2.2 6.2 7.2 4.6 9.7 
 Overall 2.2 1.1 3.3 3.6 2.3 5.0 6.9 5.1 8.6 
50 - 59 Male 6.8 4.1 9.5 6.4 4.0 8.7 7.8 5.1 10.4 
 Female 3.1 1.5 4.7 13.1 10.0 16.3 13.4 10.1 16.8 
 Overall 4.7 3.3 6.2 10.0 8.0 12.0 10.8 8.6 12.9 
60 - 69 Male 6.4 3.9 9.0 15.9 12.4 19.4 25.0 20.7 29.4 
 Female 5.5 3.4 7.7 8.4 6.0 10.7 23.0 19.1 26.9 
 Overall 5.9 4.3 7.6 11.8 9.8 13.9 24.0 21.1 26.9 
70 - 79 Male 9.6 6.4 12.9 14.8 11.4 18.3 17.9 14.5 21.4 
 Female 5.5 3.3 7.8 10.4 7.7 13.0 14.7 11.7 17.7 
 Overall 7.4 5.5 9.3 12.5 10.3 14.6 16.3 14.0 18.5 
80 - 89 Male 0.5 0.0 1.3 5.7 3.5 7.9 10.1 7.5 12.8 
 Female 0.5 0.0 1.1 8.2 5.7 10.7 16.7 13.4 20.0 
 Overall 0.5 0.0 1.0 7.0 5.3 8.7 13.5 11.4 15.6 
90+ Male 0.0 0.0 0.0 0.4 0.0 1.0 3.6 2.0 5.3 
 Female 0.0 0.0 0.0 0.4 0.0 0.9 4.9 3.0 6.8 
 Overall 0.0 0.0 0.0 0.4 0.0 0.8 4.3 3.0 5.6 
OVERALL MALE 1.8 1.4 2.2 3.7 3.2 4.2 5.5 4.9 6.0 
 FEMALE 1.6 1.3 2.0 3.8 3.3 4.2 6.1 5.6 6.7 
 ---------- 1.7 1.5 2.0 3.7 3.4 4.1 5.8 5.4 6.2 
L=Lower, U=Upper, CL=Confidence Limit; * All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
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4.1.3 ILD of known cause or associated with other diseases 
4.1.3.1 Extrinsic Allergic Alveolitis (EAA) 
The overall estimated 5-year period prevalence of EAA increased significantly from 
one measurement period to the next, with an almost three-fold increase from the 
period 1995-1999 to 2004-2009 (3.3 to 9.4 per 100’000 inhabitants). Overall gender-
specific estimates were similar in males and females in all time periods. No prevalent 
cases were found in those under 10 years of age. Age-specific estimates generally 
increased in those 50 years and older from one time period to the next. Table 4.1.3.1 
below shows overall and age-/gender-specific 5-year period prevalence estimates 
with 95% confidence intervals. 
Table 4.1.3.1 EAA: 5-yr prevalence estimates* and 95% confidence limits, stratified 
by age band and gender 



















20 - 29 Male 0.3 0.0 0.9 2.2 0.8 3.5 3.9 2.2 5.6 
 Female 0.9 0.0 1.9 1.8 0.6 3.0 1.6 0.5 2.7 
 Overall 0.6 0.0 1.2 2.0 1.1 2.9 2.8 1.7 3.8 
30 - 39 Male 9.1 5.7 12.5 4.0 2.0 5.9 2.8 1.3 4.4 
 Female 5.0 2.6 7.5 3.9 2.0 5.8 2.4 1.0 3.8 
 Overall 7.0 5.0 9.1 3.9 2.6 5.3 2.6 1.6 3.7 
40 - 49 Male 13.6 9.6 17.6 27.2 21.9 32.6 14.4 10.7 18.0 
 Female 8.2 5.4 11.0 10.0 6.9 13.1 9.5 6.6 12.4 
 Overall 10.7 8.3 13.1 18.2 15.2 21.2 11.9 9.5 14.2 
50 - 59 Male 13.3 9.6 17.1 20.0 15.8 24.2 26.4 21.5 31.4 
 Female 7.9 5.3 10.5 21.6 17.5 25.6 18.6 14.7 22.6 
 Overall 10.4 8.2 12.6 20.9 17.9 23.8 22.3 19.2 25.4 
60 - 69 Male 11.0 7.6 14.4 23.3 19.1 27.6 28.7 24.1 33.4 
 Female 8.2 5.5 10.8 28.6 24.2 32.9 39.2 34.1 44.3 
 Overall 9.5 7.4 11.6 26.1 23.1 29.2 34.3 30.8 37.7 
70 - 79 Male 7.1 4.3 9.8 26.4 21.9 31.0 34.1 29.3 38.9 
 Female 5.8 3.5 8.1 22.7 18.7 26.7 37.0 32.2 41.8 
 Overall 6.4 4.6 8.1 24.5 21.5 27.5 35.6 32.2 39.0 
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80 - 89 Male 1.3 0.2 2.5 7.7 5.2 10.3 22.4 18.4 26.3 
 Female 4.4 2.4 6.4 11.0 8.1 13.9 15.8 12.6 19.1 
 Overall 3.0 1.8 4.2 9.4 7.5 11.4 19.0 16.5 21.5 
90+ Male 1.1 0.0 2.1 0.0 0.0 0.0 4.2 2.4 6.0 
 Female 0.0 0.0 0.0 1.2 0.2 2.1 5.1 3.2 7.1 
 Overall 0.5 0.0 1.0 0.6 0.1 1.1 4.7 3.4 6.0 
OVERALL MALE 3.8 3.3 4.4 7.7 7.0 8.3 9.6 8.9 10.3 
 FEMALE 2.8 2.3 3.2 7.2 6.6 7.8 9.2 8.6 9.9 
 ---------- 3.3 2.9 3.6 7.4 7.0 7.9 9.4 8.9 9.9 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.1.3.2 Pneumoconioses 
The overall estimated 5-year period prevalence of the pneumoconioses increased 
significantly from one time period to the next, with an approximate six-fold increase 
observed from the period 1995-1999 to 2004-2009 (8.2 to 48.2 per 100’000 
inhabitants). With respect to overall gender-specific estimates, prevalence in males 
was approximately 10-15 times higher in males than in females in each period. 
Overall age-specific estimates were highest in those aged 70-79 during the periods 
2000-2004 and 2005-2009 (115.1 and 219.2 per 100’000 inhabitants, respectively). 
Table 4.1.3.2 below shows overall and age-/gender-specific 5-year period prevalence 
estimates with 95% confidence intervals. 
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Table 4.1.3.2 Pneumoconioses: 5-yr prevalence estimates* and 95% confidence 
limits, stratified by age band and gender 



















10 - 19 Male 0.3 0.0 0.8 2.3 0.9 3.7 2.5 1.1 3.9 
 Female 0.3 0.0 0.8 1.7 0.5 3.0 1.1 0.1 2.0 
 Overall 0.3 0.0 0.7 2.0 1.1 3.0 1.8 1.0 2.7 
20 - 29 Male 3.5 1.5 5.4 6.8 4.4 9.2 4.1 2.3 5.8 
 Female 0.0 0.0 0.0 2.0 0.7 3.3 3.6 1.9 5.3 
 Overall 1.8 0.8 2.8 4.4 3.1 5.8 3.9 2.6 5.1 
30 - 39 Male 2.0 0.4 3.5 9.1 6.2 12.1 18.5 14.6 22.5 
 Female 3.8 1.6 5.9 3.7 1.8 5.5 5.1 3.0 7.1 
 Overall 2.9 1.6 4.2 6.4 4.7 8.1 11.8 9.6 14.0 
40 - 49 Male 9.7 6.3 13.0 18.0 13.6 22.3 14.4 10.7 18.0 
 Female 0.8 0.0 1.6 4.5 2.4 6.6 13.9 10.4 17.4 
 Overall 4.9 3.2 6.5 10.9 8.6 13.3 14.1 11.6 16.6 
50 - 59 Male 33.8 27.8 39.7 70.0 62.2 77.8 41.2 35.0 47.4 
 Female 1.5 0.4 2.7 5.7 3.6 7.8 11.7 8.6 14.8 
 Overall 16.0 13.2 18.7 35.5 31.7 39.3 25.6 22.3 29.0 
60 - 69 Male 88.6 79.0 98.1 193.3 181.1 205.6 176.1 164.6 187.5 
 Female 2.2 0.8 3.6 10.6 8.0 13.3 22.0 18.1 25.8 
 Overall 41.2 36.8 45.6 95.4 89.6 101.3 94.9 89.1 100.6 
70 - 79 Male 81.8 72.3 91.2 227.2 213.9 240.5 424.5 407.7 441.3 
 Female 3.1 1.4 4.8 15.1 11.8 18.3 30.4 26.1 34.7 
 Overall 39.2 34.8 43.7 115.1 108.6 121.6 219.2 210.9 227.6 
80 - 89 Male 17.5 13.2 21.7 154.1 142.7 165.6 387.1 370.7 403.4 
 Female 3.3 1.6 5.0 8.6 6.0 11.2 26.7 22.6 30.9 
 Overall 9.8 7.7 12.0 77.8 72.2 83.4 201.7 193.4 209.9 
90+ Male 0.5 0.0 1.3 20.1 16.0 24.2 137.9 127.6 148.2 
 Female 0.0 0.0 0.0 3.9 2.2 5.6 17.1 13.6 20.6 
 Overall 0.2 0.0 0.6 11.6 9.5 13.8 75.7 70.4 81.0 
OVERALL MALE 16.6 15.5 17.7 50.7 49.0 52.4 90.5 88.3 92.7 
 FEMALE 1.0 0.8 1.3 3.9 3.5 4.4 9.2 8.6 9.9 
 ---------- 8.2 7.7 8.8 26.0 25.2 26.9 48.2 47.1 49.3 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
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4.1.3.3 Drug-/radiation induced ILD (DRAD-ILD) 
The overall estimated 5-year period prevalence of drug/radiation-induced ILD 
increased significantly from one time period to the next, with an approximate five-fold 
increase observed from the period 1995-1999 to 2004-2009 (0.4 to 2.1 per 100’000 
inhabitants respectively). With respect to overall gender-specific estimates, 
prevalence was higher in females than in males in all time period. No prevalent cases 
were found in those under the age of 20 years, and the highest overall age-specific 
estimates were observed in those aged 70-79. Table 4.1.2.2 below shows overall and 
age-/gender-specific 5-year period prevalence estimates with 95% confidence 
intervals. 
Table 4.1.3.3 DRAD-ILD: 5-yr. prevalence estimates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.4 
 Female 1.6 0.2 3.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.8 0.1 1.5 0.0 0.0 0.0 0.3 0.0 0.7 
40 - 49 Male 0.3 0.0 0.9 0.8 0.0 1.7 0.0 0.0 0.0 
 Female 0.8 0.0 1.6 2.5 0.9 4.0 2.1 0.7 3.4 
 Overall 0.6 0.0 1.1 1.7 0.8 2.6 1.1 0.4 1.8 
50 - 59 Male 0.3 0.0 0.8 1.1 0.1 2.1 2.9 1.3 4.6 
 Female 1.3 0.3 2.4 2.9 1.5 4.4 3.2 1.6 4.9 
 Overall 0.9 0.2 1.5 2.1 1.2 3.0 3.1 1.9 4.3 
60 - 69 Male 1.3 0.2 2.5 3.6 1.9 5.3 3.1 1.6 4.6 
 Female 1.8 0.5 3.0 4.0 2.4 5.6 4.9 3.1 6.7 
 Overall 1.6 0.7 2.4 3.8 2.7 5.0 4.0 2.8 5.2 
70 - 79 Male 0.6 0.0 1.4 5.9 3.8 8.0 6.4 4.4 8.5 
 Female 3.1 1.4 4.8 5.8 3.8 7.8 11.4 8.7 14.0 
 Overall 1.9 1.0 2.9 5.9 4.4 7.3 9.0 7.3 10.7 
80 - 89 Male 1.1 0.0 2.1 3.5 1.8 5.3 6.0 3.9 8.0 
 Female 0.0 0.0 0.0 4.6 2.7 6.5 10.0 7.5 12.6 
 Overall 0.5 0.0 1.0 4.1 2.8 5.4 8.1 6.4 9.7 
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90+ Male 0.0 0.0 0.0 0.0 0.0 0.0 2.4 1.1 3.8 
 Female 0.0 0.0 0.0 0.2 0.0 0.6 3.0 1.6 4.5 
 Overall 0.0 0.0 0.0 0.1 0.0 0.3 2.7 1.7 3.8 
OVERALL MALE 0.3 0.1 0.4 1.1 0.9 1.4 1.6 1.3 1.9 
 FEMALE 0.6 0.4 0.8 1.4 1.1 1.7 2.5 2.2 2.9 
 ---------- 0.4 0.3 0.5 1.3 1.1 1.5 2.1 1.8 2.3 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.1.3.4 ILD associated with other diseases (ILD-ODIS) 
The overall and gender-specific overall estimated 5-year period prevalence of ILD 
associated with other diseases remained relatively stable over time. No prevalent 
cases were found in those younger than 10 years of age, and the highest age-
specific estimates were observed in those 70-79 years of age. Except for those aged 
80 and over, a general decrease in 5-year period prevalence was observed from 
2000-2004 to 2005-2009. Table 4.1.3.4 below shows overall and age-/gender-
specific 5-year period prevalence estimates with 95% confidence intervals. 
Table 4.1.3.4 ILD-ODIS: 5-yr prevalence estimates* and 95% confidence limits, 
stratified by age band and gender 



















20 - 29 Male 1.4 0.2 2.7 0.0 0.0 0.0 1.0 0.1 1.8 
 Female 1.2 0.0 2.3 1.6 0.4 2.7 0.0 0.0 0.0 
 Overall 1.3 0.5 2.2 0.8 0.2 1.3 0.5 0.1 0.9 
30 - 39 Male 1.3 0.0 2.6 1.7 0.4 3.0 0.0 0.0 0.0 
 Female 2.2 0.6 3.8 2.4 0.9 4.0 1.1 0.1 2.1 
 Overall 1.8 0.7 2.8 2.1 1.1 3.1 0.5 0.1 1.0 
40 - 49 Male 2.7 0.9 4.5 2.2 0.7 3.7 1.5 0.3 2.6 
 Female 6.4 3.9 8.9 14.2 10.5 17.9 8.1 5.4 10.8 
 Overall 4.7 3.1 6.3 8.5 6.4 10.5 4.9 3.4 6.3 
50 - 59 Male 13.9 10.1 17.7 7.7 5.1 10.3 3.9 2.0 5.8 
 Female 16.7 13.0 20.5 16.9 13.3 20.4 13.4 10.1 16.8 
 Overall 15.5 12.8 18.2 12.6 10.4 14.9 8.9 6.9 10.9 
University of Basel  Page 41 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 



















60 - 69 Male 35.2 29.1 41.2 28.3 23.7 33.0 16.9 13.3 20.4 
 Female 22.1 17.8 26.4 30.5 26.0 35.0 23.9 19.9 27.9 
 Overall 28.0 24.4 31.6 29.5 26.2 32.7 20.6 17.9 23.3 
70 - 79 Male 45.6 38.5 52.6 47.6 41.5 53.7 30.1 25.6 34.6 
 Female 30.3 25.0 35.5 29.2 24.7 33.8 24.5 20.6 28.4 
 Overall 37.3 33.0 41.6 37.9 34.2 41.6 27.2 24.2 30.1 
80 - 89 Male 11.8 8.3 15.3 17.4 13.6 21.3 25.8 21.6 30.0 
 Female 14.0 10.4 17.5 25.2 20.8 29.6 25.0 21.0 29.1 
 Overall 13.0 10.5 15.5 21.5 18.6 24.4 25.4 22.5 28.3 
90+ Male 0.8 0.0 1.7 1.7 0.5 2.9 9.3 6.6 12.0 
 Female 2.1 0.7 3.5 4.5 2.7 6.3 12.2 9.2 15.1 
 Overall 1.5 0.6 2.3 3.2 2.1 4.3 10.8 8.8 12.8 
OVERALL MALE 7.9 7.1 8.6 7.8 7.2 8.5 6.6 6.0 7.2 
 FEMALE 6.7 6.1 7.4 8.8 8.1 9.5 7.7 7.1 8.3 
 ---------- 7.3 6.8 7.8 8.3 7.9 8.8 7.2 6.7 7.6 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.2 Incidence of ILD 
4.2.1 Idiopathic Interstitial Pneumonia (IIP) 
4.2.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
The overall 5-year incidence of IPF increased from the period 1995-1999 to 2000-
2004 (3.5 to 4.3 per 100'000 person-years, respectively) and then decreased during 
the period 2005-2009. The overall gender-specific rates show an approximate 2:1 
ratio of males versus females. No incident cases of IPF were observed for those 
under the age of 20 years, and the highest age-specific rates can be found in those 
aged 70-79. Table 4.2.1.1 below shows overall and age-/gender-specific 5-year 
incidence rates with 95% confidence limits. 
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Table 4.2.1.1 IPF: 5-yr incidence rates* and 95% confidence limits, stratified by age 
band and gender 



















30-39 Male 0.3 0.0 2.5 0.8 0.3 2.4 0.2 0.0 1.7 
 Female 0.3 0.0 2.4 0.3 0.0 1.9 0.2 0.0 1.8 
 Overall 0.3 0.1 1.4 0.5 0.2 1.4 0.2 0.1 1.0 
40-49 Male 1.3 0.5 3.6 1.8 0.8 3.9 0.5 0.1 2.2 
 Female 0.3 0.0 2.0 1.4 0.6 3.3 0.8 0.3 2.5 
 Overall 0.8 0.3 1.8 1.6 0.9 2.8 0.7 0.3 1.6 
50-59 Male 6.6 4.4 10.1 6.2 4.2 9.2 3.9 2.3 6.5 
 Female 2.9 1.6 5.1 3.2 1.9 5.3 1.0 0.4 2.6 
 Overall 4.6 3.3 6.4 4.6 3.4 6.3 2.4 1.5 3.7 
60-69 Male 19.3 15.2 24.6 20.9 17.2 25.6 11.1 8.5 14.7 
 Female 6.9 4.8 9.9 8.2 6.1 11.0 3.9 2.5 6.0 
 Overall 12.5 10.2 15.2 14.1 11.9 16.6 7.3 5.8 9.2 
70-79 Male 31.1 25.6 37.7 28.4 24.0 33.7 17.0 13.8 20.9 
 Female 12.2 9.2 16.2 15.4 12.4 19.2 6.8 5.0 9.4 
 Overall 20.8 17.7 24.4 21.5 18.8 24.6 11.7 9.8 13.9 
80-89 Male 10.6 7.7 14.7 21.3 17.3 26.1 12.1 9.4 15.6 
 Female 8.6 6.2 12.0 11.2 8.6 14.7 7.6 5.6 10.3 
 Overall 9.5 7.6 12.0 16.0 13.6 18.8 9.8 8.1 11.9 
90+ Male 1.1 0.4 3.0 1.3 0.6 3.0 0.4 0.1 1.8 
 Female 1.2 0.5 2.9 1.6 0.8 3.2 1.0 0.4 2.5 
 Overall 1.2 0.6 2.3 1.5 0.9 2.5 0.7 0.4 1.6 
OVERALL MALE 4.9 4.3 5.6 5.8 5.3 6.5 3.4 3.0 3.8 
 FEMALE 2.4 2.0 2.8 3.0 2.6 3.5 1.6 1.3 1.9 
 ---------- 3.5 3.2 3.9 4.3 4.0 4.7 2.4 2.2 2.7 
L=Lower, U=Upper, CL=Confidence Limit 
* All prevalence estimates and 95% CLs are per 100’000 inhabitants. 
 
4.2.2 Granulomatous ILD 
4.2.2.1 Sarcoidosis 
The overall 5-year incidence of sarcoidosis increased from the period 1995-1999 to 
2000-2004 (0.6 to 1.0 per 100'000 person-years, respectively) and thereafter 
remained stable from 2000-2004 to 2005-2009. No incident cases were observed in 
those younger than 20 years or those aged 90 years and older. In all three periods, 
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the highest overall age-specific incidence rates were found in those aged 40-49, with 
a greater than two-fold increase in this age band between the periods 1995-1999 to 
2000-2004 (2.6 to 6.1 per 100'000 person-years, respectively). Table 4.2.2.1 below 
shows overall and age-/gender-specific 5-year incidence rates with 95% confidence 
limits. 
Table 4.2.2.1 Sarcoidosis: 5-yr incidence rates* and 95% confidence limits, 
stratified by age band and gender 



















20 - 29 Male 0.6 0.2 2.5 0.7 0.2 2.1 0.4 0.1 1.7 
 Female 0.3 0.0 2.2 0.2 0.0 1.7 0.2 0.0 1.6 
 Overall 0.5 0.2 1.4 0.5 0.2 1.2 0.3 0.1 1.0 
30 - 39 Male 2.8 1.4 5.6 2.3 1.2 4.5 3.4 2.0 5.7 
 Female 0.7 0.2 2.8 2.6 1.4 4.9 2.2 1.2 4.3 
 Overall 1.7 0.9 3.2 2.5 1.6 3.9 2.8 1.9 4.2 
40 - 49 Male 4.7 2.8 7.9 7.6 5.2 11.2 7.1 4.9 10.5 
 Female 0.9 0.3 2.7 4.7 2.9 7.5 2.9 1.6 5.3 
 Overall 2.6 1.6 4.2 6.1 4.5 8.3 5.0 3.6 6.9 
50 - 59 Male 1.5 0.6 3.6 2.7 1.5 4.9 5.2 3.3 8.2 
 Female 2.7 1.5 4.8 3.2 1.9 5.3 4.2 2.6 6.8 
 Overall 2.1 1.3 3.5 3.0 2.0 4.4 4.7 3.4 6.5 
60 - 69 Male 1.8 0.8 3.9 1.9 1.0 3.7 2.0 1.0 3.8 
 Female 1.4 0.6 3.2 3.3 2.1 5.3 2.7 1.6 4.6 
 Overall 1.6 0.9 2.8 2.7 1.8 3.9 2.4 1.6 3.6 
70 - 79 Male 0.0 0.0 0.0 0.4 0.1 1.7 0.8 0.3 2.1 
 Female 0.5 0.1 2.0 2.1 1.2 3.8 0.9 0.4 2.1 
 Overall 0.3 0.1 1.1 1.3 0.8 2.3 0.8 0.4 1.6 
80 - 89 Male 0.3 0.0 2.0 0.2 0.0 1.6 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.6 0.2 1.9 0.4 0.1 1.5 
 Overall 0.1 0.0 0.9 0.4 0.2 1.2 0.2 0.0 0.8 
OVERALL MALE 0.8 0.5 1.0 1.0 0.8 1.3 1.1 0.9 1.4 
 FEMALE 0.4 0.3 0.7 1.1 0.9 1.4 0.8 0.6 1.1 
 ---------- 0.6 0.5 0.8 1.0 0.9 1.2 1.0 0.8 1.2 
L=Lower, U=Upper, CL=Confidence Limit 
* All incidence rates and 95% CLs are per 100’000 person-years. 
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4.2.2.2 Wegener’s Granulomatosis 
Overall 5-year incidence of Wegener’s Granulomatosis remained relatively steady 
across all three time periods (0.7, 0.8, and 0.9 per 100'000 person-years). Overall 
gender-specific rates were roughly equal for males and females in all periods. During 
the period 2000-2009, no incident cases were observed in those younger than 10 
years of age. Generally, the highest age-specific rates were found in those aged 50-
79. Table 4.2.2.2 below shows overall and age-/gender-specific 5-year incidence 
rates with 95% confidence limits. 
Table 4.2.2.2 WG: 5-yr incidence rates* and 95% confidence limits, stratified by age 
band and gender 



















10 - 19 Male 0.3 0.0 2.0 0.4 0.1 1.8 0.0 0.0 0.0 
 Female 0.3 0.0 2.1 0.2 0.0 1.6 0.7 0.2 2.2 
 Overall 0.3 0.1 1.2 0.3 0.1 1.0 0.3 0.1 1.1 
20 - 29 Male 0.0 0.0 0.0 0.5 0.1 1.8 0.4 0.1 1.7 
 Female 1.3 0.5 3.4 0.5 0.1 1.9 0.2 0.0 1.6 
 Overall 0.6 0.2 1.7 0.5 0.2 1.2 0.3 0.1 1.0 
30 - 39 Male 0.0 0.0 0.0 1.3 0.5 3.1 0.5 0.1 1.9 
 Female 0.7 0.2 2.8 1.3 0.5 3.2 0.7 0.2 2.3 
 Overall 0.3 0.1 1.4 1.3 0.7 2.4 0.6 0.3 1.5 
40 - 49 Male 0.7 0.2 2.7 1.2 0.4 3.1 1.9 0.9 4.0 
 Female 0.9 0.3 2.7 1.4 0.6 3.3 2.4 1.3 4.6 
 Overall 0.8 0.3 1.8 1.3 0.7 2.5 2.2 1.3 3.5 
50 - 59 Male 2.1 1.0 4.4 3.5 2.1 5.8 4.7 2.9 7.6 
 Female 1.2 0.5 2.9 3.6 2.3 5.9 4.2 2.6 6.8 
 Overall 1.6 0.9 2.8 3.6 2.5 5.1 4.4 3.2 6.2 
60 - 69 Male 2.3 1.2 4.7 3.0 1.8 5.1 3.5 2.1 5.7 
 Female 2.6 1.4 4.7 0.9 0.4 2.2 3.1 1.9 5.1 
 Overall 2.5 1.6 3.9 1.9 1.2 3.0 3.3 2.3 4.7 
70 - 79 Male 3.3 1.9 6.0 2.2 1.2 4.0 1.0 0.4 2.3 
 Female 3.3 1.9 5.7 2.7 1.6 4.5 1.6 0.8 3.0 
 Overall 3.3 2.2 5.0 2.4 1.6 3.6 1.3 0.8 2.2 
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80 - 89 Male 0.6 0.1 2.3 0.9 0.3 2.5 1.2 0.5 2.7 
 Female 0.2 0.0 1.7 0.8 0.3 2.2 1.3 0.6 2.7 
 Overall 0.4 0.1 1.2 0.9 0.4 1.8 1.2 0.7 2.1 
90+ Male 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.6 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.8 
OVERALL MALE 0.6 0.5 0.9 0.9 0.7 1.2 0.9 0.7 1.1 
 FEMALE 0.7 0.5 1.0 0.8 0.6 1.0 0.9 0.7 1.2 
 ---------- 0.7 0.5 0.9 0.8 0.7 1.0 0.9 0.7 1.1 
L=Lower, U=Upper, CL=Confidence Limit;* All incidence rates and 95% CLs are per 100’000 person-years. 
 
4.2.3 ILD of known cause or associated with other diseases 
4.2.3.1 Extrinsic Allergic Alveolitis (EAA) 
Overall 5-year incidence of EAA remained relatively stable across all three time 
periods (1.3, 1.3, and 1.1 per 100'000 person-years). Overall gender-specific rates 
were roughly equal for males and females in all periods. During all periods, no 
incident cases were observed in those younger than 10 years of age.  Generally, the 
highest age-specific rates were found in those aged 50-79. Table 4.2.3.1 below 
shows overall and age-/gender-specific 5-year incidence rates with 95% confidence 
limits. 
 
Table 4.2.3.1 EAA: 5-year incidence rates* and 95% confidence limits, stratified by 
age band and gender 



















10 - 19 Male 0.3 0.0 2.0 0.7 0.2 2.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.5 0.1 1.8 0.0 0.0 0.0 
 Overall 0.1 0.0 1.0 0.6 0.2 1.3 0.0 0.0 0.0 
20 - 29 Male 0.3 0.0 2.2 0.5 0.1 1.8 0.2 0.0 1.5 
 Female 0.3 0.0 2.2 0.7 0.2 2.2 0.2 0.0 1.6 
 Overall 0.3 0.1 1.2 0.6 0.2 1.4 0.2 0.1 0.9 
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30 - 39 Male 3.1 1.6 6.0 1.3 0.5 3.1 0.7 0.2 2.2 
 Female 2.1 0.9 4.6 1.3 0.5 3.2 0.5 0.1 2.0 
 Overall 2.6 1.6 4.3 1.3 0.7 2.4 0.6 0.3 1.5 
40 - 49 Male 5.0 3.0 8.3 1.8 0.8 3.9 3.0 1.7 5.5 
 Female 2.6 1.3 4.9 1.1 0.4 2.9 2.9 1.6 5.3 
 Overall 3.7 2.5 5.5 1.4 0.8 2.6 3.0 2.0 4.5 
50 - 59 Male 5.4 3.4 8.6 4.0 2.4 6.5 4.4 2.7 7.2 
 Female 3.4 2.0 5.7 6.6 4.7 9.4 6.7 4.6 9.8 
 Overall 4.3 3.0 6.1 5.4 4.1 7.2 5.6 4.2 7.6 
60 - 69 Male 4.7 2.9 7.6 6.3 4.4 9.0 3.3 2.0 5.4 
 Female 3.8 2.3 6.2 5.6 3.9 8.0 4.7 3.1 7.0 
 Overall 4.2 3.0 5.9 5.9 4.6 7.6 4.0 2.9 5.5 
70 - 79 Male 4.3 2.5 7.2 3.9 2.4 6.2 4.1 2.6 6.2 
 Female 2.5 1.4 4.7 2.3 1.3 4.0 1.8 0.9 3.3 
 Overall 3.3 2.2 5.0 3.0 2.1 4.3 2.8 2.0 4.1 
80 - 89 Male 0.9 0.3 2.7 0.7 0.2 2.1 1.2 0.5 2.7 
 Female 1.5 0.7 3.3 1.0 0.4 2.5 0.6 0.2 1.7 
 Overall 1.2 0.6 2.3 0.9 0.4 1.8 0.9 0.4 1.7 
90+ Male 0.3 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.2 0.0 1.4 0.0 0.0 0.0 
 Overall 0.1 0.0 0.9 0.1 0.0 0.8 0.0 0.0 0.0 
OVERALL MALE 1.6 1.3 2.0 1.3 1.1 1.6 1.1 0.9 1.4 
 FEMALE 1.1 0.9 1.4 1.3 1.1 1.7 1.1 0.9 1.4 
 ---------- 1.3 1.1 1.6 1.3 1.2 1.6 1.1 0.9 1.3 
L=Lower, U=Upper, CL=Confidence Limit 
* All incidence rates and 95% CLs are per 100’000 person-years. 
 
4.2.3.2 Pneumoconioses 
Overall 5-year incidence of the Pneumoconioses increased approximately two-fold 
from the period 1995-1999 to 2000-2004 (3.7 to 7.2 per 100'000 person-years, 
respectively). For all three periods, overall gender-specific rates were roughly 10-20 
times higher in males than in females. Incident cases were found in all age bands, 
with the highest age-specific rates observed in those aged 50-79. Table 4.2.3.2 
below shows overall and age-/gender-specific 5-year incidence rates with 95% 
confidence limits. 
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Table 4.2.3.2 Pneumoconioses: 5-year incidence rates* and 95% confidence limits, 
stratified by age band and gender 



















<10 Male 0.0 0.0 0.0 0.6 0.2 1.9 0.4 0.1 1.7 
 Female 0.5 0.1 1.9 0.2 0.0 1.5 0.0 0.0 0.0 
 Overall 0.2 0.1 0.9 0.4 0.2 1.1 0.2 0.1 0.9 
10 - 19 Male 0.3 0.0 2.0 0.7 0.2 2.0 0.5 0.1 1.8 
 Female 0.3 0.0 2.1 0.7 0.2 2.1 0.0 0.0 0.0 
 Overall 0.3 0.1 1.2 0.7 0.3 1.5 0.2 0.1 0.9 
20 - 29 Male 1.2 0.5 3.3 2.5 1.4 4.5 1.7 0.8 3.4 
 Female 0.0 0.0 0.0 0.2 0.0 1.7 1.1 0.5 2.6 
 Overall 0.6 0.2 1.7 1.4 0.8 2.4 1.4 0.8 2.4 
30 - 39 Male 1.0 0.3 3.2 2.1 1.0 4.2 2.7 1.5 4.8 
 Female 1.0 0.3 3.2 1.3 0.5 3.2 2.5 1.3 4.6 
 Overall 1.0 0.5 2.3 1.7 1.0 2.9 2.6 1.7 3.9 
40 - 49 Male 3.3 1.8 6.2 6.8 4.5 10.2 3.8 2.3 6.5 
 Female 0.3 0.0 2.0 1.9 0.9 4.1 1.9 0.9 3.9 
 Overall 1.7 0.9 3.1 4.3 3.0 6.1 2.8 1.9 4.4 
50 - 59 Male 16.0 12.2 21.0 28.5 23.7 34.2 22.6 18.2 28.1 
 Female 1.0 0.4 2.6 2.4 1.3 4.3 5.0 3.2 7.7 
 Overall 7.6 5.9 9.9 14.5 12.1 17.2 13.3 11.0 16.2 
60 - 69 Male 39.5 33.4 46.8 61.1 54.4 68.7 71.6 64.3 79.8 
 Female 1.2 0.5 2.9 4.3 2.8 6.4 4.9 3.3 7.2 
 Overall 18.4 15.5 21.7 30.6 27.3 34.2 36.3 32.7 40.3 
70 - 79 Male 38.1 31.9 45.4 62.5 55.7 70.1 67.7 61.0 75.2 
 Female 1.3 0.5 3.1 4.0 2.6 6.1 4.6 3.1 6.7 
 Overall 18.0 15.2 21.4 31.4 28.1 35.1 34.7 31.3 38.3 
80 - 89 Male 7.5 5.1 11.0 26.1 21.7 31.4 35.6 30.7 41.2 
 Female 1.0 0.4 2.6 2.9 1.7 4.9 3.5 2.3 5.5 
 Overall 4.0 2.8 5.7 13.9 11.7 16.5 19.0 16.5 21.9 
90+ Male 0.3 0.0 2.0 0.4 0.1 1.8 1.1 0.5 2.6 
 Female 0.0 0.0 0.0 0.2 0.0 1.4 0.6 0.2 1.9 
 Overall 0.1 0.0 0.9 0.3 0.1 1.0 0.9 0.4 1.7 
OVERALL MALE 7.5 6.7 8.3 13.8 12.9 14.7 15.1 14.2 16.1 
 FEMALE 0.4 0.3 0.7 1.3 1.0 1.6 1.6 1.4 2.0 
 ---------- 3.7 3.3 4.1 7.2 6.7 7.6 8.1 7.6 8.6 
L=Lower, U=Upper, CL=Confidence Limit 
* All incidence rates and 95% CLs are per 100’000 person-years. 
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4.2.3.3 Drug-/radiation-induced ILD (DRAD-ILD) 
The overall 5-year incidence of drug/radiation-induced ILD increased steadily from 
the period 1995-1999 to 2005-2009 (0.2 to 0.5 per 100'000 person-years, 
respectively). In all periods, overall gender-specific rates were roughly equal in males 
and females. No incident cases were observed in those younger than 20 years or 
those aged 90 years and older. In all three periods, the highest overall age-specific 
incidence rates were found in those aged 60-79. Table 4.2.3.3 below shows overall 
and age-/gender-specific 5-year incidence rates with 95% confidence limits. 
Table 4.2.3.3 DRAD- ILD: 5-year incidence rates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.3 0.0 1.8 0.0 0.0 0.0 
 Female 0.7 0.2 2.8 0.0 0.0 0.0 0.5 0.1 2.0 
 Overall 0.3 0.1 1.4 0.1 0.0 0.9 0.2 0.1 1.0 
40 - 49 Male 0.3 0.0 2.4 0.0 0.0 0.0 0.5 0.1 2.2 
 Female 0.3 0.0 2.0 0.8 0.3 2.6 0.0 0.0 0.0 
 Overall 0.3 0.1 1.2 0.4 0.1 1.3 0.3 0.1 1.1 
50 - 59 Male 0.3 0.0 2.1 0.2 0.0 1.8 1.4 0.6 3.3 
 Female 1.0 0.4 2.6 0.4 0.1 1.7 1.5 0.7 3.3 
 Overall 0.7 0.3 1.6 0.3 0.1 1.1 1.4 0.8 2.6 
60 - 69 Male 1.2 0.4 3.1 2.4 1.3 4.3 1.5 0.7 3.2 
 Female 0.9 0.4 2.5 1.3 0.6 2.7 2.9 1.8 4.8 
 Overall 1.0 0.5 2.1 1.8 1.1 2.9 2.3 1.5 3.4 
70 - 79 Male 0.3 0.0 2.2 2.6 1.5 4.6 1.5 0.8 3.1 
 Female 1.5 0.7 3.4 1.9 1.0 3.5 1.4 0.7 2.8 
 Overall 1.0 0.5 2.0 2.2 1.5 3.4 1.5 0.9 2.4 
80 - 89 Male 0.6 0.1 2.3 0.9 0.3 2.5 0.8 0.3 2.1 
 Female 0.0 0.0 0.0 1.0 0.4 2.5 0.9 0.4 2.2 
 Overall 0.3 0.1 1.1 1.0 0.5 1.9 0.9 0.4 1.7 
OVERALL MALE 0.2 0.1 0.4 0.5 0.3 0.7 0.4 0.3 0.6 
 FEMALE 0.3 0.2 0.5 0.4 0.3 0.6 0.5 0.4 0.7 
 ---------- 0.2 0.2 0.4 0.4 0.3 0.6 0.5 0.4 0.6 
L=Lower, U=Upper, CL=Confidence Limit 
* All incidence rates and 95% CLs are per 100’000 person-years. 
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4.2.3.4 ILD associated with other diseases (ILD-ODIS) 
The overall 5-year incidence of ILD associated with other diseases decreased four-
fold from the period 1995-1999 to 2005-2009 (2.8 to 0.7 per 100'000 person-years, 
respectively). Except in the period 1995-1999, overall gender-specific rates were 
roughly equal in males and females. No incident cases were observed in those 
younger than 10 of age and the highest overall age-specific incidence rates were 
found in those aged 50-79. Table 4.2.3.4 below shows overall and age-/gender-
specific 5-year incidence rates with 95% confidence limits. 
Table 4.2.3.4 ILD-ODIS: 5-year incidence rates* and 95% confidence limits, stratified 
by age band and gender 



















20 - 29 Male 0.3 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.3 0.0 2.2 0.5 0.1 1.9 0.0 0.0 0.0 
 Overall 0.3 0.1 1.2 0.2 0.1 0.9 0.0 0.0 0.0 
30 - 39 Male 0.3 0.0 2.5 0.3 0.0 1.8 0.0 0.0 0.0 
 Female 0.7 0.2 2.8 2.1 1.1 4.2 0.2 0.0 1.8 
 Overall 0.5 0.2 1.6 1.2 0.6 2.3 0.1 0.0 0.9 
40 - 49 Male 0.7 0.2 2.7 0.6 0.1 2.4 0.5 0.1 2.2 
 Female 2.3 1.1 4.6 2.2 1.1 4.4 0.8 0.3 2.5 
 Overall 1.5 0.8 2.9 1.4 0.8 2.6 0.7 0.3 1.6 
50 - 59 Male 6.0 3.9 9.4 2.0 1.0 4.0 1.9 0.9 4.1 
 Female 6.3 4.3 9.2 3.2 1.9 5.3 1.2 0.5 3.0 
 Overall 6.2 4.6 8.2 2.6 1.8 4.0 1.6 0.9 2.8 
60 - 69 Male 12.0 8.8 16.3 5.4 3.6 8.0 3.1 1.8 5.2 
 Female 8.1 5.8 11.3 3.7 2.4 5.8 2.1 1.2 3.9 
 Overall 9.8 7.8 12.3 4.5 3.4 6.0 2.6 1.7 3.8 
70 - 79 Male 19.2 15.0 24.6 7.1 5.1 10.0 2.9 1.7 4.8 
 Female 11.7 8.8 15.6 4.6 3.1 6.8 3.0 1.9 4.8 
 Overall 15.1 12.5 18.2 5.8 4.4 7.5 2.9 2.1 4.2 
80 - 89 Male 5.7 3.7 8.9 1.4 0.6 3.1 2.6 1.5 4.4 
 Female 5.4 3.6 8.2 2.7 1.6 4.7 2.0 1.1 3.7 
 Overall 5.6 4.1 7.5 2.1 1.3 3.3 2.3 1.5 3.4 
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90+ Male 0.6 0.1 2.3 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 1.2 0.5 2.9 0.0 0.0 0.0 0.2 0.0 1.5 
 Overall 0.9 0.4 1.9 0.0 0.0 0.0 0.1 0.0 0.8 
OVERALL MALE 3.1 2.7 3.7 1.2 1.0 1.5 0.8 0.6 1.0 
 FEMALE 2.6 2.2 3.0 1.3 1.1 1.6 0.7 0.5 0.9 
 ---------- 2.8 2.5 3.2 1.3 1.1 1.5 0.7 0.6 0.9 
L=Lower, U=Upper, CL=Confidence Limit 
* All incidence rates and 95% CLs are per 100’000 person-years. 
 
4.3 All-cause mortality 
4.3.1 Idiopathic Interstitial Pneumonia (IIP) 
4.3.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
Overall 5-year all-cause mortality in IPF patients increased more than two-fold from 
the period 1995-1999 to 2000-2004 (0.9 to 2.3 per 100'000 inhabitants). Overall 
gender-specific rates showed all-cause mortality to be more than twice as high in 
males as in females. No deaths were observed in those under the age of 30 years, 
and the highest overall age-specific rates were found in those 70-79 years of age. 
Table 4.3.1.1 below shows overall and age-/gender-specific 5-year mortality rates 
with 95% confidence limits. 
Table 4.3.1.1 IPF: 5-year all-cause mortality rates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 
40 - 49 Male 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 1.9 
 Female 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.1 0.0 0.4 0.5 0.0 0.9 
50 - 59 Male 0.8 0.0 1.7 2.0 0.7 3.4 2.9 1.3 4.6 
 Female 0.2 0.0 0.7 0.8 0.0 1.6 0.6 0.0 1.4 
 Overall 0.5 0.0 1.0 1.4 0.6 2.1 1.7 0.8 2.6 
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60 - 69 Male 2.1 0.7 3.6 11.5 8.5 14.4 12.6 9.6 15.7 
 Female 1.5 0.4 2.7 3.0 1.6 4.4 3.3 1.8 4.8 
 Overall 1.8 0.9 2.7 6.9 5.3 8.5 7.7 6.1 9.4 
70 - 79 Male 9.6 6.4 12.9 18.7 14.9 22.5 16.0 12.7 19.3 
 Female 3.1 1.4 4.8 7.8 5.5 10.1 6.1 4.1 8.0 
 Overall 6.1 4.4 7.9 13.0 10.8 15.1 10.8 9.0 12.7 
80 - 89 Male 5.4 3.0 7.7 12.6 9.3 15.8 9.6 7.0 12.1 
 Female 4.0 2.1 5.8 6.6 4.3 8.8 5.3 3.4 7.1 
 Overall 4.6 3.1 6.1 9.4 7.5 11.4 7.4 5.8 8.9 
90+ Male 0.5 0.0 1.3 1.1 0.1 2.0 0.2 0.0 0.6 
 Female 0.2 0.0 0.7 1.2 0.2 2.1 1.1 0.2 2.1 
 Overall 0.4 0.0 0.8 1.1 0.5 1.8 0.7 0.2 1.2 
OVERALL MALE 1.3 1.0 1.6 3.4 2.9 3.8 3.2 2.8 3.6 
 FEMALE 0.6 0.4 0.8 1.4 1.1 1.7 1.2 1.0 1.5 
 ---------- 0.9 0.8 1.1 2.3 2.1 2.6 2.2 1.9 2.4 
L=Lower, U=Upper, CL=Confidence Limit; * All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
4.3.2 Granulomatous ILD 
4.3.2.1 Sarcoidosis 
Overall 5-year all-cause mortality in sarcoidosis patients was estimated at 0.1 per 
100’000 inhabitants during the periods 2000-2004 and 2005-2009. No deaths were 
observed in those below 30 years or above 90 years of age.  Table 4.3.2.1 below 
shows overall and age- /gender-specific 5-year mortality rates with 95% confidence 
limits. 
Table 4.3.2.1 Sarcoidosis: 5-year all-cause mortality rates* and 95% confidence 
limits, stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 
40 - 49 Male 0.0 0.0 0.0 0.5 0.0 1.3 0.5 0.0 1.2 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.1 
 Overall 0.0 0.0 0.0 0.3 0.0 0.6 0.5 0.0 0.9 
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50 - 59 Male 0.3 0.0 0.8 0.2 0.0 0.7 0.2 0.0 0.7 
 Female 0.0 0.0 0.0 0.2 0.0 0.6 0.4 0.0 1.0 
 Overall 0.1 0.0 0.4 0.2 0.0 0.5 0.3 0.0 0.7 
60 - 69 Male 0.0 0.0 0.0 0.2 0.0 0.6 1.0 0.1 1.8 
 Female 0.0 0.0 0.0 0.2 0.0 0.5 0.5 0.0 1.1 
 Overall 0.0 0.0 0.0 0.2 0.0 0.4 0.7 0.2 1.2 
70 - 79 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 1.1 
 Female 0.0 0.0 0.0 0.4 0.0 0.9 0.3 0.0 0.8 
 Overall 0.0 0.0 0.0 0.2 0.0 0.5 0.4 0.1 0.8 
80 - 89 Male 0.0 0.0 0.0 0.4 0.0 1.1 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.5 
 Overall 0.0 0.0 0.0 0.2 0.0 0.5 0.1 0.0 0.3 
OVERALL MALE 0.0 0.0 0.1 0.1 0.0 0.2 0.2 0.1 0.3 
 FEMALE 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.2 
 ---------- 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.2 
L=Lower, U=Upper, CL=Confidence Limit 
* All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
4.3.2.2 Wegener’s Granulomatosis (WG) 
Overall 5-year all-cause mortality in WG patients remained relatively stable across all 
three time periods (0.1, 0.2, and 0.2 per 100’000 inhabitants). Generally, mortality in 
males was more frequent than in females and the highest overall age-specific rates 
were observed in those 70-79 years of age. Table 4.3.2.2 below shows overall and 
age-/gender-specific 5-year mortality rates with 95% confidence limits. 
Table 4.3.2.2 WG: 5-year all-cause mortality rates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.7 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 
40 - 49 Male 0.0 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.3 0.0 0.6 0.0 0.0 0.0 
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50 - 59 Male 0.0 0.0 0.0 0.7 0.0 1.5 1.2 0.1 2.3 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.3 0.0 0.7 0.6 0.1 1.1 
60 - 69 Male 0.3 0.0 0.8 1.4 0.4 2.4 0.2 0.0 0.6 
 Female 0.2 0.0 0.7 0.7 0.0 1.4 0.2 0.0 0.5 
 Overall 0.2 0.0 0.6 1.0 0.4 1.6 0.2 0.0 0.4 
70 - 79 Male 0.8 0.0 1.8 1.2 0.2 2.2 1.2 0.3 2.1 
 Female 0.7 0.0 1.5 0.9 0.1 1.7 1.3 0.4 2.2 
 Overall 0.8 0.2 1.4 1.1 0.4 1.7 1.3 0.6 1.9 
80 - 89 Male 0.3 0.0 0.8 0.2 0.0 0.7 1.1 0.2 1.9 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.8 
 Overall 0.1 0.0 0.4 0.1 0.0 0.3 0.7 0.2 1.2 
90+ Male 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 
OVERALL MALE 0.1 0.0 0.2 0.3 0.1 0.4 0.3 0.2 0.4 
 FEMALE 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.2 
 ---------- 0.1 0.0 0.1 0.2 0.1 0.3 0.2 0.1 0.3 
L=Lower, U=Upper, CL=Confidence Limit 
* All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
4.3.3 ILD of known cause or associated with other diseases 
4.3.3.1 Extrinsic Allergic Alveolitis (EAA) 
Overall 5-year all-cause mortality in EAA patients increased three-fold from the 
period 1995-1999 to 2000-2004 (0.1 to 0.3 per 100’000 inhabitants, respectively). No 
deaths were observed in those under 30 years of age, and the highest age-specific 
rates were found in those 60-79 year of age. Generally, in all age bands and across 
all time periods, mortality rates were higher in males than in females. Table 4.3.3.1 
below shows overall and age- /gender-specific 5-year mortality rates with 95% 
confidence limits. 
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Table 4.3.3.1 EAA: 5-year all-cause mortality rates* and 95% confidence limits, 
stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 
 Female 0.3 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.2 0.0 0.5 0.1 0.0 0.4 0.0 0.0 0.0 
40 - 49 Male 0.0 0.0 0.0 0.5 0.0 1.3 0.2 0.0 0.7 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.3 0.0 0.6 0.1 0.0 0.4 
50 - 59 Male 0.5 0.0 1.3 0.5 0.0 1.1 1.0 0.0 1.9 
 Female 0.0 0.0 0.0 0.4 0.0 0.9 0.4 0.0 1.0 
 Overall 0.2 0.0 0.6 0.4 0.0 0.8 0.7 0.1 1.2 
60 - 69 Male 0.3 0.0 0.8 1.2 0.2 2.2 1.7 0.6 2.9 
 Female 0.2 0.0 0.7 0.9 0.1 1.6 1.2 0.3 2.1 
 Overall 0.2 0.0 0.6 1.0 0.4 1.6 1.5 0.7 2.2 
70 - 79 Male 1.1 0.0 2.2 1.4 0.4 2.5 2.1 0.9 3.3 
 Female 0.2 0.0 0.7 0.7 0.0 1.4 0.3 0.0 0.8 
 Overall 0.6 0.1 1.2 1.1 0.4 1.7 1.2 0.6 1.8 
80 - 89 Male 0.3 0.0 0.8 0.7 0.0 1.4 0.4 0.0 0.9 
 Female 0.0 0.0 0.0 1.0 0.1 1.9 0.2 0.0 0.5 
 Overall 0.1 0.0 0.4 0.8 0.3 1.4 0.3 0.0 0.6 
90+ Male 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.6 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.3 
OVERALL MALE 0.2 0.0 0.3 0.3 0.2 0.5 0.4 0.2 0.5 
 FEMALE 0.0 0.0 0.1 0.2 0.1 0.3 0.2 0.1 0.3 
 ---------- 0.1 0.0 0.2 0.3 0.2 0.4 0.3 0.2 0.4 
L=Lower, U=Upper, CL=Confidence Limit 
* All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
4.3.3.2 Pneumoconioses 
Overall 5-year all-cause mortality of the Pneumoconioses increased more than five-
fold from the period 1995-1999 to 2004-2009 (0.4 to 2.2 per 100’000 inhabitants, 
respectively).  No deaths were observed in those below age 30, and the highest 
overall age-specific rates were found among those 70-79 years of age. In all age 
bands and across all time periods, rates were much higher in males than in females. 
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Table 4.3.3.2 below shows overall and age-/gender-specific 5-year mortality rates 
with 95% confidence limits. 
Table 4.3.3.2 Pneumoconioses: 5-year all-cause mortality rates* and 95% 
confidence limits, stratified by age band and gender 



















20 - 29 Male 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 
30 - 39 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
40 - 49 Male 0.0 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.0 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.1 0.0 0.4 0.0 0.0 0.0 
50 - 59 Male 0.8 0.0 1.7 1.8 0.6 3.1 2.4 0.9 3.9 
 Female 0.0 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.0 
 Overall 0.4 0.0 0.8 0.9 0.3 1.6 1.1 0.4 1.9 
60 - 69 Male 2.1 0.7 3.6 8.6 6.1 11.2 13.6 10.4 16.8 
 Female 0.0 0.0 0.0 0.5 0.0 1.1 0.7 0.0 1.4 
 Overall 1.0 0.3 1.6 4.3 3.1 5.5 6.8 5.2 8.3 
70 - 79 Male 6.2 3.6 8.8 14.4 11.1 17.8 24.0 20.0 28.0 
 Female 0.0 0.0 0.0 0.5 0.0 1.2 1.0 0.2 1.7 
 Overall 2.9 1.7 4.1 7.1 5.5 8.7 12.0 10.0 14.0 
80 - 89 Male 1.6 0.3 2.9 9.7 6.8 12.6 14.3 11.1 17.4 
 Female 0.5 0.0 1.1 0.6 0.0 1.3 2.0 0.9 3.2 
 Overall 1.0 0.3 1.7 4.9 3.5 6.3 8.0 6.3 9.6 
90+ Male 0.0 0.0 0.0 0.4 0.0 1.0 0.6 0.0 1.3 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.9 
 Overall 0.0 0.0 0.0 0.2 0.0 0.5 0.5 0.1 0.9 
OVERALL MALE 0.8 0.5 1.0 2.6 2.2 3.0 4.2 3.7 4.6 
 FEMALE 0.0 0.0 0.1 0.1 0.1 0.2 0.3 0.2 0.4 
 ---------- 0.4 0.3 0.5 1.3 1.1 1.5 2.2 1.9 2.4 
L=Lower, U=Upper, CL=Confidence Limit; * All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
4.3.3.3 Drug-/radiation-induced ILD (DRAD-ILD) 
Overall 5-year all-cause mortality in drug-/radiation-induced ILD patients increased 
three-fold from the period 1995-1999 to 2000-2004 (0.1 to 0.3 per 100’000 
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inhabitants, respectively). No deaths were observed in those under 30 years of age, 
and the highest age-specific rates were found in those 60-89 years of age. Across all 
time periods mortality rates in the age group 60-79 were generally higher in males 
than in females. Table 4.3.3.3 below shows overall and age-/gender-specific 5-year 
mortality rates with 95% confidence limits. 
Table 4.3.3.3 DRAD-ILD: 5-year all-cause mortality rates* and 95% confidence 
limits, stratified by age band and gender 



















30 - 39 Male 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 
 Female 0.3 0.0 0.9 0.0 0.0 0.0 0.2 0.0 0.7 
 Overall 0.2 0.0 0.5 0.1 0.0 0.4 0.1 0.0 0.3 
40 - 49 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.7 
 Female 0.0 0.0 0.0 0.2 0.0 0.7 0.0 0.0 0.0 
 Overall 0.0 0.0 0.0 0.1 0.0 0.4 0.1 0.0 0.4 
50 - 59 Male 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 1.5 
 Female 0.4 0.0 1.1 0.2 0.0 0.6 0.0 0.0 0.0 
 Overall 0.2 0.0 0.6 0.1 0.0 0.3 0.3 0.0 0.7 
60 - 69 Male 0.5 0.0 1.3 0.6 0.0 1.3 1.9 0.7 3.1 
 Female 0.2 0.0 0.7 0.3 0.0 0.8 1.2 0.3 2.1 
 Overall 0.4 0.0 0.8 0.5 0.1 0.9 1.6 0.8 2.3 
70 - 79 Male 0.0 0.0 0.0 1.0 0.1 1.9 1.0 0.2 1.9 
 Female 0.2 0.0 0.7 0.4 0.0 0.9 0.5 0.0 1.0 
 Overall 0.1 0.0 0.4 0.7 0.2 1.2 0.8 0.3 1.2 
80 - 89 Male 0.3 0.0 0.8 0.4 0.0 1.1 0.5 0.0 1.2 
 Female 0.0 0.0 0.0 0.6 0.0 1.3 1.0 0.2 1.8 
 Overall 0.1 0.0 0.4 0.5 0.1 1.0 0.8 0.3 1.3 
OVERALL MALE 0.1 0.0 0.1 0.2 0.1 0.3 0.3 0.2 0.4 
 FEMALE 0.1 0.0 0.2 0.1 0.0 0.2 0.2 0.1 0.3 
 ---------- 0.1 0.0 0.1 0.1 0.1 0.2 0.3 0.2 0.3 
L=Lower, U=Upper, CL=Confidence Limit 
* All mortality rates and 95% CLs are per 100’000 inhabitants. 
 
University of Basel  Page 57 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
4.3.3.4 ILD associated with other diseases (ILD-ODIS) 
Overall 5-year all-cause mortality in patients with ILD associated with other diseases 
remained relatively stable across all three time periods (0.7, 0.7, and 0.6 per 100’000 
inhabitants). Generally, mortality in males was more frequent than in females and the 
highest overall age-specific rates were observed in those 70-89 years of age. No 
deaths were observed in patients under 40 years of age. Table 4.3.3.4 below shows 
overall and age-/gender-specific 5-year mortality rates with 95% confidence limits. 
Table 4.3.3.4 ILD-ODIS: 5-year all-cause mortality rates* and 95% confidence limits, 
stratified by age band and gender 



















40 - 49 Male 0.0 0.0 0.0 0.5 0.0 1.3 0.2 0.0 0.7 
 Female 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.7 
 Overall 0.0 0.0 0.0 0.3 0.0 0.6 0.2 0.0 0.6 
50 - 59 Male 0.8 0.0 1.7 0.9 0.0 1.8 1.2 0.1 2.3 
 Female 0.4 0.0 1.1 1.0 0.1 1.8 1.3 0.3 2.3 
 Overall 0.6 0.1 1.1 0.9 0.3 1.6 1.3 0.5 2.0 
60 - 69 Male 1.3 0.2 2.5 3.8 2.1 5.5 2.7 1.3 4.1 
 Female 0.9 0.0 1.8 1.9 0.8 3.0 1.7 0.7 2.8 
 Overall 1.1 0.4 1.8 2.8 1.8 3.8 2.2 1.3 3.1 
70 - 79 Male 6.8 4.1 9.5 5.9 3.8 8.0 3.7 2.1 5.2 
 Female 2.9 1.3 4.5 3.3 1.8 4.8 2.4 1.2 3.6 
 Overall 4.7 3.1 6.2 4.5 3.2 5.8 3.0 2.0 4.0 
80 - 89 Male 2.4 0.8 4.0 1.8 0.5 3.0 1.4 0.4 2.4 
 Female 2.6 1.0 4.1 0.8 0.0 1.6 2.2 1.0 3.4 
 Overall 2.5 1.4 3.6 1.3 0.5 2.0 1.8 1.1 2.6 
90+ Male 0.5 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 
 Female 0.9 0.0 1.8 0.0 0.0 0.0 0.2 0.0 0.6 
 Overall 0.7 0.1 1.3 0.0 0.0 0.0 0.1 0.0 0.3 
OVERALL MALE 0.8 0.6 1.1 0.9 0.7 1.2 0.7 0.5 0.9 
 FEMALE 0.5 0.4 0.7 0.5 0.4 0.7 0.6 0.4 0.8 
 ---------- 0.7 0.5 0.8 0.7 0.6 0.9 0.6 0.5 0.8 
L=Lower, U=Upper, CL=Confidence Limit 
* All mortality rates and 95% CLs are per 100’000 inhabitants. 
University of Basel  Page 58 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
4.4 Characteristics of ILD cases and controls 
4.4.1 Idiopathic Interstitial Pneumonia (IIP) 
4.4.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
No direct match for the diagnostic term ‘IPF’ was found in the GPRD. The Read 
Codes used to identify the present IPF study population were ‘Cryptogenic Fibrosing 
Alveolitis,’ Idiopathic Fibrosing Alveolitis,’ and ‘Idiopathic Fibrosing Alveolitis NOS.’ 
which are the diagnostic terms commonly used in the UK over the last 20-30 years. 
The use of these terms for IPF is discussed Section 5.0. Using these diagnostic 
terms, we identified 1269 incident cases of IPF between 1995 and 2009. The mean 
(SD) age was roughly 73 (10.2) years and 816 (64%) were male. The proportion of 
ex-smokers was markedly higher among IPF cases compared to controls (36.2% vs. 
24.3%), and the raised odds ratio for ex-smokers vs. non-smokers was significant at 
the 5% level (OR=1.96, 95%CI:1.6 to 2.4). Higher frequencies of practice visits and 
drug prescriptions prior to index date were statistically significantly associated with a 
diagnosis of IPF.  Further characteristics of IPF cases and their matched controls can 
be found in Table 4.4.1.1 below. 




















Age in years [mean (sd)]  72.86(10.24) 72.85(10.23) ---- ---- ---- 
 Min. 29 29 ---- ---- ---- 
 Max. 95 97 ---- ---- ---- 
 
Gender Males 816 (64.3) 816 (64.3) ---- ---- ---- 
 Females 453 (35.7) 453 (35.7) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 351 (27.7) 364 (28.7) 1.00 ---- ---- 
 14.0 - 18.4 16 (1.3) 15 (1.2) 1.16 0.57 2.37 
 25.0 - 29.9 475 (37.4) 430 (33.9) 1.15 0.95 1.41 
 30.0 - 39.9 207 (16.3) 152 (12.0) 1.42 1.09 1.83 
 40.0 - 55.9 6 (0.5) 12 (0.9) 0.52 0.19 1.41 
 Unknown 214 (16.9) 296 (23.3) 0.68 0.53 0.87 
University of Basel  Page 59 





















Smoking status Non-smkrs (Ref.) 533 (42.0) 627 (49.4) 1.00 ---- ---- 
 Curr-smkrs 195 (15.4) 191 (15.1) 1.23 0.96 1.57 
 Ex-smkrs 459 (36.2) 308 (24.3) 1.96 1.60 2.40 
 Unknown 82 (6.5) 143 (11.3) 0.57 0.41 0.80 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 109 (8.6) 98 (7.7) 1.00 ---- ---- 
 1 - 10 147 (11.6) 119 (9.4) 1.12 0.77 1.64 
 11 - 20 86 (6.8) 63 (5.0) 1.29 0.82 2.03 
 21+ 32 (2.5) 15 (1.2) 1.88 0.95 3.69 
 Unknown 895 (70.5) 974 (76.8) 0.82 0.60 1.11 
 
Last alcohol status prior to index 
date None (Ref.) 191 (15.1) 236 (18.6) 1.00 ---- ---- 
 Current 839 (66.1) 816 (64.3) 1.39 1.08 1.78 
 Never 214 (16.9) 198 (15.6) 1.45 1.08 1.96 
 Ex 25 (2.0) 19 (1.5) 1.85 0.95 3.60 
 
Categories of alcohol units/week (for 
last recording prior to index date) 0 (Ref.) 705 (55.6) 717 (56.5) 1.00 ---- ---- 
 1 - 7 293 (23.1) 297 (23.4) 1.02 0.83 1.25 
 8 - 14 144 (11.3) 125 (9.9) 1.19 0.90 1.56 
 15 - 29 87 (6.9) 82 (6.5) 1.09 0.78 1.54 
 30+ 40 (3.2) 48 (3.8) 0.87 0.56 1.34 
 
Categories of avg. alcohol units/week 
(for all recorded alcohol units 
recorded prior to index date) 0 units/wk (Ref.) 596 (47.0) 635 (50.0) 1.00 ---- ---- 
 0.01 - 7.99 398 (31.4) 383 (30.2) 1.15 0.95 1.40 
 8.00 - 14.99 141 (11.1) 120 (9.5) 1.33 0.99 1.79 
 15.00 - 29.99 100 (7.9) 86 (6.8) 1.27 0.92 1.75 
 30+ 34 (2.7) 45 (3.5) 0.85 0.52 1.38 
 
Categories of Hb1Ac level before 
index date (closest recording prior to 
index date) <6.5 (Ref.) 62 (4.9) 42 (3.3) 1.00 ---- ---- 
 6.5 - 7.4 51 (4.0) 41 (3.2) 0.85 0.47 1.53 
 7.5 - 8.9 30 (2.4) 30 (2.4) 0.68 0.36 1.29 
 >=9.0 17 (1.3) 12 (0.9) 0.95 0.40 2.26 
 Unknown 1109 (87.4) 1144 (90.1) 0.64 0.43 0.97 
 
Categories of average level of Hb1Ac 
before index date <6.5 (Ref.) 52 (4.1) 43 (3.4) 1.00 ---- ---- 
 6.5 - 7.4 39 (3.1) 34 (2.7) 0.93 0.50 1.73 
 7.5 - 8.9 49 (3.9) 37 (2.9) 1.06 0.59 1.92 
 >=9.0 20 (1.6) 11 (0.9) 1.52 0.64 3.62 
 Unknown 1109 (87.4) 1144 (90.1) 0.77 0.50 1.19 
 
Categories of no. of practice visits 
prior to the index date based on 
diagnoses recordings 0 - 29 (Ref.) 306 (24.1) 444 (35.0) 1.00 ---- ---- 
 30 - 58 345 (27.2) 337 (26.6) 2.01 1.57 2.58 
 59 - 104 309 (24.3) 281 (22.1) 2.55 1.92 3.37 
 105+ 309 (24.3) 207 (16.3) 4.31 3.10 5.99 
 
Categories of no. of practice visits 
prior to index date based on 
diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 268 (21.1) 380 (29.9) 1.00 ---- ---- 
 55 - 111 322 (25.4) 332 (26.2) 1.61 1.26 2.04 
 112 - 199 366 (28.8) 309 (24.3) 2.20 1.70 2.85 
 200+ 313 (24.7) 248 (19.5) 2.86 2.09 3.91 
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Categories of no. of practice visits 
based on diagnoses recordings 
(falling on separate dates) during 1 
year prior to index date (index date 
visit excluded) 0 - 4 (Ref.) 193 (15.2) 489 (38.5) 1.00 ---- ---- 
 5 - 10 362 (28.5) 381 (30.0) 3.65 2.76 4.83 
 11 - 18 377 (29.7) 244 (19.2) 6.91 5.09 9.38 
 19+ 337 (26.6) 155 (12.2) 12.08 8.53 17.12 
 
Categories of no. of practice visits 
based on diagnoses and 
prescriptions recordings (falling on 
separate dates) during 1 year prior to 
index date (index date visit excluded) 0 - 9 (Ref.) 193 (15.2) 405 (31.9) 1.00 ---- ---- 
 10 - 18 328 (25.8) 366 (28.8) 2.19 1.70 2.82 
 19 - 28 364 (28.7) 303 (23.9) 3.20 2.46 4.16 
 29+ 384 (30.3) 195 (15.4) 5.85 4.36 7.84 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 245 (19.3) 327 (25.8) 1.00 ---- ---- 
 43 - 135 322 (25.4) 334 (26.3) 1.41 1.11 1.80 
 136 - 323 358 (28.2) 340 (26.8) 1.66 1.29 2.12 
 324+ 344 (27.1) 268 (21.1) 2.30 1.72 3.07 
 
Categories of no. of drug 
prescriptions during 1 year prior to 
index date (index date excluded) 0 - 7 (Ref.) 194 (15.3) 347 (27.3) 1.00 ---- ---- 
 8 - 24 322 (25.4) 338 (26.6) 1.82 1.43 2.32 
 25 - 51 368 (29.0) 322 (25.4) 2.36 1.83 3.04 
 52+ 385 (30.3) 262 (20.6) 3.31 2.52 4.35 
CL=Confidence Limit 
 
4.4.2 Granulomatous ILD 
4.4.2.1 Sarcoidosis 
Three hundred and thirty incident cases of sarcoidosis were identified between 1995 
and 2009. The mean (SD) age was roughly 52 (13) years and 171 (52%) were male. 
For those cases and controls where smoking status was available, fewer cases vs. 
controls were found to be either current or ex-smokers (9.7% vs. 23% and 16.7% vs. 
18.8%, respectively). Higher frequencies of practice visits and drug prescriptions prior 
to index date were statistically significantly associated with a diagnosis of 
sarcoidosis. Further characteristics of sarcoidosis cases and controls can be found in 
Table 4.4.2.1 below. 
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Table 4.4.2.1 Characteristics of Sarcoidosis cases and matched controls at / prior 

















Age in years [mean (sd)]  51.55(13.01) 51.55(13.00) ---- ---- ---- 
 Min. 23 23 ---- ---- ---- 
 Max. 84 84 ---- ---- ---- 
 
Gender Males 171 (51.8) 171 (51.8) ---- ---- ---- 
 Females 159 (48.2) 159 (48.2) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 102 (30.9) 90 (27.3) 1.00 ---- ---- 
 14.0 - 18.4 9 (2.7) 1 (0.3) 7.62 0.93 62.06 
 25.0 - 29.9 95 (28.8) 90 (27.3) 0.96 0.63 1.46 
 30.0 - 39.9 71 (21.5) 47 (14.2) 1.37 0.83 2.26 
 40.0 - 55.9 12 (3.6) 15 (4.5) 0.65 0.27 1.56 
 Unknown 41 (12.4) 87 (26.4) 0.36 0.21 0.61 
 
Smoking status Non-smkrs (Ref.) 218 (66.1) 154 (46.7) 1.00 ---- ---- 
 Curr-smkrs 32 (9.7) 76 (23.0) 0.27 0.16 0.45 
 Ex-smkrs 55 (16.7) 62 (18.8) 0.63 0.41 0.97 
 Unknown 25 (7.6) 38 (11.5) 0.43 0.24 0.77 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 17 (5.2) 21 (6.4) 1.00 ---- ---- 
 1 - 10 26 (7.9) 44 (13.3) 0.69 0.29 1.64 
 11 - 20 13 (3.9) 36 (10.9) 0.42 0.16 1.10 
 21+ 2 (0.6) 8 (2.4) 0.33 0.06 1.84 
 Unknown 272 (82.4) 221 (67.0) 1.45 0.71 2.96 
 
Last alcohol status prior to index 
date None (Ref.) 53 (16.1) 70 (21.2) 1.00 ---- ---- 
 Current 225 (68.2) 216 (65.5) 1.40 0.92 2.14 
 Never 48 (14.5) 38 (11.5) 1.78 0.97 3.26 
 Ex 4 (1.2) 6 (1.8) 0.95 0.25 3.55 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 175 (53.0) 167 (50.6) 1.00 ---- ---- 
 1 - 7 89 (27.0) 73 (22.1) 1.20 0.80 1.81 
 8 - 14 39 (11.8) 52 (15.8) 0.68 0.41 1.11 
 15 - 29 11 (3.3) 25 (7.6) 0.43 0.21 0.90 
 30+ 16 (4.8) 13 (3.9) 1.10 0.51 2.37 
 
Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 157 (47.6) 156 (47.3) 1.00 ---- ---- 
 0.01 - 7.99 109 (33.0) 88 (26.7) 1.28 0.86 1.92 
 8.00 - 14.99 36 (10.9) 47 (14.2) 0.74 0.44 1.23 
 15.00 - 29.99 19 (5.8) 27 (8.2) 0.69 0.36 1.32 
 30+ 9 (2.7) 12 (3.6) 0.71 0.29 1.73 
 
Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 18 (5.5) 12 (3.6) 1.00 ---- ---- 
 6.5 - 7.4 5 (1.5) 6 (1.8) 0.57 0.14 2.30 
 7.5 - 8.9 6 (1.8) 3 (0.9) 1.45 0.30 6.91 
 >=9.0 7 (2.1) 3 (0.9) 1.63 0.35 7.56 
 Unknown 294 (89.1) 306 (92.7) 0.61 0.28 1.31 
 
Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 17 (5.2) 9 (2.7) 1.00 ---- ---- 
 6.5 - 7.4 6 (1.8) 4 (1.2) 0.78 0.18 3.47 
 7.5 - 8.9 5 (1.5) 7 (2.1) 0.43 0.10 1.77 
 >=9.0 8 (2.4) 4 (1.2) 0.96 0.22 4.23 
 Unknown 294 (89.1) 306 (92.7) 0.49 0.21 1.16 
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Categories of no. of practice 
visits prior to the index date 
based on diagnoses recordings 0 - 29 (Ref.) 84 (25.5) 144 (43.6) 1.00 ---- ---- 
 30 - 58 102 (30.9) 98 (29.7) 3.09 1.88 5.08 
 59 - 104 83 (25.2) 53 (16.1) 5.96 3.26 10.93 
 105+ 61 (18.5) 35 (10.6) 8.98 4.33 18.61 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 111 (33.6) 165 (50.0) 1.00 ---- ---- 
 55 - 111 115 (34.8) 86 (26.1) 2.65 1.70 4.12 
 112 - 199 64 (19.4) 44 (13.3) 3.60 2.00 6.47 
 200+ 40 (12.1) 35 (10.6) 3.21 1.58 6.53 
 
Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 46 (13.9) 176 (53.3) 1.00 ---- ---- 
 5 - 10 115 (34.8) 87 (26.4) 6.61 3.75 11.66 
 11 - 18 88 (26.7) 42 (12.7) 11.85 6.13 22.92 
 19+ 81 (24.5) 25 (7.6) 23.31 10.84 50.13 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 81 (24.5) 198 (60.0) 1.00 ---- ---- 
 10 - 18 115 (34.8) 63 (19.1) 5.08 3.15 8.17 
 19 - 28 80 (24.2) 39 (11.8) 7.99 4.41 14.46 
 29+ 54 (16.4) 30 (9.1) 8.32 4.28 16.17 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 127 (38.5) 171 (51.8) 1.00 ---- ---- 
 43 - 135 113 (34.2) 81 (24.5) 2.08 1.40 3.10 
 136 - 323 51 (15.5) 46 (13.9) 1.88 1.08 3.27 
 324+ 39 (11.8) 32 (9.7) 2.17 1.15 4.11 
 
Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 131 (39.7) 184 (55.8) 1.00 ---- ---- 
 8 - 24 110 (33.3) 77 (23.3) 2.38 1.56 3.62 
 25 - 51 52 (15.8) 39 (11.8) 2.33 1.37 3.97 
 52+ 37 (11.2) 30 (9.1) 2.33 1.25 4.33 
CL=Confidence Limit 
 
4.4.2.2 Wegener’s Granulomatosis 
Three hundred and one incident cases of WG were identified between 1995 and 
2009. The mean (SD) age was 59 (16.5) years and 142 (47%) were male. Higher 
frequencies of practice visits and drug prescriptions prior to index date were 
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statistically significantly associated with a diagnosis of WG. Further characteristics of 
Wegener’s Granulomatosis cases and controls can be found in Table 4.4.2.1 below. 


















Age in years [mean (sd)]  58.99(16.52) 58.97(16.48) ---- ---- ---- 
 Min. 9 9 ---- ---- ---- 
 Max. 92 92 ---- ---- ---- 
 
Gender Males 142 (47.2) 142 (47.2) ---- ---- ---- 
 Females 159 (52.8) 159 (52.8) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 88 (29.2) 90 (29.9) 1.00 ---- ---- 
 14.0 - 18.4 5 (1.7) 1 (0.3) 5.05 0.58 44.19 
 25.0 - 29.9 82 (27.2) 86 (28.6) 0.96 0.63 1.46 
 30.0 - 39.9 52 (17.3) 45 (15.0) 1.16 0.70 1.93 
 40.0 - 55.9 6 (2.0) 11 (3.7) 0.56 0.19 1.61 
 Unknown 68 (22.6) 68 (22.6) 1.04 0.63 1.71 
 
Smoking status Non-smkrs (Ref.) 155 (51.5) 161 (53.5) 1.00 ---- ---- 
 Curr-smkrs 43 (14.3) 53 (17.6) 0.79 0.48 1.30 
 Ex-smkrs 71 (23.6) 51 (16.9) 1.49 0.97 2.31 
 Unknown 32 (10.6) 36 (12.0) 0.79 0.42 1.51 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 21 (7.0) 23 (7.6) 1.00 ---- ---- 
 1 - 10 28 (9.3) 28 (9.3) 1.12 0.49 2.54 
 11 - 20 23 (7.6) 24 (8.0) 1.06 0.45 2.46 
 21+ 8 (2.7) 3 (1.0) 2.98 0.68 12.97 
 Unknown 221 (73.4) 223 (74.1) 1.12 0.59 2.12 
 
Last alcohol status prior to index 
date None (Ref.) 58 (19.3) 63 (20.9) 1.00 ---- ---- 
 Current 186 (61.8) 194 (64.5) 1.10 0.67 1.82 
 Never 51 (16.9) 38 (12.6) 1.59 0.84 3.02 
 Ex 6 (2.0) 6 (2.0) 1.14 0.30 4.35 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 177 (58.8) 165 (54.8) 1.00 ---- ---- 
 1 - 7 69 (22.9) 75 (24.9) 0.83 0.54 1.26 
 8 - 14 25 (8.3) 33 (11.0) 0.67 0.37 1.21 
 15 - 29 23 (7.6) 24 (8.0) 0.86 0.44 1.66 
 30+ 7 (2.3) 4 (1.3) 1.65 0.48 5.68 
 
Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 156 (51.8) 148 (49.2) 1.00 ---- ---- 
 0.01 - 7.99 89 (29.6) 99 (32.9) 0.80 0.52 1.22 
 8.00 - 14.99 30 (10.0) 28 (9.3) 0.95 0.51 1.79 
 15.00 - 29.99 20 (6.6) 24 (8.0) 0.80 0.41 1.57 
 30+ 6 (2.0) 2 (0.7) 2.69 0.53 13.63 
 
Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 15 (5.0) 12 (4.0) 1.00 ---- ---- 
 6.5 - 7.4 2 (0.7) 6 (2.0) 0.28 0.05 1.62 
 7.5 - 8.9 4 (1.3) 5 (1.7) 0.63 0.12 3.30 
 >=9.0 3 (1.0) 3 (1.0) 0.85 0.15 4.82 
 Unknown 277 (92.0) 275 (91.4) 0.82 0.37 1.83 
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Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 14 (4.7) 10 (3.3) 1.00 ---- ---- 
 6.5 - 7.4 4 (1.3) 7 (2.3) 0.41 0.10 1.75 
 7.5 - 8.9 4 (1.3) 5 (1.7) 0.51 0.10 2.50 
 >=9.0 2 (0.7) 4 (1.3) 0.36 0.05 2.43 
 Unknown 277 (92.0) 275 (91.4) 0.73 0.31 1.71 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses recordings 0 - 29 (Ref.) 70 (23.3) 127 (42.2) 1.00 ---- ---- 
 30 - 58 81 (26.9) 72 (23.9) 3.01 1.75 5.18 
 59 - 104 80 (26.6) 62 (20.6) 4.29 2.41 7.66 
 105+ 70 (23.3) 40 (13.3) 8.08 3.96 16.48 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 83 (27.6) 125 (41.5) 1.00 ---- ---- 
 55 - 111 84 (27.9) 78 (25.9) 2.00 1.24 3.21 
 112 - 199 75 (24.9) 52 (17.3) 3.14 1.81 5.44 
 200+ 59 (19.6) 46 (15.3) 3.51 1.79 6.87 
 
Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 32 (10.6) 146 (48.5) 1.00 ---- ---- 
 5 - 10 75 (24.9) 102 (33.9) 4.04 2.19 7.46 
 11 - 18 86 (28.6) 29 (9.6) 26.62 11.35 62.46 
 19+ 108 (35.9) 24 (8.0) 46.54 19.04 113.7 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 41 (13.6) 152 (50.5) 1.00 ---- ---- 
 10 - 18 86 (28.6) 83 (27.6) 6.12 3.18 11.79 
 19 - 28 78 (25.9) 42 (14.0) 14.89 6.81 32.56 
 29+ 96 (31.9) 24 (8.0) 48.83 19.36 123.1 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 83 (27.6) 122 (40.5) 1.00 ---- ---- 
 43 - 135 97 (32.2) 76 (25.2) 2.38 1.47 3.86 
 136 - 323 70 (23.3) 55 (18.3) 2.39 1.43 4.00 
 324+ 51 (16.9) 48 (15.9) 2.14 1.14 3.99 
 
Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 59 (19.6) 146 (48.5) 1.00 ---- ---- 
 8 - 24 103 (34.2) 70 (23.3) 5.39 3.09 9.40 
 25 - 51 74 (24.6) 47 (15.6) 6.55 3.52 12.16 
 52+ 65 (21.6) 38 (12.6) 7.64 3.93 14.84 
CL=Confidence Limit 
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4.4.3 ILD of known cause or associated with other diseases 
4.4.3.1 Extrinsic Allergic Alveolitis 
Four hundred and sixty-six incident cases of EAA were identified between 1995 and 
2009. The mean (SD) age was 59 (14.2) years and there were equal numbers of 
males and females. Higher frequencies of practice visits and drug prescriptions prior 
to index date were statistically significantly associated with a diagnosis of EAA. 
Further characteristics of EAA cases and controls can be found in Table 4.4.3.1 
below. 


















Age in years [mean (sd)]  59.18(14.26) 59.16(14.25) ---- ---- ---- 
 Min. 13 13 ---- ---- ---- 
 Max. 90 90 ---- ---- ---- 
 
Gender Males 233 (50.0) 233 (50.0) ---- ---- ---- 
 Females 233 (50.0) 233 (50.0) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 136 (29.2) 115 (24.7) 1.00 ---- ---- 
 14.0 - 18.4 10 (2.1) 3 (0.6) 2.92 0.79 10.78 
 25.0 - 29.9 156 (33.5) 161 (34.5) 0.82 0.57 1.16 
 30.0 - 39.9 92 (19.7) 83 (17.8) 0.91 0.62 1.34 
 40.0 - 55.9 1 (0.2) 7 (1.5) 0.13 0.02 1.10 
 Unknown 71 (15.2) 97 (20.8) 0.55 0.36 0.86 
 
Smoking status Non-smkrs (Ref.) 251 (53.9) 240 (51.5) 1.00 ---- ---- 
 Curr-smkrs 64 (13.7) 86 (18.5) 0.71 0.49 1.04 
 Ex-smkrs 121 (26.0) 98 (21.0) 1.24 0.87 1.75 
 Unknown 30 (6.4) 42 (9.0) 0.60 0.34 1.07 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 27 (5.8) 37 (7.9) 1.00 ---- ---- 
 1 - 10 26 (5.6) 45 (9.7) 0.82 0.41 1.65 
 11 - 20 42 (9.0) 36 (7.7) 1.61 0.83 3.12 
 21+ 12 (2.6) 7 (1.5) 2.27 0.78 6.60 
 Unknown 359 (77.0) 341 (73.2) 1.46 0.86 2.49 
 
Last alcohol status prior to index 
date None (Ref.) 77 (16.5) 88 (18.9) 1.00 ---- ---- 
 Current 313 (67.2) 305 (65.5) 1.20 0.82 1.75 
 Never 74 (15.9) 65 (13.9) 1.34 0.81 2.21 
 Ex 2 (0.4) 8 (1.7) 0.31 0.06 1.53 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 248 (53.2) 249 (53.4) 1.00 ---- ---- 
 1 - 7 139 (29.8) 115 (24.7) 1.25 0.90 1.75 
 8 - 14 46 (9.9) 53 (11.4) 0.85 0.55 1.32 
 15 - 29 24 (5.2) 35 (7.5) 0.68 0.38 1.20 
 30+ 9 (1.9) 14 (3.0) 0.67 0.29 1.56 
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Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 218 (46.8) 216 (46.4) 1.00 ---- ---- 
 0.01 - 7.99 164 (35.2) 143 (30.7) 1.14 0.84 1.56 
 8.00 - 14.99 47 (10.1) 58 (12.4) 0.78 0.50 1.22 
 15.00 - 29.99 29 (6.2) 36 (7.7) 0.77 0.44 1.33 
 30+ 8 (1.7) 13 (2.8) 0.62 0.25 1.52 
 
Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 20 (4.3) 17 (3.6) 1.00 ---- ---- 
 6.5 - 7.4 11 (2.4) 6 (1.3) 1.67 0.47 5.96 
 7.5 - 8.9 8 (1.7) 2 (0.4) 3.33 0.61 18.14 
 >=9.0 6 (1.3) 6 (1.3) 0.85 0.23 3.09 
 Unknown 421 (90.3) 435 (93.3) 0.83 0.42 1.65 
 
Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 17 (3.6) 20 (4.3) 1.00 ---- ---- 
 6.5 - 7.4 12 (2.6) 4 (0.9) 3.79 0.99 14.46 
 7.5 - 8.9 8 (1.7) 5 (1.1) 2.13 0.56 8.10 
 >=9.0 7 (1.5) 3 (0.6) 2.83 0.62 13.04 
 Unknown 422 (90.6) 434 (93.1) 1.21 0.60 2.46 
 
Categories of no. of practice 
visits prior to the index date 
based on diagnoses recordings 0 - 29 (Ref.) 136 (29.2) 182 (39.1) 1.00 ---- ---- 
 30 - 58 105 (22.5) 131 (28.1) 1.35 0.93 1.97 
 59 - 104 114 (24.5) 95 (20.4) 2.55 1.65 3.94 
 105+ 111 (23.8) 58 (12.4) 5.58 3.20 9.72 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 153 (32.8) 192 (41.2) 1.00 ---- ---- 
 55 - 111 110 (23.6) 129 (27.7) 1.26 0.87 1.83 
 112 - 199 105 (22.5) 87 (18.7) 2.45 1.54 3.90 
 200+ 98 (21.0) 58 (12.4) 4.32 2.47 7.56 
 
Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 77 (16.5) 222 (47.6) 1.00 ---- ---- 
 5 - 10 137 (29.4) 138 (29.6) 5.22 3.19 8.55 
 11 - 18 131 (28.1) 71 (15.2) 10.16 5.86 17.62 
 19+ 121 (26.0) 35 (7.5) 25.02 12.92 48.45 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 105 (22.5) 236 (50.6) 1.00 ---- ---- 
 10 - 18 135 (29.0) 111 (23.8) 3.67 2.43 5.55 
 19 - 28 103 (22.1) 79 (17.0) 4.73 2.95 7.58 
 29+ 123 (26.4) 40 (8.6) 10.52 6.24 17.76 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 149 (32.0) 186 (39.9) 1.00 ---- ---- 
 43 - 135 123 (26.4) 135 (29.0) 1.31 0.92 1.87 
 136 - 323 94 (20.2) 82 (17.6) 1.89 1.21 2.95 
 324+ 100 (21.5) 63 (13.5) 2.80 1.74 4.51 
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Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 125 (26.8) 219 (47.0) 1.00 ---- ---- 
 8 - 24 137 (29.4) 105 (22.5) 2.83 1.93 4.15 
 25 - 51 101 (21.7) 85 (18.2) 2.60 1.73 3.90 




Two thousand four hundred and eighteen incident pneumoconiosis cases were 
identified between 1995 and 2009. The mean (SD) age was 68 (12.5) years and 
2191 (90%) were male. The proportion of current and ex-smokers was higher among 
Pneumoconiosis cases compared to controls (20.9% vs. 17.9% and 40.6% vs. 
31.9%, respectively), and the raised odds ratios for current (OR=1.48, 95%CI:1.3 to 
1.8) and ex-smokers (OR=1.71, 95%CI:1.5 to 2.0) vs. non-smokers were significant 
at the 5% level. Higher frequencies of practice visits and drug prescriptions prior to 
index date were statistically significantly associated with a diagnosis of 
Pneumoconiosis.  Further characteristics of Pneumoconiosis cases and their 
matched controls can be found in Table 4.4.3.2 below. 
Table 4.4.3.2 Characteristics of Pneumoconioses cases and matched controls at / 

















Age in years [mean (sd)]  67.90(12.54) 67.88(12.53) ---- ---- ---- 
 Min. 4 4 ---- ---- ---- 
 Max. 96 94 ---- ---- ---- 
 
Gender Males 2191 (90.6) 2191 (90.6) ---- ---- ---- 
 Females 227 (9.4) 227 (9.4) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 672 (27.8) 676 (28.0) 1.00 ---- ---- 
 14.0 - 18.4 40 (1.7) 33 (1.4) 1.20 0.75 1.91 
 25.0 - 29.9 940 (38.9) 847 (35.0) 1.12 0.97 1.29 
 30.0 - 39.9 352 (14.6) 385 (15.9) 0.92 0.77 1.11 
 40.0 - 55.9 25 (1.0) 12 (0.5) 2.05 1.02 4.11 
 Unknown 389 (16.1) 465 (19.2) 0.80 0.66 0.96 
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Smoking status Non-smkrs (Ref.) 785 (32.5) 998 (41.3) 1.00 ---- ---- 
 Curr-smkrs 505 (20.9) 434 (17.9) 1.48 1.26 1.75 
 Ex-smkrs 982 (40.6) 772 (31.9) 1.71 1.49 1.97 
 Unknown 146 (6.0) 214 (8.9) 0.76 0.59 0.99 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 274 (11.3) 224 (9.3) 1.00 ---- ---- 
 1 - 10 339 (14.0) 239 (9.9) 1.18 0.92 1.51 
 11 - 20 213 (8.8) 174 (7.2) 1.01 0.76 1.33 
 21+ 56 (2.3) 54 (2.2) 0.89 0.58 1.37 
 Unknown 1536 (63.5) 1727 (71.4) 0.71 0.59 0.87 
 
Last alcohol status prior to index 
date None (Ref.) 331 (13.7) 411 (17.0) 1.00 ---- ---- 
 Current 1733 (71.7) 1685 (69.7) 1.37 1.15 1.65 
 Never 282 (11.7) 267 (11.0) 1.39 1.10 1.76 
 Ex 72 (3.0) 55 (2.3) 1.77 1.20 2.62 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 1147 (47.4) 1167 (48.3) 1.00 ---- ---- 
 1 - 7 546 (22.6) 594 (24.6) 0.94 0.81 1.10 
 8 - 14 334 (13.8) 283 (11.7) 1.21 1.01 1.46 
 15 - 29 250 (10.3) 246 (10.2) 1.04 0.85 1.27 
 30+ 141 (5.8) 128 (5.3) 1.13 0.87 1.47 
 
Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 913 (37.8) 946 (39.1) 1.00 ---- ---- 
 0.01 - 7.99 744 (30.8) 776 (32.1) 1.01 0.87 1.17 
 8.00 - 14.99 326 (13.5) 313 (12.9) 1.10 0.91 1.34 
 15.00 - 29.99 298 (12.3) 266 (11.0) 1.19 0.97 1.45 
 30+ 137 (5.7) 117 (4.8) 1.24 0.95 1.62 
 
Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 129 (5.3) 119 (4.9) 1.00 ---- ---- 
 6.5 - 7.4 84 (3.5) 98 (4.1) 0.79 0.54 1.16 
 7.5 - 8.9 53 (2.2) 50 (2.1) 0.99 0.63 1.56 
 >=9.0 25 (1.0) 23 (1.0) 1.01 0.55 1.87 
 Unknown 2127 (88.0) 2128 (88.0) 0.92 0.71 1.20 
 
Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 112 (4.6) 111 (4.6) 1.00 ---- ---- 
 6.5 - 7.4 84 (3.5) 83 (3.4) 1.00 0.68 1.49 
 7.5 - 8.9 72 (3.0) 75 (3.1) 0.95 0.62 1.45 
 >=9.0 23 (1.0) 22 (0.9) 1.03 0.54 1.96 
 Unknown 2127 (88.0) 2127 (88.0) 0.99 0.75 1.31 
 
Categories of no. of practice 
visits prior to the index date 
based on diagnoses recordings 0 - 29 (Ref.) 552 (22.8) 801 (33.1) 1.00 ---- ---- 
 30 - 58 620 (25.6) 628 (26.0) 1.82 1.52 2.17 
 59 - 104 652 (27.0) 557 (23.0) 2.63 2.15 3.22 
 105+ 594 (24.6) 432 (17.9) 3.59 2.86 4.52 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 564 (23.3) 752 (31.1) 1.00 ---- ---- 
 55 - 111 620 (25.6) 609 (25.2) 1.52 1.28 1.80 
 112 - 199 644 (26.6) 559 (23.1) 1.97 1.63 2.38 
 200+ 590 (24.4) 498 (20.6) 2.23 1.80 2.76 
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Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 410 (17.0) 931 (38.5) 1.00 ---- ---- 
 5 - 10 719 (29.7) 722 (29.9) 2.86 2.39 3.43 
 11 - 18 693 (28.7) 470 (19.4) 4.65 3.81 5.68 
 19+ 596 (24.6) 295 (12.2) 7.43 5.91 9.34 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 464 (19.2) 847 (35.0) 1.00 ---- ---- 
 10 - 18 658 (27.2) 686 (28.4) 2.06 1.73 2.45 
 19 - 28 650 (26.9) 501 (20.7) 3.14 2.60 3.80 
 29+ 646 (26.7) 384 (15.9) 4.36 3.55 5.35 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 553 (22.9) 720 (29.8) 1.00 ---- ---- 
 43 - 135 624 (25.8) 611 (25.3) 1.47 1.24 1.74 
 136 - 323 652 (27.0) 558 (23.1) 1.81 1.50 2.17 
 324+ 589 (24.4) 529 (21.9) 1.82 1.48 2.22 
 
Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 526 (21.8) 784 (32.4) 1.00 ---- ---- 
 8 - 24 609 (25.2) 598 (24.7) 1.65 1.40 1.95 
 25 - 51 636 (26.3) 535 (22.1) 2.11 1.76 2.52 
 52+ 647 (26.8) 501 (20.7) 2.41 2.00 2.92 
CL=Confidence Limit 
 
4.4.3.3 Drug-/radiation-induced ILD (DRAD-ILD) 
One hundred and forty-five incident cases of drug/radiation-induced ILD were 
identified between 1995 and 2009. The mean (SD) age was 67 (12) years and 80 
(55%) were female.  Higher frequencies of practice visits and drug prescriptions prior 
to index date were statistically significantly associated with a diagnosis of 
drug/radiation-induced ILD.  Further characteristics of cases and matched controls 
can be found in Table 4.4.3.3 below. 
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Age in years [mean (sd)]  66.86(12.01) 66.88(12.04) ---- ---- ---- 
 Min. 20 20 ---- ---- ---- 
 Max. 87 87 ---- ---- ---- 
 
Gender Males 65 (44.8) 65 (44.8) ---- ---- ---- 
 Females 80 (55.2) 80 (55.2) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 51 (35.2) 45 (31.0) 1.00 ---- ---- 
 14.0 - 18.4 2 (1.4) 3 (2.1) 0.49 0.08 3.14 
 25.0 - 29.9 49 (33.8) 41 (28.3) 1.13 0.61 2.11 
 30.0 - 39.9 24 (16.6) 23 (15.9) 0.82 0.39 1.73 
 40.0 - 55.9 0 (0.0) 3 (2.1) 0.00 0.00 ---- 
 Unknown 19 (13.1) 30 (20.7) 0.49 0.22 1.07 
 
Smoking status Non-smkrs (Ref.) 59 (40.7) 74 (51.0) 1.00 ---- ---- 
 Curr-smkrs 25 (17.2) 27 (18.6) 1.18 0.56 2.52 
 Ex-smkrs 55 (37.9) 31 (21.4) 2.19 1.23 3.89 
 Unknown 6 (4.1) 13 (9.0) 0.38 0.10 1.45 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 13 (9.0) 14 (9.7) 1.00 ---- ---- 
 1 - 10 26 (17.9) 14 (9.7) 2.03 0.75 5.48 
 11 - 20 16 (11.0) 9 (6.2) 1.81 0.61 5.43 
 21+ 3 (2.1) 3 (2.1) 1.11 0.19 6.51 
 Unknown 87 (60.0) 105 (72.4) 0.77 0.33 1.78 
 
Last alcohol status prior to index 
date None (Ref.) 17 (11.7) 23 (15.9) 1.00 ---- ---- 
 Current 99 (68.3) 91 (62.8) 1.70 0.73 3.95 
 Never 27 (18.6) 25 (17.2) 1.57 0.60 4.08 
 Ex 2 (1.4) 6 (4.1) 0.54 0.09 3.32 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 86 (59.3) 86 (59.3) 1.00 ---- ---- 
 1 - 7 28 (19.3) 28 (19.3) 0.96 0.49 1.88 
 8 - 14 20 (13.8) 18 (12.4) 1.17 0.55 2.47 
 15 - 29 6 (4.1) 12 (8.3) 0.46 0.15 1.37 
 30+ 5 (3.4) 1 (0.7) 5.24 0.60 45.94 
 
Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 70 (48.3) 67 (46.2) 1.00 ---- ---- 
 0.01 - 7.99 43 (29.7) 48 (33.1) 0.82 0.44 1.53 
 8.00 - 14.99 19 (13.1) 18 (12.4) 0.97 0.46 2.04 
 15.00 - 29.99 8 (5.5) 10 (6.9) 0.80 0.29 2.22 
 30+ 5 (3.4) 2 (1.4) 2.21 0.40 12.04 
 
Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 6 (4.1) 8 (5.5) 1.00 ---- ---- 
 6.5 - 7.4 5 (3.4) 5 (3.4) 1.41 0.29 6.85 
 7.5 - 8.9 5 (3.4) 5 (3.4) 1.29 0.24 6.89 
 >=9.0 5 (3.4) 2 (1.4) 3.35 0.47 23.70 
 Unknown 124 (85.5) 125 (86.2) 1.33 0.46 3.87 
 
Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 5 (3.4) 8 (5.5) 1.00 ---- ---- 
 6.5 - 7.4 5 (3.4) 5 (3.4) 1.51 0.25 9.08 
 7.5 - 8.9 8 (5.5) 4 (2.8) 2.60 0.58 11.66 
 >=9.0 3 (2.1) 3 (2.1) 1.40 0.19 10.06 
 Unknown 124 (85.5) 125 (86.2) 1.40 0.44 4.43 
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Categories of no. of practice 
visits prior to the index date 
based on diagnoses recordings 0 - 29 (Ref.) 18 (12.4) 43 (29.7) 1.00 ---- ---- 
 30 - 58 31 (21.4) 37 (25.5) 7.99 1.81 35.34 
 59 - 104 38 (26.2) 25 (17.2) 19.02 4.07 88.89 
 105+ 58 (40.0) 40 (27.6) 38.28 7.26 201.9 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 21 (14.5) 45 (31.0) 1.00 ---- ---- 
 55 - 111 33 (22.8) 33 (22.8) 3.44 1.36 8.67 
 112 - 199 40 (27.6) 34 (23.4) 7.02 2.45 20.17 
 200+ 51 (35.2) 33 (22.8) 16.35 4.73 56.54 
 
Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 10 (6.9) 49 (33.8) 1.00 ---- ---- 
 5 - 10 22 (15.2) 42 (29.0) 7.12 1.60 31.71 
 11 - 18 32 (22.1) 29 (20.0) 19.01 3.95 91.60 
 19+ 81 (55.9) 25 (17.2) 84.37 16.20 439.4 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 11 (7.6) 54 (37.2) 1.00 ---- ---- 
 10 - 18 22 (15.2) 32 (22.1) 5.38 1.70 16.99 
 19 - 28 38 (26.2) 36 (24.8) 9.76 3.21 29.71 
 29+ 74 (51.0) 23 (15.9) 46.82 13.18 166.3 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 23 (15.9) 46 (31.7) 1.00 ---- ---- 
 43 - 135 37 (25.5) 37 (25.5) 2.57 1.22 5.43 
 136 - 323 45 (31.0) 26 (17.9) 5.32 2.23 12.70 
 324+ 40 (27.6) 36 (24.8) 3.91 1.52 10.05 
 
Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 13 (9.0) 52 (35.9) 1.00 ---- ---- 
 8 - 24 38 (26.2) 35 (24.1) 15.60 3.57 68.23 
 25 - 51 45 (31.0) 28 (19.3) 21.59 4.95 94.15 
 52+ 49 (33.8) 30 (20.7) 27.55 6.11 124.1 
CL=Confidence Limit 
 
4.4.3.4 ILD associated with other diseases (ILD-ODIS) 
Five hundred and sixty incident cases of ILD associated with other diseases were 
identified between 1995 and 2009. The mean (SD) age was 68 (12.6) years and 283 
(50.5%) were female. For those cases and controls where smoking status was 
available, the proportion of ex-smokers among cases was higher than in the control 
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group (25% vs. 19%, respectively). The elevated odds ratio of ex- vs. non-smokers 
(OR=1.7, 95%CI:1.2 to 2.4) was significant at the 5% level.  Higher frequencies of 
practice visits and drug prescriptions prior to index date were statistically significantly 
associated with a diagnosis of ILD associated with other diseases. Further 
characteristics of cases and controls can be found in Table 4.4.3.4 below. 


















Age in years [mean (sd)]  68.02(12.58) 68.02(12.56) ---- ---- ---- 
 Min. 12 12 ---- ---- ---- 
 Max. 96 97 ---- ---- ---- 
 
Gender Males 277 (49.5) 277 (49.5) ---- ---- ---- 
 Females 283 (50.5) 283 (50.5) ---- ---- ---- 
 
BMI(kg/m2) 18.5 - 24.9 (Ref.) 198 (35.4) 186 (33.2) 1.00 ---- ---- 
 14.0 - 18.4 18 (3.2) 9 (1.6) 1.87 0.83 4.21 
 25.0 - 29.9 166 (29.6) 163 (29.1) 0.96 0.72 1.27 
 30.0 - 39.9 59 (10.5) 77 (13.8) 0.73 0.50 1.07 
 40.0 - 55.9 4 (0.7) 7 (1.3) 0.52 0.13 2.12 
 Unknown 115 (20.5) 118 (21.1) 0.92 0.64 1.30 
 
Smoking status Non-smkrs (Ref.) 251 (44.8) 285 (50.9) 1.00 ---- ---- 
 Curr-smkrs 108 (19.3) 106 (18.9) 1.19 0.85 1.68 
 Ex-smkrs 140 (25.0) 104 (18.6) 1.67 1.19 2.35 
 Unknown 61 (10.9) 65 (11.6) 1.06 0.69 1.64 
 
Categories of no. of cigarettes 
smoked/day 0 (Ref.) 47 (8.4) 47 (8.4) 1.00 ---- ---- 
 1 - 10 63 (11.3) 49 (8.8) 1.24 0.71 2.18 
 11 - 20 51 (9.1) 34 (6.1) 1.43 0.79 2.57 
 21+ 8 (1.4) 10 (1.8) 0.83 0.30 2.34 
 Unknown 391 (69.8) 420 (75.0) 0.90 0.57 1.41 
 
Last alcohol status prior to index 
date None (Ref.) 99 (17.7) 107 (19.1) 1.00 ---- ---- 
 Current 334 (59.6) 340 (60.7) 1.08 0.77 1.52 
 Never 120 (21.4) 105 (18.8) 1.28 0.85 1.93 
 Ex 7 (1.3) 8 (1.4) 0.95 0.33 2.76 
 
Categories of alcohol units/week 
(for last recording prior to index 
date) 0 (Ref.) 334 (59.6) 321 (57.3) 1.00 ---- ---- 
 1 - 7 126 (22.5) 142 (25.4) 0.85 0.64 1.13 
 8 - 14 45 (8.0) 43 (7.7) 1.00 0.64 1.56 
 15 - 29 39 (7.0) 40 (7.1) 0.94 0.58 1.52 
 30+ 16 (2.9) 14 (2.5) 1.09 0.53 2.27 
 
Categories of avg. alcohol 
units/week (for all recorded 
alcohol units recorded prior to 
index date) 0 units/wk (Ref.) 299 (53.4) 282 (50.4) 1.00 ---- ---- 
 0.01 - 7.99 160 (28.6) 177 (31.6) 0.84 0.63 1.11 
 8.00 - 14.99 48 (8.6) 48 (8.6) 0.92 0.59 1.45 
 15.00 - 29.99 36 (6.4) 36 (6.4) 0.92 0.55 1.54 
 30+ 17 (3.0) 17 (3.0) 0.94 0.47 1.87 
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Categories of Hb1Ac level before 
index date (closest recording 
prior to index date) <6.5 (Ref.) 18 (3.2) 16 (2.9) 1.00 ---- ---- 
 6.5 - 7.4 13 (2.3) 13 (2.3) 0.89 0.33 2.43 
 7.5 - 8.9 8 (1.4) 14 (2.5) 0.50 0.17 1.53 
 >=9.0 7 (1.3) 7 (1.3) 0.85 0.24 2.99 
 Unknown 514 (91.8) 510 (91.1) 0.88 0.44 1.77 
 
Categories of average level of 
Hb1Ac before index date <6.5 (Ref.) 18 (3.2) 17 (3.0) 1.00 ---- ---- 
 6.5 - 7.4 11 (2.0) 10 (1.8) 1.02 0.35 2.94 
 7.5 - 8.9 12 (2.1) 16 (2.9) 0.70 0.25 1.94 
 >=9.0 5 (0.9) 7 (1.3) 0.67 0.18 2.56 
 Unknown 514 (91.8) 510 (91.1) 0.94 0.47 1.86 
 
Categories of no. of practice 
visits prior to the index date 
based on diagnoses recordings 0 - 29 (Ref.) 109 (19.5) 206 (36.8) 1.00 ---- ---- 
 30 - 58 147 (26.3) 170 (30.4) 2.93 1.93 4.46 
 59 - 104 146 (26.1) 100 (17.9) 6.35 3.89 10.39 
 105+ 158 (28.2) 84 (15.0) 12.68 7.16 22.46 
 
Categories of no. of practice 
visits prior to index date based 
on diagnoses and prescriptions 
recordings 0 - 54 (Ref.) 80 (14.3) 183 (32.7) 1.00 ---- ---- 
 55 - 111 162 (28.9) 166 (29.6) 3.27 2.16 4.95 
 112 - 199 164 (29.3) 137 (24.5) 4.81 3.06 7.57 
 200+ 154 (27.5) 74 (13.2) 12.98 7.40 22.78 
 
Categories of no. of practice 
visits based on diagnoses 
recordings (falling on separate 
dates) during 1 year prior to 
index date (index date visit 
excluded) 0 - 4 (Ref.) 84 (15.0) 223 (39.8) 1.00 ---- ---- 
 5 - 10 121 (21.6) 164 (29.3) 2.68 1.77 4.04 
 11 - 18 170 (30.4) 105 (18.8) 7.92 4.93 12.71 
 19+ 185 (33.0) 68 (12.1) 19.91 11.34 34.94 
 
Categories of no. of practice 
visits based on diagnoses and 
prescriptions recordings (falling 
on separate dates) during 1 year 
prior to index date (index date 
visit excluded) 0 - 9 (Ref.) 52 (9.3) 209 (37.3) 1.00 ---- ---- 
 10 - 18 122 (21.8) 170 (30.4) 3.72 2.32 5.96 
 19 - 28 174 (31.1) 95 (17.0) 12.13 7.19 20.47 
 29+ 212 (37.9) 86 (15.4) 18.95 10.99 32.68 
 
Categories of no. of drug 
prescriptions ever, prior to index 
date (index date excluded) 0 - 42 (Ref.) 70 (12.5) 170 (30.4) 1.00 ---- ---- 
 43 - 135 141 (25.2) 161 (28.8) 2.84 1.87 4.32 
 136 - 323 169 (30.2) 142 (25.4) 4.62 2.95 7.23 
 324+ 180 (32.1) 87 (15.5) 9.60 5.82 15.84 
 
Categories of no. of drug 
prescriptions during 1 year prior 
to index date (index date 
excluded) 0 - 7 (Ref.) 60 (10.7) 182 (32.5) 1.00 ---- ---- 
 8 - 24 108 (19.3) 156 (27.9) 2.44 1.60 3.74 
 25 - 51 173 (30.9) 125 (22.3) 5.69 3.63 8.91 
 52+ 219 (39.1) 97 (17.3) 10.26 6.39 16.46 
CL=Confidence Limit 
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4.5 All-cause mortality and comorbidity after index date 
4.5.1 Idiopathic Interstitial Pneumonia (IIP) 
4.5.1.1 Idiopathic Pulmonary Fibrosis (IPF) 
During the follow-up period 755 (60%) IPF and 315 (25%) non-IPF subjects died. 
When investigating all-cause mortality as the outcome of interest, the mean (SD) 
survival time in the IPF cohort was 3.1 (3.0) years versus 5.3 (3.5) years in the 
control group.  The crude rate for all-cause mortality in the IPF cohort was more than 
5 times higher than the crude rate in the control group (RR 5.3 95%CI: 4.4  to 6.4). 
Furthermore, no decrease in this rate ratio was observed when simultaneously 
adjusting for smoking status, body mass index, and alcohol consumption status (RR 
5.5 95%CI:4.5 to 6.8). Similar analyses for non-incident outcomes such as 
pneumonia and respiratory (non-pneumonia) infections yielded elevated, adjusted 
rate ratios for IPF vs. non-IPF subjects (RR 4.8, 95%CI:3.0 to 7.8, RR 2.3, 95%CI:1.9 
to 2.7, respectively). Likewise, elevated rate ratios were observed for several incident 
cardiovascular outcomes such as congestive heart failure, ischemic heart disease, 
myocardial infarction, deep vein thrombosis and pulmonary embolism. Further details 
of these analyses can be found in tables 4.5.1.1a-c below. 
 
Table 4.5.1.1a IPF: Results of proportional hazards regression analyses for mortality 



















Failures [n (%)] 755 (59.5) 315 (24.8)             
Surv. time in yrs [mean (sd)]  3.1 (3.0) 5.3 (3.5)             
                
IPF vs. Non-IPF     5.34 4.40 6.47 5.51 4.49 6.77 
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) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.51 0.65 3.55 2.20 0.72 6.77 
  25.0 - 29.9 0.88 0.68 1.13 0.81 0.57 1.15 
  30.0 - 39.9 1.30 0.93 1.82 1.32 0.82 2.12 
  40.0 - 55.9 1.47 0.35 6.24 7.30 1.57 34.09 
  Unknown 0.71 0.52 0.97 1.00 0.61 1.63 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.41 1.02 1.94 1.52 0.97 2.37 
  Ex-smkrs 1.95 1.50 2.54 1.57 1.10 2.24 
  Unknown 0.69 0.46 1.05 0.80 0.40 1.63 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.18 0.86 1.61 0.68 0.39 1.18 
  Never 1.35 0.92 1.97 0.89 0.48 1.67 
  
Ex 1.11 0.49 2.50 0.66 0.20 2.20 
Pneumonia 
Failures [n (%)] 140 (11.0) 68 (5.4)             
Surv. time in yrs [mean (sd)]  3.0 (2.9) 5.2 (3.4)             
                
IPF vs. Non-IPF     4.65 3.05 7.11 4.84 3.02 7.76 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 3.90 0.42 35.99 2.51 0.16 38.57 
  25.0 - 29.9 1.22 0.68 2.19 1.55 0.72 3.35 
  30.0 - 39.9 0.58 0.25 1.32 0.94 0.31 2.87 
  40.0 - 55.9 2.29 0.20 26.16 4.90 0.26 92.48 
  Unknown 0.84 0.40 1.76 1.70 0.50 5.77 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.32 0.62 2.82 1.09 0.36 3.28 
  Ex-smkrs 1.44 0.82 2.54 1.33 0.62 2.81 
  Unknown 0.86 0.35 2.10 0.80 0.18 3.53 
                
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.50 0.24 1.06 0.56 0.16 1.88 
  Never 0.64 0.27 1.52 0.70 0.19 2.63 
  
Ex 1.62 0.14 18.49 1.39 0.05 40.11 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 634 (50.0) 534 (42.1)             
Surv. time in yrs [mean (sd)]  1.3 (1.9) 3.6 (3.1)             
                
IPF vs. Non-IPF     2.33 1.98 2.75 2.26 1.91 2.67 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.62 0.45 5.85 1.76 0.43 7.19 
  25.0 - 29.9 1.21 0.93 1.57 1.10 0.82 1.47 
  30.0 - 39.9 1.55 1.09 2.21 1.44 0.98 2.13 
  40.0 - 55.9 1.69 0.55 5.24 2.25 0.65 7.80 
  Unknown 0.80 0.58 1.12 1.04 0.69 1.58 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.97 0.71 1.33 0.91 0.64 1.28 
  Ex-smkrs 1.59 1.21 2.10 1.34 0.99 1.82 
  Unknown 0.61 0.39 0.95 0.65 0.36 1.19 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.17 0.84 1.64 0.86 0.54 1.37 
  Never 1.18 0.79 1.75 0.78 0.46 1.32 
  
Ex 3.21 1.11 9.26 1.99 0.61 6.52 
Pneumothorax 
Failures [n (%)] 10 (0.79) 5 (0.39)             
Surv. time in yrs [mean (sd)]  3.1 (3.0) 5.3 (3.5)             
                
IPF vs. Non-IPF     2.3 0.7 7.3 2.00 0.18 22.06 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.43 0.03 6.21 . . . 
  30.0 - 39.9 1.00 0.06 15.99 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.66 0.03 15.05 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.50 0.05 5.51 . . . 
  Ex-smkrs . . . . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current . . . . . . 
  Never . . . . . . 
  
Ex . . . . . . 
Bone fractures 
Failures [n (%)] 52 (4.1) 109 (8.6)             
Surv. time in yrs [mean (sd)]  3.0 (2.9) 5.0 (3.4)             
                
IPF vs. Non-IPF     0.80 0.53 1.21 0.71 0.44 1.15 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.65 0.77 3.55 1.43 0.62 3.30 
  30.0 - 39.9 0.57 0.20 1.60 0.38 0.12 1.25 
  40.0 - 55.9 0.75 0.04 12.99 0.39 0.01 12.74 
  Unknown 0.50 0.17 1.43 0.24 0.06 0.96 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.56 0.24 1.32 0.51 0.20 1.30 
  Ex-smkrs 1.42 0.58 3.46 1.30 0.48 3.51 
  Unknown 1.26 0.26 6.07 2.99 0.23 38.24 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.02 0.36 2.90 0.91 0.17 4.94 
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  Never 0.82 0.20 3.32 0.79 0.11 5.90 
  
Ex 1.89 0.14 26.35 1.59 0.08 32.81 






Table 4.5.1.1b IPF: Results of proportional hazards regression analyses for incident 
cardiovascular-cerebrovascular-/pulmonary-related comorbidities 


















Congestive Heart Failure 
No. of subjects for analysis 948 948             
Failures [n (%)] 73 (7.7) 57 (6.0)             
Surv. time in yrs [mean (sd)]  3.3 (3.0) 5.3 (3.5)             
                
IPF vs. Non-IPF     2.21 1.42 3.42 2.59 1.50 4.46 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.98 0.18 22.12 3.22 0.18 56.74 
  25.0 - 29.9 0.98 0.50 1.92 1.27 0.56 2.91 
  30.0 - 39.9 1.06 0.41 2.74 1.28 0.40 4.05 
  40.0 - 55.9 . . . . . . 
  Unknown 0.69 0.27 1.74 0.32 0.06 1.92 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.09 0.87 5.00 1.88 0.62 5.75 
  Ex-smkrs 1.10 0.49 2.45 0.89 0.32 2.43 
  Unknown 1.08 0.39 3.02 0.10 0.01 1.25 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.52 0.22 1.26 0.05 0.00 0.54 
  Never 0.45 0.16 1.27 0.02 0.00 0.28 
  
Ex . . . . . . 
Ischemic Heart Disease 
No. of subjects for analysis 736 736             
Failures [n (%)] 72 (9.8) 50 (6.8)             
Surv. time in yrs [mean (sd)]  3.3 (3.1) 5.3 (3.4)             
                  
IPF vs. Non-IPF     2.07 1.34 3.20 1.80 1.06 3.06 
          
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 3.49 0.27 44.65 5.84 0.36 94.06 
  25.0 - 29.9 1.75 0.74 4.11 1.78 0.64 4.95 
  30.0 - 39.9 1.82 0.65 5.06 1.59 0.46 5.47 
  40.0 - 55.9 . . . . . . 
  Unknown 0.42 0.15 1.15 0.20 0.04 1.03 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.08 0.44 2.67 1.17 0.39 3.51 
  Ex-smkrs 2.38 1.08 5.25 1.83 0.72 4.61 
  Unknown 1.20 0.33 4.35 2.62 0.43 16.08 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.07 0.50 2.29 0.39 0.09 1.62 
  Never 1.14 0.42 3.15 0.39 0.08 1.88 
  
Ex . . . . . . 
Myocardial Infarction 
No. of subjects for analysis 1024 1024             
Failures [n (%)] 48 (4.7) 26 (2.5)             
Surv. time in yrs [mean (sd)]  3.2 (3.0) 5.3 (3.4)             
                
IPF vs. Non-IPF     2.8 1.6 4.9 2.58 1.20 5.55 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.54 0.49 4.88 1.13 0.23 5.71 
  30.0 - 39.9 1.43 0.45 4.59 0.93 0.17 4.94 
  40.0 - 55.9 . . . . . . 
  Unknown 0.30 0.09 1.05 0.08 0.01 0.99 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.22 0.34 4.34 1.04 0.16 6.66 
  Ex-smkrs 3.06 1.01 9.23 3.61 0.79 16.62 
  Unknown 0.79 0.21 3.05 7.62 0.56 102.92 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.30 0.49 3.48 0.50 0.07 3.49 
  Never 2.28 0.63 8.29 1.14 0.15 8.96 
  
Ex . . . . . . 
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 1059 1059             
Failures [n (%)] 47 (4.4) 74 (7.0)             
Surv. time in yrs [mean (sd)]  3.1 (3.0) 5.2 (3.4)             
                
IPF vs. Non-IPF     1.21 0.74 1.97 1.37 0.78 2.41 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.42 0.58 3.48 1.61 0.61 4.24 
  30.0 - 39.9 1.47 0.48 4.50 2.33 0.63 8.61 
  40.0 - 55.9 . . . . . . 
  Unknown 0.88 0.29 2.66 1.32 0.31 5.60 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.86 0.25 2.95 1.10 0.29 4.24 
  Ex-smkrs 1.44 0.57 3.62 1.98 0.70 5.60 
  Unknown 0.47 0.12 1.88 0.50 0.08 3.31 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.42 0.50 4.03 1.00 0.18 5.47 
  Never 2.15 0.57 8.17 1.78 0.27 11.77 
  
Ex . . . . . . 
Deep Vein Thrombosis 
No. of subjects for analysis 1198 1198             
Failures [n (%)] 19 (1.6) 22 (1.8)             
Surv. time in yrs [mean (sd)]  3.1 (2.9) 5.3 (3.4)             
                
IPF vs. Non-IPF     2.43 1.01 5.86 5.74 1.33 24.82 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.66 0.08 33.85 2.29 0.04 127.78 
  25.0 - 29.9 2.74 0.40 18.86 3.21 0.24 42.40 
  30.0 - 39.9 2.21 0.20 24.95 3.88 0.05 324.65 
  40.0 - 55.9 . . . . . . 
  Unknown 1.44 0.18 11.38 26.03 0.05 
14350.
89 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.34 0.05 2.35 0.09 0.01 1.80 
  Ex-smkrs 0.66 0.16 2.75 0.28 0.03 2.63 
  Unknown 0.38 0.06 2.34 0.11 0.00 50.04 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 2.33 0.41 13.45 2.26 0.01 437.18 
  Never 1.00 0.11 9.27 1.39 0.01 166.99 
  
Ex . . . . . . 
Pulmonary Embolism 
No. of subjects for analysis 1216 1216             
Failures [n (%)] 30 (2.5) 16 (1.3)             
Surv. time in yrs [mean (sd)]  3.1 (2.9) 5.3 (3.4)             
                  
IPF vs. Non-IPF     3.57 1.55 8.26 11.83 1.91 73.19 
          
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.90 0.25 3.17 0.26 0.02 3.17 
  30.0 - 39.9 1.36 0.23 7.93 2.21 0.08 57.86 
  40.0 - 55.9 . . . . . . 
  Unknown 1.06 0.25 4.53 0.71 0.01 62.84 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.81 0.12 5.62 0.11 0.00 3.69 
  Ex-smkrs 1.38 0.39 4.86 0.54 0.06 5.04 
  Unknown 1.60 0.26 9.81 1.01 0.00 518.91 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.25 0.34 4.66 1.47 0.04 51.51 
  Never 1.25 0.16 9.92 0.07 0.00 26.37 
  
Ex . . . . . . 
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No. of subjects for analysis 1266 1266             
Failures [n (%)] 12 (0.9) 2 (0.2)             
Surv. time in yrs [mean (sd)]  3.1 (3.0) 5.3 (3.5)             
                  
IPF vs. Non-IPF     10.00 1.28 78.11 . . . 
          
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.33 0.04 3.21 . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.44 0.16 37.13 . . . 
  Ex-smkrs 1.34 0.21 8.53 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current . . . . . . 
  Never . . . . . . 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
Table 4.5.1.1c IPF: Results of proportional hazards regression analyses for an 
incident diagnosis of cancer after index date 
IPF 
















Cancer in Situ Metastasis 
No. of subjects for analysis 1039 1039             
Failures [n (%)] 109 (10.5) 126 (12.1)             
Surv. time in yrs [mean (sd)]  3.1 (3.0) 5.2 (3.4)             
                  
IPF vs. Non-IPF     1.64 1.17 2.29 1.38 0.95 2.00 
          
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.18 0.02 1.60 0.12 0.01 1.39 
  25.0 - 29.9 1.63 0.92 2.86 1.64 0.89 3.02 
  30.0 - 39.9 0.43 0.18 1.04 0.42 0.17 1.05 
  40.0 - 55.9 . . . 0.00 0.00 . 
  Unknown 1.20 0.57 2.55 1.64 0.65 4.11 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.54 0.78 3.07 1.54 0.70 3.36 
  Ex-smkrs 2.10 1.09 4.03 1.89 0.92 3.88 
  Unknown 0.73 0.26 2.06 0.75 0.19 3.00 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.27 0.60 2.72 1.34 0.47 3.80 
  Never 1.65 0.65 4.19 1.79 0.54 5.88 
  
Ex 0.76 0.06 9.57 0.32 0.01 11.03 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
4.5.2 Granulomatous ILD 
4.5.2.1 Sarcoidosis 
During the follow-up period 33 (10%) sarcoidosis and 17 (5%) non-sarcoidosis 
subjects died. When investigating all-cause mortality as the outcome of interest, the 
mean (SD) survival time in the sarcoidosis cohort was 4.9 (3.5) years versus 4.6 (3.5) 
years in the control group.  After adjusting for smoking status, body mass index, and 
alcohol consumption status, the rate of all-cause mortality in the Sarcoidosis cohort 
was more than 5 times higher than the rate in the control group (RR 5.2, 95%CI:1.3 
to 21.4). Likewise, among the non-incident comorbidities investigated, the adjusted 
rate ratio for respiratory (non-pneumonia) infections was significantly elevated (RR 
2.2, 95% CI:1.6 to 3.1). Adjusted rate ratios and confidence intervals for other non-
incident and incident comorbidities under investigation were largely non-estimable 
due to sparsely populated strata. Further details of these analyses can be found in 
tables 4.5.2.1a-c below. 
Table 4.5.2.1a Sarcoidosis: Results of proportional hazards regression analyses for 




















Failures [n (%)] 33 (10.0) 17 (5.2)             
Surv. time in yrs [mean (sd)]  4.9 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis 1.86 0.97 3.56 5.20 1.26 21.42 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 2.05 0.17 25.06 0.33 0.02 7.17 
  25.0 - 29.9 0.89 0.25 3.21 1.89 0.30 11.85 
  30.0 - 39.9 1.20 0.32 4.48 0.56 0.05 6.01 
  40.0 - 55.9 0.89 0.10 7.94 0.23 0.01 7.85 
  Unknown 0.85 0.23 3.13 1.03 0.15 6.89 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 5.13 1.03 25.49 2.70 0.39 19.01 
  Ex-smkrs 2.64 0.75 9.30 5.66 0.80 40.10 
  Unknown 1.11 0.17 7.36 2.75 0.10 77.60 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.27 0.42 3.90 5.45 0.38 78.33 
  Never 0.39 0.07 2.19 0.41 0.03 6.52 
  
Ex . . . . . . 
Pneumonia 
Failures [n (%)] 10 (3.0) 7 (2.1)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.5 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis 1.33 0.46 3.84 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.38 0.02 6.63 . . . 
  30.0 - 39.9 1.09 0.05 22.00 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 1.51 0.12 19.33 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.00 0.18 22.05 . . . 
  Ex-smkrs 1.00 0.14 7.10 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.25 0.03 2.24 . . . 
  Never . . . . . . 
  
Ex . . . . . . 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 183 (55.5) 116 (35.2)             
Surv. time in yrs [mean (sd)]  2.5 (2.6) 3.2 (3.0)             
                
Sarcoidosis vs. Non-sarcoidosis 2.09 1.55 2.82 2.23 1.59 3.14 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 4.37 0.46 41.57 3.30 0.32 33.83 
  25.0 - 29.9 1.12 0.67 1.89 1.12 0.63 1.96 
  30.0 - 39.9 1.30 0.71 2.38 1.16 0.60 2.24 
  40.0 - 55.9 1.31 0.46 3.72 1.49 0.47 4.70 
  Unknown 0.66 0.36 1.19 1.51 0.66 3.47 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.80 0.45 1.41 1.29 0.68 2.48 
  Ex-smkrs 1.18 0.66 2.10 1.39 0.73 2.65 
  Unknown 0.42 0.21 0.86 0.53 0.20 1.39 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.74 1.02 2.97 1.32 0.57 3.04 
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  Never 1.92 0.92 3.98 1.71 0.63 4.61 
  
Ex 3.49 0.30 40.75 3.22 0.23 45.28 
Pneumothorax 
Failures [n (%)] 0 (0) 1 (0.3)             
Surv. time in yrs [mean (sd)]  4.9 (3.5) 4.6 (3.5)             
                
            
Bone fractures 
Failures [n (%)] 16 (4.8) 8 (2.4)             
Surv. time in yrs [mean (sd)]  4.7 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis 1.3 0.5 3.2     
             
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 2.62 0.39 17.53 . . . 
  30.0 - 39.9 1.63 0.16 17.16 . . . 
  40.0 - 55.9 0.26 0.01 5.68 . . . 
  Unknown 0.39 0.03 4.94 . . 
. 
           
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.00 0.37 10.92     
  Ex-smkrs 2.00 0.18 22.05 . . . 
  Unknown 0.50 0.05 5.51 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.42 0.04 4.32 . . . 
  Never 0.12 0.01 2.45 . . . 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
Table 4.5.2.1b Sarcoidosis: Results of proportional hazards regression analyses for 
incident cardiovascular-/ cerebrovascular-/pulmonary-related 
comorbidities after index date 













Congestive Heart Failure 
No. of subjects for analysis 319 319             
Failures [n (%)] 8 (2.5) 1 (0.3)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.7 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis     7.0 0.9 56.9 . . . 
            
Ischemic Heart Disease 
No. of subjects for analysis 294 294             
Failures [n (%)] 7 (2.4) 4 (1.4)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.7 (3.6)             
                
Sarcoidosis vs. Non-sarcoidosis     3.0 0.6 14.9 . . . 
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No. of subjects for analysis 330 330             
Failures [n (%)] 5 (1.5) 0 (0)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis  . . . . . . 
        
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 313 313             
Failures [n (%)] 3 (0.01) 4 (0.01)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis     0.50 0.09 2.73 . . . 
                  
Deep Vein Thrombosis 
No. of subjects for analysis 317 317             
Failures [n (%)] 7 (2.2) 0 (0)             
Surv. time in yrs [mean (sd)]  4.8 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis   . . . . . . 
        
Pulmonary Embolism 
No. of subjects for analysis 320 320             
Failures [n (%)] 4 (1.3) 0 (0)             
Surv. time in yrs [mean (sd)]  4.9 (3.5) 4.7 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis   . . . . . . 
        
Pulmonary Hypertension 
No. of subjects for analysis 329 329             
Failures [n (%)] 2 (0.6) 0 (0)             
Surv. time in yrs [mean (sd)]  4.9 (3.5) 4.6 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis  . . . . . . 
        
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
Table 4.5.2.1c Sarcoidosis: Results of proportional hazards regression analyses for 
an incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 295 295             
Failures [n (%)] 16 (5.4) 13 (4.4)             
Surv. time in yrs [mean (sd)]  4.9 (3.5) 4.5 (3.5)             
                
Sarcoidosis vs. Non-sarcoidosis 0.92 0.41 2.08 0.97 0.28 3.37 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . 0.00 0.00 . 
  25.0 - 29.9 1.00 0.23 4.41 0.90 0.11 7.60 
  30.0 - 39.9 1.00 0.22 4.53 1.67 0.25 11.14 
  40.0 - 55.9 1.00 0.12 8.57 2.14 0.14 32.64 
  Unknown 1.00 0.18 5.49 0.37 0.01 16.43 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.00 0.37 10.92 3.24 0.38 27.98 
  Ex-smkrs 1.50 0.25 8.98 1.12 0.07 18.70 
  Unknown 2.00 0.18 22.05 2.30 0.08 63.87 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.74 0.16 3.41 0.45 0.03 6.63 
  Never 0.80 0.08 7.77 0.66 0.04 11.99 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
4.5.2.2 Wegener’s Granulomatosis (WG) 
During the follow-up period 69 (23%) WG and 24 (8%) non-WG subjects died. When 
investigating all-cause mortality as the outcome of interest, the mean (SD) survival 
time in the Sarcoidosis cohort was 4.4 (3.7) years versus 5.2 (3.7) years in the 
control group.  After adjusting for smoking status, body mass index, and alcohol 
consumption status, the rate of all-cause mortality in the WG cohort was more than 7 
times higher than the rate in the control group (RR 7.2, 95%CI:3.2  to 16.3). Likewise, 
among the non-incident comorbidities investigated, the adjusted rate ratios for 
respiratory (non-pneumonia) infections and bone fractures were significantly elevated 
(RR 2.5 95% CI:1.8  to 3.6 and RR 13.3 95% CI:1.9  to 91.8, respectively). Crude 
and adjusted rate ratios for other non-incident and incident comorbidities under 
investigation were largely non-estimable due to lack of failures and/or sparsely 
populated strata. Further details of these analyses can be found in tables 4.5.2.2a-c 
below. 
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Table 4.5.2.2a WG: Results of proportional hazards regression analyses for all-cause 


















Failures [n (%)] 69 (22.9) 24 (8.0)             
Surv. time in yrs [mean (sd)]  4.4 (3.7) 5.2 (3.7)             
                
WG (cases) vs. Non-WG (controls) 4.13 2.35 7.27 7.21 3.20 16.26 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.44 0.60 3.47 1.85 0.46 7.48 
  30.0 - 39.9 1.32 0.45 3.87 1.31 0.26 6.56 
  40.0 - 55.9 . . . . . . 
  Unknown 1.82 0.72 4.60 1.16 0.27 5.03 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 4.32 1.28 14.60 10.99 2.10 57.68 
  Ex-smkrs 0.96 0.41 2.26 0.67 0.18 2.59 
  Unknown 2.32 0.63 8.50 1.67 0.12 22.88 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.73 0.29 1.86 0.60 0.08 4.78 
  Never 0.70 0.22 2.26 0.40 0.04 4.16 
  
Ex 0.37 0.03 4.82 0.13 0.00 455.24 
Pneumonia 
Failures [n (%)] 21 (7.0) 6 (2.0)             
Surv. time in yrs [mean (sd)]  4.2 (3.6) 5.1 (3.7)             
                
WG (cases) vs. Non-WG (controls) 3.0 1.2 7.6    
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.47 0.22 9.67 . . . 
  30.0 - 39.9 1.89 0.22 16.16 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.15 0.02 1.22 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.21 0.30 4.84 . . . 
  Ex-smkrs 1.37 0.30 6.21 . . . 
  Unknown 0.72 0.11 4.66 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.73 0.16 3.47 . . . 
  Never 0.79 0.13 4.87 . . . 
  
Ex 0.73 0.03 17.60 . . . 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 155 (51.5) 104 (34.6)             
Surv. time in yrs [mean (sd)] 2.2 (2.5) 3.8 (3.4)             
                
WG (cases) vs. Non-WG (controls) 2.44 1.77 3.37 2.50 1.76 3.56 
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) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.54 0.05 6.11 0.38 0.03 5.00 
  25.0 - 29.9 1.12 0.66 1.92 1.24 0.67 2.32 
  30.0 - 39.9 1.78 0.85 3.74 2.19 0.96 5.04 
  40.0 - 55.9 1.92 0.50 7.40 1.81 0.40 8.20 
  Unknown 0.51 0.26 1.02 0.50 0.20 1.28 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.35 0.72 2.55 1.69 0.79 3.59 
  Ex-smkrs 2.41 1.26 4.59 1.94 0.94 4.02 
  Unknown 0.48 0.20 1.12 0.54 0.16 1.85 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.26 0.65 2.43 0.49 0.17 1.41 
  Never 1.95 0.87 4.38 0.83 0.26 2.67 
  
Ex 1.35 0.24 7.63 0.34 0.04 2.87 
Pneumothorax 
Failures [n (%)] 2 (0.7) 0 (0)             
Surv. time in yrs [mean (sd)]  4.4 (3.7) 5.2 (3.7)             
                
WG (cases) vs. Non-WG (controls) . . . . . . 
        
Bone fractures 
Failures [n (%)] 27 (9.0) 16 (5.3)             
Surv. time in yrs [mean (sd)]  4.0 (3.5) 4.9 (3.6)             
                
WG (cases) vs. Non-WG (controls) 2.20 1.04 4.65 13.33 1.94 91.77 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.04 0.32 3.41 3.04 0.37 24.67 
  30.0 - 39.9 0.53 0.09 3.37 0.51 0.03 9.80 
  40.0 - 55.9 . . . . . . 
  Unknown 1.34 0.21 8.64 1.50 0.12 19.59 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.00 0.15 6.89 0.02 0.00 1.29 
  Ex-smkrs 3.00 0.56 15.96 0.94 0.10 9.21 
  Unknown 0.33 0.02 6.53 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.61 0.10 3.87 . . . 
  Never 0.77 0.11 5.18 . . . 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
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Table 4.5.2.2b WG: Results of proportional hazards regression analyses for incident 
cardiovascular-/ cerebrovascular-/pulmonary-related comorbidities 
after index date 













Congestive Heart Failure 
No. of subjects for analysis 289 289             
Failures [n (%)] 9 (2.5) 10 (0.3)             
Surv. time in yrs [mean (sd)]  4.4 (3.6) 5.1 (3.7)             
                
WG (cases) vs. Non-WG (controls) 1.40 0.44 4.41 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.50 0.05 5.51 . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.50 0.05 5.51 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 0.50 0.05 5.51 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.33 0.04 3.21 1.00 0.06 15.99 
  Never 0.67 0.03 18.06 . . . 
  
Ex . . . . . . 
Ischemic Heart Disease 
No. of subjects for analysis 244 244             
Failures [n (%)] 12 (2.4) 10 (1.0)             
Surv. time in yrs [mean (sd)]  4.4 (3.6) 5.0 (3.7)             
                
WG (cases) vs. Non-WG (controls) 1.57 0.61 4.05 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.37 0.19 9.77 . . . 
  30.0 - 39.9 3.07 0.19 50.83 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.73 0.10 5.23 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.53 0.09 3.21 . . . 
  Ex-smkrs 0.33 0.04 3.21 . . . 
  Unknown 0.45 0.05 3.83 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.70 0.15 3.22 . . . 
  Never 1.13 0.13 9.81 . . . 
  
Ex . . . . . . 
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No. of subjects for analysis 301 301             
Failures [n (%)] 11 (3.7) 7 (2.3)             
Surv. time in yrs [mean (sd)]  4.2 (3.6) 5.1 (3.7)             
                
WG (cases) vs. Non-WG (controls) 2.50 0.78 7.97 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.00 0.14 7.10 0.40 0.02 7.93 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
                
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 1.00 0.06 15.99 3.56 0.09 148.59 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.82 0.18 3.79 12.65 0.09 
1706.0
8 
  Never 1.87 0.16 21.73 15.08 0.24 942.71 
  
Ex . . . . . . 
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 274 274             
Failures [n (%)] 12 (1.0) 5 (1.3)             
Surv. time in yrs [mean (sd)]  4.3 (3.6) 5.2 (3.8)             
                
WG (cases) vs. Non-WG (controls) 4.50 0.97 20.83 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 2.08 0.18 24.55 . . . 
  30.0 - 39.9 2.08 0.05 85.13 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 1.13 0.21 5.92 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 1.00 0.04 24.55 . . . 
  Unknown 1.00 0.04 24.55 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.00 0.14 7.10 . . . 
  Never 0.33 0.02 6.65 . . . 
  
Ex . . . . . . 
Deep Vein Thrombosis 
No. of subjects for analysis 286 286             
Failures [n (%)] 9 (3.1) 2 (0.7)             
Surv. time in yrs [mean (sd)]  4.3 (3.7) 5.2 (3.7)             
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WG (cases) vs. Non-WG (controls) 4.00 0.85 18.84 . . . 
                  
Pulmonary Embolism 
No. of subjects for analysis 295 295             
Failures [n (%)] 2 (0.7) 0 (0)             
Surv. time in yrs [mean (sd)]  4.4 (3.7) 5.2 (3.7)             
                
WG (cases) vs. Non-WG (controls) . . . . . . 
                  
Pulmonary Hypertension 
No. of subjects for analysis 301 301             
Failures [n (%)] 0 (0) 0 (0)             
Surv. time in yrs [mean (sd)]  4.4 (3.7) 5.2 (3.7)             
                
WG (cases) vs. Non-WG (controls) . . . . . . 
                  
                  
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
Table 4.5.2.2c WG: Results of proportional hazards regression analyses for an 
incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 253 253             
Failures [n (%)] 19 (7.5) 15 (5.9)             
Surv. time in yrs [mean (sd)]  4.2 (3.6) 5.0 (3.7)             
                
WG (cases) vs. Non-WG (controls) 1.89 0.84 4.24 12.14 0.45 325.98 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.58 0.41 6.07 23.12 0.20 
2710.9
3 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.75 0.16 3.61 3.08 0.04 217.14 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 0.33 0.04 3.21 0.25 0.01 5.78 
  Unknown 2.00 0.18 22.06 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 3.00 0.61 14.86 . . . 
  Never 1.50 0.25 8.98 . . . 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
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4.5.3 ILD of known cause or associated with other diseases 
4.5.3.1 Extrinsic Allergic Alveolitis (EAA) 
During the follow-up period 89 (19%) EAA and 49 (11%) non-EAA subjects died. 
When investigating all-cause mortality as the outcome of interest, the mean (SD) 
survival time in the EAA cohort was 5.1 (3.8) years versus 5.4 (3.8) years in the 
control group. After adjusting for smoking status, body mass index, and alcohol 
consumption status, the rate of all-cause mortality in the EAA cohort was around 3 
times higher than the rate in the control group (RR 2.9, 95%CI: 1.8  to 4.8). Likewise, 
among the non-incident comorbidities investigated, the adjusted rate ratio for 
respiratory (non-pneumonia) infections was significantly elevated (RR 1.9 95% CI: 
1.5  to 2.4). Crude and adjusted rate ratios for other non-incident and incident 
comorbidities under investigation were largely non-estimable due to lack of failures 
and/or sparsely populated strata. Further details of these analyses can be found in 
tables 4.5.3.1a-c below. 
Table 4.5.3.1a EAA: Results of proportional hazards regression analyses for all-




















Failures [n (%)] 89 (19.1) 49 (10.5)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.8)             
                
EAA (cases) vs. Non-EAA (controls) 2.40 1.57 3.67 2.91 1.76 4.81 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.00 0.06 15.99 0.22 0.01 4.27 
  25.0 - 29.9 0.80 0.38 1.68 0.93 0.37 2.32 
  30.0 - 39.9 1.05 0.45 2.42 1.46 0.53 4.01 
  40.0 - 55.9 . . . . . . 
  Unknown 1.54 0.62 3.85 2.17 0.57 8.21 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.32 0.57 3.07 1.28 0.45 3.66 
  Ex-smkrs 0.83 0.40 1.72 0.88 0.37 2.10 
  Unknown 1.36 0.46 4.08 0.53 0.10 2.81 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.51 0.23 1.15 0.43 0.14 1.31 
  Never 0.38 0.14 1.04 0.21 0.05 0.88 
  
Ex . . . . . . 
Pneumonia 
Failures [n (%)] 28 (6.0) 9 (1.9)             
Surv. time in yrs [mean (sd)]  4.9 (3.8) 5.4 (3.8)             
                
EAA (cases) vs. Non-EAA (controls) 5.20 2.00 13.54 . . . 
                  
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.21 0.27 5.36 . . . 
  30.0 - 39.9 0.53 0.05 6.16 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 1.12 0.24 5.18 . . . 
                
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.79 0.21 3.04 . . . 
  Ex-smkrs 0.95 0.27 3.40 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.47 0.11 1.89 . . . 
  Never 0.86 0.13 5.65 . . . 
  
Ex . . . . . . 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 275 (59.0) 198 (42.5)             
Surv. time in yrs [mean (sd)]  2.7 (2.9) 3.4 (3.0)             
                
EAA (cases) vs. Non-EAA (controls) 1.86 1.47 2.35 1.87 1.46 2.41 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.74 0.19 2.85 0.55 0.13 2.25 
  25.0 - 29.9 0.97 0.63 1.50 1.06 0.66 1.70 
  30.0 - 39.9 0.93 0.56 1.54 0.96 0.56 1.63 
  40.0 - 55.9 4.88 0.57 42.05 7.72 0.85 70.21 
  Unknown 0.62 0.36 1.07 0.69 0.34 1.40 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.78 0.49 1.25 0.80 0.48 1.32 
  Ex-smkrs 1.32 0.84 2.06 1.14 0.70 1.86 
  Unknown 1.03 0.54 1.96 1.23 0.53 2.90 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.93 0.59 1.46 0.81 0.44 1.46 
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  Never 1.35 0.73 2.49 1.13 0.54 2.39 
  
Ex 0.43 0.08 2.40 0.64 0.10 4.08 
Pneumothorax 
Failures [n (%)] 6 (1.9) 0 (0)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.8)             
                
EAA (cases) vs. Non-EAA (controls) . . . . . . 
            
Bone fractures 
Failures [n (%)] 33 (7.1) 32 (6.9)             
Surv. time in yrs [mean (sd)]  4.8 (3.7) 5.1 (3.8)             
                
EAA (cases) vs. Non-EAA (controls) 1.12 0.65 1.92 1.04 0.55 1.97 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.52 0.17 1.64 0.40 0.11 1.44 
  30.0 - 39.9 0.35 0.11 1.14 0.29 0.08 1.08 
  40.0 - 55.9 . . . . . . 
  Unknown 0.34 0.10 1.24 0.52 0.12 2.25 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.58 0.14 2.38 0.79 0.16 3.86 
  Ex-smkrs 0.99 0.36 2.73 1.13 0.33 3.86 
  Unknown 0.53 0.08 3.57 1.23 0.12 12.62 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 3.23 0.84 12.46 4.04 0.73 22.50 
  Never 2.44 0.51 11.75 2.58 0.40 16.58 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  




Table 4.5.3.1b EAA: Results of proportional hazards regression analyses for incident 
cardiovascular-/cerebrovascular-/pulmonary-related comorbidities 
after index date 













Congestive Heart Failure 
No. of subjects for analysis 421 421             
Failures [n (%)] 18 (4.3) 7 (1.7)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 4.50 1.52 13.30 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.00 0.06 15.99 . . . 
  25.0 - 29.9 0.63 0.07 5.53 . . . 
  30.0 - 39.9 1.46 0.18 11.85 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.57 0.11 2.95 . . . 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.50 0.09 2.73 . . . 
  Ex-smkrs 1.00 0.06 15.99 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.25 0.26 5.96 . . . 
  Never 1.57 0.24 10.21 . . . 
  
Ex . . . . . . 
Ischemic Heart Disease 
No. of subjects for analysis 366 366             
Failures [n (%)] 20 (5.5) 15 (4.1)             
Surv. time in yrs [mean (sd)]  5.2 (3.8) 5.2 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 1.23 0.59 2.56 0.19 0.01 2.49 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 . . . . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.29 0.24 6.78 0.88 0.00 . 
  Ex-smkrs 1.29 0.17 9.95 2.72 0.02 331.79 
  Unknown 0.19 0.02 1.66 0.04 0.00 11.70 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 10.35 1.21 88.60 67.68 0.62 
7410.1
5 
  Never 6.82 0.70 66.76 8.99 0.23 355.73 
  
Ex . . . . . . 
Myocardial Infarction 
No. of subjects for analysis 466 466             
Failures [n (%)] 8 (1.7) 11 (2.4)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.3 (3.8)             
                
EAA (cases) vs. Non-EAA (controls) 0.75 0.26 2.16 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.23 0.02 2.67 . . . 
  30.0 - 39.9 0.61 0.04 8.62 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.14 0.01 2.55 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.74 0.27 28.14 . . . 
  Ex-smkrs 4.08 0.20 83.13 . . . 
  Unknown . . . . . . 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 3.52 0.36 34.68 . . . 
  Never 4.95 0.41 59.93 . . . 
  
Ex . . . . . . 
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 431 431             
Failures [n (%)] 18 (4.2) 19 (4.4)             
Surv. time in yrs [mean (sd)]  5.2 (3.8) 5.3 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 1.00 0.49 2.05 1.47 0.55 3.97 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 2.31 0.51 10.54 2.81 0.48 16.35 
  30.0 - 39.9 2.09 0.43 10.19 3.50 0.40 31.00 
  40.0 - 55.9 . . . . . . 
  Unknown 1.20 0.28 5.13 1.03 0.11 9.42 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.38 0.56 10.10 4.64 0.71 30.40 
  Ex-smkrs 1.39 0.38 5.11 1.83 0.34 9.87 
  Unknown 0.31 0.03 2.87 0.60 0.03 10.99 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.84 0.53 6.40 0.76 0.10 5.96 
  Never 1.08 0.14 8.43 0.91 0.05 17.31 
  
Ex . . . . . . 
Deep Vein Thrombosis 
No. of subjects for analysis 447 447             
Failures [n (%)] 5 (1.1) 5 (1.1)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 1.00 0.25 4.00    
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.26 0.02 4.48 . . . 
  30.0 - 39.9 1.46 0.07 30.97 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.61 0.01 33.61 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 4.54 0.29 69.98 . . . 
  Ex-smkrs 2.13 0.17 26.15 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.00 0.05 19.36 . . . 
  Never 1.00 0.05 19.36 . . . 
  
Ex . . . . . . 
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No. of subjects for analysis 451 451             
Failures [n (%)] 7 (1.6) 5 (1.1)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 1.75 0.51 5.98 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 3.00 0.31 28.84 . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.00 0.06 15.99 . . . 
  Ex-smkrs 1.00 0.06 15.99 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current . . . . . . 
  Never . . . . . . 
  
Ex . . . . . . 
Pulmonary Hypertension 
No. of subjects for analysis 465 465             
Failures [n (%)] 4 (0.9) 0 (0)             
Surv. time in yrs [mean (sd)]  4.1 (3.8) 5.4 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) . . . . . . 
        
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
Table 4.5.3.1c EAA: Results of proportional hazards regression analyses for an 
incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 403 403             
Failures [n (%)] 27 (6.7) 26 (6.5)             
Surv. time in yrs [mean (sd)]  5.1 (3.8) 5.4 (3.9)             
                
EAA (cases) vs. Non-EAA (controls) 1.05 0.58 1.88 1.24 0.58 2.66 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.79 0.05 13.97 0.56 0.03 12.90 
  25.0 - 29.9 0.63 0.16 2.43 1.03 0.16 6.82 
  30.0 - 39.9 1.29 0.39 4.26 2.07 0.43 10.02 
  40.0 - 55.9 . . . . . . 
  Unknown 1.60 0.39 6.64 1.83 0.23 14.40 
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Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.38 0.41 4.69 1.24 0.58 2.66 
  Ex-smkrs 1.68 0.57 4.93 1.41 0.34 5.94 
  Unknown 1.62 0.34 7.71 1.53 0.41 5.68 
                
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.24 0.34 4.51 1.49 0.25 8.96 
  Never 0.23 0.04 1.39 0.28 0.03 2.57 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
4.5.3.2 Pneumoconioses 
During the follow-up period 545 (23%) subjects with pneumoconioses and 363 (15%) 
non-pneumoconioses subjects died. When investigating all-cause mortality as the 
outcome of interest, the mean (SD) survival time in the pneumoconioses cohort was 
4.0 (3.2) years versus 4.4 (3.3) years in the control group.  After adjusting for 
smoking status, body mass index, and alcohol consumption status, the rate of all-
cause mortality in the pneumoconioses cohort remained  twice as high as the rate in 
the control group (RR 2.0, 95%CI:1.7 to 2.4). Likewise, among the non-incident 
comorbidities investigated, rate ratios for pneumonia, respiratory (non-pneumonia) 
infections, and haemoptysis remained elevated after adjustment for smoking status, 
body mass index, and alcohol consumption status (see RRs and 95% CIs  below). 
Among the incident cardiovascular outcomes investigated, adjusted rate ratios for 
myocardial infarction, ischemic heart disease, and congestive heart failure were all 
significantly elevated. Among these incident outcomes of interest, the highest 
adjusted rate ratio was observed for congestive heart failure (RR 2.9, 95%CI:1.9 to 
4.4). Among the other incident comorbidities under investigation, the rate ratio for 
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cancer remained elevated after adjustment (RR 1.6, 95%CI:1.3 to 2.0).  Crude and 
adjusted rate ratios for certain incident comorbidities under investigation were non-
estimable due to lack of failures and/or sparsely populated strata. Further details of 
these analyses can be found in tables 4.5.3.2a-c below. 
Table 4.5.3.2a Pneumoconioses: Results of proportional hazards regression 
analyses for all-cause mortality and selected, non-incident 



















Failures [n (%)] 545 (22.5) 363 (15.0)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 2.01 1.71 2.36 2.01 1.70 2.37 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 3.14 1.34 7.35 2.46 0.99 6.08 
  25.0 - 29.9 0.85 0.65 1.11 0.87 0.65 1.16 
  30.0 - 39.9 0.68 0.47 0.98 0.74 0.49 1.10 
  40.0 - 55.9 . . . . . . 
  Unknown 0.87 0.62 1.22 0.94 0.62 1.42 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.04 1.50 2.79 1.72 1.23 2.42 
  Ex-smkrs 1.28 0.97 1.69 1.12 0.82 1.52 
  Unknown 1.11 0.72 1.71 1.21 0.69 2.11 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.96 0.70 1.34 0.92 0.60 1.41 
  Never 1.13 0.76 1.70 1.08 0.66 1.76 
  
Ex 1.06 0.49 2.28 1.04 0.46 2.36 
Pneumonia 
Failures [n (%)] 162 (6.7) 73 (3.0)             
Surv. time in yrs [mean (sd)]  3.9 (3.2) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 2.98 2.12 4.17 3.17 2.18 4.63 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 3.06 0.59 15.90 5.03 0.76 33.26 
  25.0 - 29.9 1.07 0.66 1.71 1.16 0.65 2.04 
  30.0 - 39.9 1.16 0.61 2.22 1.20 0.54 2.67 
  40.0 - 55.9 . . . . . . 
  Unknown 0.70 0.36 1.39 0.68 0.27 1.71 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.94 1.04 3.61 0.88 0.41 1.89 
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  Ex-smkrs 1.44 0.85 2.43 1.01 0.54 1.88 
  Unknown 0.84 0.33 2.13 0.43 0.11 1.70 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.89 0.46 1.74 0.33 0.11 0.98 
  Never 0.63 0.29 1.36 0.30 0.10 0.94 
  
Ex 0.87 0.22 3.45 0.59 0.11 3.30 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 
1233 
(51.0) 862 (35.6)             
Surv. time in yrs [mean (sd)]  2.3 (2.4) 3.1 (2.8)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 2.00 1.79 2.24 1.93 1.72 2.16 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.75 0.40 1.39 0.78 0.40 1.52 
  25.0 - 29.9 0.98 0.82 1.19 0.95 0.78 1.17 
  30.0 - 39.9 0.91 0.71 1.16 0.95 0.73 1.23 
  40.0 - 55.9 1.77 0.74 4.21 1.72 0.69 4.29 
  Unknown 0.65 0.51 0.84 0.75 0.55 1.02 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.48 1.20 1.83 1.39 1.11 1.74 
  Ex-smkrs 1.68 1.40 2.03 1.50 1.23 1.83 
  Unknown 0.84 0.61 1.17 1.08 0.71 1.62 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.44 1.13 1.82 1.06 0.76 1.47 
  Never 1.44 1.06 1.96 1.11 0.76 1.63 
  
Ex 1.45 0.85 2.47 0.95 0.52 1.73 
Pneumothorax 
Failures [n (%)] 10 (0.4) 2 (0.08)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 10.00 1.28 78.11    
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.47 0.08 2.79 . . . 
  30.0 - 39.9 0.68 0.04 13.20 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.00 0.00 . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 1.00 0.14 7.10 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.00 0.06 15.99 . . . 
  Never 1.00 0.02 50.40 . . . 
  
Ex . . . . . . 
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Failures [n (%)] 144 (6.0) 133 (5.5)             
Surv. time in yrs [mean (sd)]  3.8 (3.2) 4.3 (3.2)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.14 0.87 1.50 1.11 0.83 1.49 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.56 0.35 0.90 0.58 0.35 0.95 
  30.0 - 39.9 0.38 0.20 0.73 0.37 0.18 0.73 
  40.0 - 55.9 . . . . . . 
  Unknown 0.73 0.39 1.39 0.66 0.30 1.45 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.23 0.75 2.03 1.05 0.61 1.81 
  Ex-smkrs 0.98 0.60 1.57 0.91 0.54 1.53 
  Unknown 1.55 0.69 3.47 2.07 0.74 5.83 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.98 0.55 1.75 1.31 0.59 2.93 
  Never 0.90 0.37 2.18 1.07 0.37 3.07 
  
Ex 3.35 0.63 17.68 3.97 0.65 24.08 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
 
Table 4.5.3.2b Pneumoconioses: Results of proportional hazards regression 
analyses for incident cardiovascular- / cerebrovascular- / pulmonary-
related comorbidities after index date 













Congestive Heart Failure 
No. of subjects for analysis 2084 2084             
Failures [n (%)] 121 (5.8) 66 (3.2)             
Surv. time in yrs [mean (sd)]  4.0 (3.3) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 2.53 1.75 3.64 2.90 1.91 4.42 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.15 0.07 18.78 1.52 0.04 54.14 
  25.0 - 29.9 1.32 0.71 2.43 1.44 0.69 3.01 
  30.0 - 39.9 2.62 1.10 6.23 4.52 1.64 12.43 
  40.0 - 55.9 . . . . . . 
  Unknown 1.11 0.51 2.41 2.08 0.77 5.59 
                
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.81 0.41 1.58 0.63 0.28 1.40 
  Ex-smkrs 1.32 0.74 2.36 0.97 0.47 1.98 
  Unknown 0.42 0.15 1.14 0.32 0.08 1.33 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.36 0.67 2.77 0.97 0.31 3.05 
  Never 0.95 0.38 2.37 0.54 0.14 2.05 
  
Ex 1.05 0.24 4.65 0.66 0.09 4.81 
Ischemic Heart Disease 
No. of subjects for analysis 1518 1518             
Failures [n (%)] 112 (7.4) 74 (4.9)             
Surv. time in yrs [mean (sd)]  4.0 (3.3) 4.4 (3.4)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.71 1.23 2.38 1.81 1.26 2.59 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.02 0.61 1.71 1.04 0.59 1.83 
  30.0 - 39.9 0.88 0.42 1.85 1.06 0.48 2.34 
  40.0 - 55.9 . . . . . . 
  Unknown 0.72 0.33 1.56 0.46 0.18 1.17 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.03 0.59 1.80 1.33 0.71 2.50 
  Ex-smkrs 0.84 0.47 1.48 0.78 0.41 1.49 
  Unknown 0.81 0.27 2.48 0.52 0.14 1.92 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.67 0.31 1.44 0.46 0.17 1.24 
  Never 1.00 0.39 2.54 0.80 0.27 2.43 
  
Ex 1.47 0.31 6.85 1.31 0.24 7.22 
Myocardial Infarction 
No. of subjects for analysis 2418 2418             
Failures [n (%)] 85 (3.5) 70 (2.9)             
Surv. time in yrs [mean (sd)]  3.9 (3.2) 4.3 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.58 1.10 2.27 1.70 1.14 2.52 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.63 0.06 7.26 0.34 0.02 5.51 
  25.0 - 29.9 1.43 0.78 2.64 1.68 0.85 3.30 
  30.0 - 39.9 1.03 0.42 2.52 1.30 0.51 3.32 
  40.0 - 55.9 . . . . . . 
  Unknown 1.62 0.69 3.81 1.99 0.62 6.34 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.72 0.84 3.54 1.77 0.81 3.90 
  Ex-smkrs 1.01 0.54 1.88 0.86 0.44 1.66 
  Unknown 0.53 0.13 2.25 0.33 0.04 2.58 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.02 0.43 2.42 0.79 0.21 2.98 
  Never 1.52 0.50 4.60 1.23 0.29 5.33 
  
Ex 1.69 0.33 8.54 1.34 0.19 9.30 
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Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 2041 2041             
Failures [n (%)] 105 (5.1) 82 (4.0)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.77 1.24 2.52 1.96 1.27 3.03 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.98 0.06 15.94 0.89 0.03 27.50 
  25.0 - 29.9 0.96 0.54 1.73 0.80 0.40 1.59 
  30.0 - 39.9 0.58 0.25 1.35 0.68 0.26 1.81 
  40.0 - 55.9 . . . . . . 
  Unknown 0.70 0.31 1.57 0.47 0.16 1.37 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.05 1.01 4.18 2.16 0.94 4.96 
  Ex-smkrs 2.22 1.18 4.17 2.17 1.06 4.45 
  Unknown 4.73 1.38 16.20 13.57 2.66 69.27 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.98 0.44 2.19 1.13 0.35 3.72 
  Never 1.67 0.57 4.88 3.42 0.84 13.93 
  
Ex 0.72 0.16 3.21 1.54 0.25 9.42 
Deep Vein Thrombosis 
No. of subjects for analysis 2305 2305             
Failures [n (%)] 27 (1.2) 22 (1.0)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.5 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.50 0.80 2.82 1.66 0.73 3.80 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 2.33 0.52 10.41 4.67 0.57 38.47 
  30.0 - 39.9 2.50 0.51 12.41 3.06 0.41 22.66 
  40.0 - 55.9 . . . . . . 
  Unknown 2.04 0.38 10.97 6.85 0.41 114.70 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.50 0.09 2.82 0.40 0.03 5.38 
  Ex-smkrs 2.00 0.65 6.17 1.42 0.33 6.18 
  Unknown 0.50 0.05 5.51 3.51 0.11 112.95 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.28 0.21 7.98 16.78 0.28 992.51 




Ex . . . . . . 
Pulmonary Embolism 
No. of subjects for analysis 2334 2334             
Failures [n (%)] 21 (0.9) 9 (0.4)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.4 (3.3)             
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Pneumocon. (cases) vs. Non-Pneumocon. (controls) 2.00 0.86 4.67 1.45 0.27 7.73 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 . . . . . . 
  30.0 - 39.9 2.00 0.18 22.06 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.32 0.03 2.99 . . . 
  Ex-smkrs 1.94 0.48 7.86 0.26 0.02 3.61 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 2.00 0.18 22.06 . . . 
  Never . . . . . . 
  
Ex . . . . . . 
Pulmonary Hypertension 
No. of subjects for analysis 2409 2409             
Failures [n (%)] 5 (0.2) 2 (0.08)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.4 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 4.00 0.45 35.79 . . . 
            
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
Table 4.5.3.2c Pneumoconioses: Results of proportional hazards regression 
analyses for an incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 1955 1955             
Failures [n (%)] 255 (13.0) 184 (9.4)             
Surv. time in yrs [mean (sd)]  4.0 (3.2) 4.5 (3.3)             
                
Pneumocon. (cases) vs. Non-Pneumocon. (controls) 1.61 1.30 1.99 1.61 1.28 2.03 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 2.30 0.59 8.90 1.39 0.34 5.68 
  25.0 - 29.9 0.93 0.65 1.32 0.95 0.65 1.39 
  30.0 - 39.9 0.68 0.41 1.12 0.79 0.46 1.34 
  40.0 - 55.9 0.82 0.05 13.48 0.32 0.02 5.71 
  Unknown 0.46 0.28 0.76 0.44 0.24 0.82 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.04 1.34 3.11 1.80 1.14 2.85 
  Ex-smkrs 1.01 0.70 1.46 0.84 0.57 1.25 
  Unknown 0.58 0.29 1.17 0.71 0.30 1.72 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.42 0.87 2.34 0.75 0.37 1.52 
  Never 1.56 0.83 2.92 0.93 0.42 2.07 
  
Ex 1.70 0.51 5.61 0.99 0.25 3.94 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
4.5.3.3 Drug-/radiation-induced ILD (DRAD) 
During the follow-up period 68 (47%) subjects with DRAD-ILD and 16 (11%) non-
DRAD-ILD subjects died. When investigating all-cause mortality as the outcome of 
interest, the mean (SD) survival time in the DRAD-ILD cohort was 2.8 (3.0) years 
versus 4.5 (3.3) years in the non-DRAD-ILD group.  After adjusting for smoking 
status, body mass index, and alcohol consumption status, the rate of all-cause 
mortality in the DRAD-ILD cohort remained significantly elevated compared with the 
rate in the control group (RR 23.0, 95%CI: 3.8 to 139.4). Likewise, among the non-
incident comorbidities investigated, the rate ratio for respiratory (non-pneumonia) 
infections remained elevated after adjustment for smoking status, body mass index, 
and alcohol consumption status (RR 3.3, 95%CI: 1.7 to 6.4). Crude and adjusted rate 
ratios for incident comorbidities under investigation were largely non-estimable due to 
lack of failures and/or sparsely populated strata. Further details of these analyses 
can be found in tables 4.5.3.2a-c below. 
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Table 4.5.3.3a Drug-/radiation-induced ILD: Results of proportional hazards 
regression analyses for all-cause mortality and selected non-incident 



















Failures [n (%)] 68 (46.9) 16 (11.0)             
Surv. time in yrs [mean (sd)]  2.8  (3.0) 4.5 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 7.63 3.65 15.93 23.01 3.80 139.35 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.78 0.33 1.86 0.09 0.01 0.86 
  30.0 - 39.9 0.69 0.23 2.12 0.33 0.02 4.69 
  40.0 - 55.9 . . . . . . 
  Unknown 0.33 0.10 1.01 0.34 0.03 4.48 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 2.28 0.77 6.74 2.30 0.22 24.59 
  Ex-smkrs 3.48 1.32 9.17 11.47 0.94 140.26 
  Unknown 1.02 0.16 6.43 5.95 0.08 465.13 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 2.52 0.59 10.72 0.85 0.03 29.36 
  Never 0.98 0.18 5.28 0.05 0.00 4.57 
  
Ex 0.65 0.04 11.64 0.45 0.00 68.88 
Pneumonia 
Failures [n (%)] 9 (6.2) 5 (3.4)             
Surv. time in yrs [mean (sd)]  2.8 (3.0) 4.5 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 2.67 0.71 10.05 1.00 0.06 15.99 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 . . . . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown . . . . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 3.23 0.31 33.47 . . . 
  Ex-smkrs 2.44 0.16 37.14 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current . . . . . . 
  Never . . . . . . 
  
Ex . . . . . . 
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Respiratory (non-pneumonia) infections 
Failures [n (%)] 74 (51.0) 61 (42.1)             
Surv. time in yrs [mean (sd)]  1.4 (2.1) 2.8 (2.6)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 3.71 2.17 6.33 3.31 1.72 6.38 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 0.71 0.09 5.60 3.30 0.15 74.79 
  25.0 - 29.9 1.05 0.41 2.69 1.02 0.31 3.33 
  30.0 - 39.9 0.36 0.12 1.11 0.43 0.11 1.74 
  40.0 - 55.9 . . . 0.00 0.00 . 
  Unknown 0.23 0.07 0.79 0.23 0.03 1.65 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.37 0.46 4.07 1.48 0.38 5.77 
  Ex-smkrs 3.85 1.57 9.46 3.69 1.10 12.35 
  Unknown 0.33 0.04 3.00 2.75 0.08 100.02 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 5.82 1.22 27.81 3.03 0.37 24.85 
  Never 3.83 0.76 19.30 4.77 0.46 50.00 
  
Ex 3.27 0.31 34.52 3.78 0.13 107.80 
Pneumothorax 
Failures [n (%)] 2 (1.4) 0 (0)       
Surv. time in yrs [mean (sd)]  2.8 (3.0) 4.5 (3.3)       
          
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) . . . . . . 
            
Bone fractures 
Failures [n (%)] 8 (5.5) 8 (5.5)             
Surv. time in yrs [mean (sd)]  2.7 (3.0) 4.3 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 1.40 0.44 4.41 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.37 0.04 3.89 . . . 
  30.0 - 39.9 1.65 0.10 28.06 . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 1.28 0.06 29.44 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs . . . . . . 
  Ex-smkrs 0.50 0.05 5.51 . . . 
  Unknown . . . . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.00 0.12 8.13 . . . 
  Never 1.00 0.05 19.36 . . . 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
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Table 4.5.3.3b DRAD-ILD: Results of proportional hazards regression analyses for 
incident cardiovascular-/cerebrovascular-/pulmonary-related 
comorbidities after index date 













Congestive Heart Failure 
No. of subjects for analysis 121 121             
Failures [n (%)] 5 (4.1) 1 (0.8)             
Surv. time in yrs [mean (sd)]  2.8 (3.1) 4.7 (3.5)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 5.00 0.58 42.79 . . . 
            
Ischemic Heart Disease 
No. of subjects for analysis 101 101             
Failures [n (%)] 1 (1.0) 3 (3.0)             
Surv. time in yrs [mean (sd)]  2.9 (3.1) 4.5 (3.4)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 0.50 0.05 5.51 . . . 
                  
Myocardial Infarction 
No. of subjects for analysis 145 145             
Failures [n (%)] 3 (2.1) 1 (0.7)             
Surv. time in yrs [mean (sd)]  2.8 (3.0) 4.5 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) . . . . . . 
                  
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 122 122             
Failures [n (%)] 2 (1.6) 3 (2.5)             
Surv. time in yrs [mean (sd)]  2.9 (3.0) 4.8 (3.4)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 1.00 0.14 7.10 . . . 
                  
Deep Vein Thrombosis 
No. of subjects for analysis 135 135             
Failures [n (%)] 3 (2.2) 1 (0.7)             
Surv. time in yrs [mean (sd)]  2.8 (2.9) 4.4 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) . . . . . . 
        
Pulmonary Embolism 
No. of subjects for analysis 139 139             
Failures [n (%)] 6 (4.3) 0 (0)             
Surv. time in yrs [mean (sd)]  2.8 (3.1) 4.5 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) . . . . . . 
                  
Pulmonary Hypertension 
No. of subjects for analysis 139 139             
Failures [n (%)] 3 (2.2) 0 (0)             
Surv. time in yrs [mean (sd)]  2.8 (3.0) 4.5 (3.3)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) . . . . . . 
                  
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
University of Basel  Page 108 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
Table 4.5.3.3c DRAD-ILD: Results of proportional hazards regression analyses for an 
incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 32 32             
Failures [n (%)] 5 (15.6) 3 (9.4)             
Surv. time in yrs [mean (sd)]  3.2 (2.8) 4.6 (3.6)             
                
DRAD-ILD (cases) vs. Non-DRAD-ILD (controls) 1.33 0.30 5.96 . . . 
                  
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; L=Lower, U=Upper, CL=Confidence Limit, RR=Rate ratio  
. = Non-estimable 
 
4.5.3.4 ILD associated with other diseases (ILD-ODIS) 
During the follow-up period 271 (48%) subjects with ILD-ODIS and 128 (29%) non-
ILD-ODIS subjects died. When investigating all-cause mortality as the outcome of 
interest, the mean (SD) survival time in the ILD-ODIS cohort was 4.5 (3.8) years 
versus 6.6 (4.2) years in the control group.  After adjusting for smoking status, body 
mass index, and alcohol consumption status, the rate of all-cause mortality in the 
ILD-ODIS cohort remained approximately 5 times higher than the rate in the non-ILD-
ODIS control group (RR 5.1, 95%CI: 3.6 to 7.2). Likewise, among the non-incident 
comorbidities investigated, rate ratios for pneumonia and respiratory (non-
pneumonia) infections remained elevated after adjustment for smoking status, body 
mass index, and alcohol consumption status (see RRs and 95% CIs  below). Among 
the incident cardiovascular outcomes investigated, the adjusted rate ratio for 
congestive heart failure was elevated (RR 3.4, 95%CI: 1.5 to 7.7).  Among the other 
incident outcomes under investigation, the adjusted rate ratio for rheumatoid arthritis 
significantly elevated (RR 15.9, 95%CI: 3.2 to 79.6). Crude and adjusted rate ratios 
for certain incident comorbidities under investigation were non-estimable due to lack 
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of failures and/or sparsely populated strata. Further details of these analyses can be 
found in tables 4.5.3.4a-c below. 
Table 4.5.3.4a ILD-ODIS: Results of proportional hazards regression analyses for all-




















Failures [n (%)] 271 (48.4) 128 (28.9)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.6 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 4.60 3.37 6.29 5.11 3.62 7.21 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.91 0.48 7.56 0.96 0.17 5.47 
  25.0 - 29.9 0.74 0.47 1.16 0.72 0.39 1.34 
  30.0 - 39.9 0.38 0.20 0.71 0.42 0.18 0.98 
  40.0 - 55.9 2.80 0.29 27.02 15.92 1.52 166.68 
  Unknown 0.83 0.51 1.37 0.74 0.32 1.73 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.66 1.00 2.73 1.24 0.61 2.52 
  Ex-smkrs 1.46 0.86 2.46 1.16 0.58 2.34 
  Unknown 0.99 0.56 1.74 0.50 0.18 1.41 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.98 0.61 1.56 0.49 0.19 1.30 
  Never 0.96 0.55 1.67 0.37 0.13 1.06 
  
Ex 0.98 0.19 5.15 0.46 0.05 4.02 
Pneumonia 
Failures [n (%)] 78 (13.9) 31 (5.5)       
Surv. time in yrs [mean (sd)]  4.3 (3.7) 6.5 (4.2)       
          
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 7.22 3.60 14.50 16.72 4.71 59.43 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.21 0.57 2.58 1.12 0.27 4.66 
  30.0 - 39.9 0.93 0.29 2.95 2.49 0.29 21.28 
  40.0 - 55.9 1.10 0.07 18.10 30.70 0.92 1029.05 
  Unknown 1.10 0.43 2.79 3.65 0.61 21.74 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.85 0.36 2.01 0.48 0.09 2.53 
  Ex-smkrs 2.91 0.97 8.74 4.43 0.44 44.48 
  Unknown 0.85 0.31 2.33 2.39 0.15 37.02 
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Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.39 0.61 3.18 4.20 0.50 35.05 
  Never 1.45 0.46 4.57 1.39 0.12 16.54 
  
Ex . . . 0.00 0.00 . 
Respiratory (non-pneumonia) infections 
Failures [n (%)] 369 (65.9) 270 (48.2)             
Surv. time in yrs [mean (sd)]  1.9 (2.3) 4.0 (3.5)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 3.03 2.40 3.83 3.25 2.52 4.19 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 2.56 0.90 7.31 2.60 0.80 8.49 
  25.0 - 29.9 0.76 0.53 1.09 0.74 0.49 1.13 
  30.0 - 39.9 0.87 0.54 1.41 1.28 0.72 2.27 
  40.0 - 55.9 2.18 0.38 12.55 5.32 0.73 38.61 
  Unknown 0.86 0.57 1.31 1.21 0.66 2.20 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.25 0.83 1.88 1.23 0.76 2.00 
  Ex-smkrs 1.59 1.05 2.40 1.16 0.71 1.89 
  Unknown 0.93 0.55 1.57 0.73 0.33 1.63 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.17 0.79 1.75 1.25 0.64 2.45 
  Never 0.98 0.60 1.60 0.79 0.38 1.65 
  
Ex 1.16 0.32 4.20 1.02 0.20 5.31 
Pneumothorax 
Failures [n (%)] 6 (1.1) 1 (0.18)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.6 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 5.00 0.58 42.79 . . . 
                  
Bone fractures 
Failures [n (%)] 46 (8.2) 56 (10.0)             
Surv. time in yrs [mean (sd)]  4.3 (3.7) 6.2 (4.1)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 1.46 0.91 2.37 1.64 0.91 2.94 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 2.46 0.21 28.92 2.54 0.14 45.74 
  25.0 - 29.9 0.80 0.35 1.80 0.61 0.24 1.56 
  30.0 - 39.9 1.80 0.53 6.06 2.07 0.55 7.75 
  40.0 - 55.9 . . . . . . 
  Unknown 1.12 0.40 3.13 0.89 0.26 3.05 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 0.87 0.34 2.19 0.62 0.21 1.84 
  Ex-smkrs 1.60 0.64 4.02 1.41 0.47 4.22 
  Unknown 1.20 0.38 3.79 0.63 0.12 3.41 
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Alcohol status None (Ref.) 1.00 -- 1.00 -- -- 
  Current 0.60 0.21 1.71 0.55 0.11 2.83 
  Never 0.57 0.14 2.38 0.46 0.07 3.23 
  
Ex 0.77 0.05 13.26 1.12 0.03 40.88 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status; CL=Confidence Limit, L=Lower, U=Upper, RR=Rate ratio 
. = Non-estimable 
 
Table 4.5.3.4b ILD-ODIS: Results of proportional hazards regression analyses for 
incident cardiovascular- / cerebrovascular- / pulmonary-related 
comorbidities after index date 













Congestive Heart Failure 
No. of subjects for analysis 429 429             
Failures [n (%)] 40 (9.3) 19 (4.4)             
Surv. time in yrs [mean (sd)]  4.8 (3.8) 6.8 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 3.60 1.79 7.25 3.40 1.50 7.70 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 2.03 0.18 23.00 1.28 0.05 35.36 
  25.0 - 29.9 1.12 0.37 3.44 1.73 0.33 9.00 
  30.0 - 39.9 0.87 0.23 3.28 1.48 0.27 8.08 
  40.0 - 55.9 . . . . . . 
  Unknown 1.04 0.34 3.18 1.62 0.14 18.71 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 4.58 0.90 23.35 4.26 0.49 36.79 
  Ex-smkrs 3.18 0.81 12.49 3.78 0.59 24.05 
  Unknown 2.65 0.61 11.57 0.86 0.05 13.74 
                
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.60 0.16 2.28 0.64 0.01 28.90 
  Never 0.83 0.18 3.86 0.32 0.01 15.40 
  
Ex . . . . . . 
Ischemic Heart Disease 
No. of subjects for analysis 366 366             
Failures [n (%)] 28 (7.7) 29 (7.9)             
Surv. time in yrs [mean (sd)]  4.7 (3.9) 6.5 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 1.75 0.86 3.56 4.21 0.52 34.18 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.02 0.06 18.41 0.76 0.02 33.42 
  25.0 - 29.9 4.55 0.92 22.53 43.57 0.84 
2262.4
3 
  30.0 - 39.9 4.06 0.41 40.22 21.21 0.33 
1359.8
1 
  40.0 - 55.9 . . . . . . 
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  Unknown 1.04 0.20 5.46 0.90 0.03 31.66 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 8.83 1.24 63.05 241.62 0.33 
17706
1.40 
  Ex-smkrs 2.92 0.74 11.49 7.19 0.53 98.26 
  Unknown 2.37 0.25 23.04 52.41 0.04 
71792.
94 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.41 0.44 4.47 0.14 0.01 2.60 
  Never 1.33 0.20 8.64 0.04 0.00 3.68 
  
Ex . . . . . . 
Myocardial Infarction 
No. of subjects for analysis 560 560             
Failures [n (%)] 20 (3.6) 25 (4.5)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.4 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 1.00 0.45 2.23 0.62 0.11 3.49 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 1.77 0.42 7.54 6.12 0.22 169.36 
  30.0 - 39.9 0.58 0.10 3.37 0.03 0.00 1.76 
  40.0 - 55.9 . . . . . . 
  Unknown 1.58 0.35 7.18 0.37 0.00 33.83 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 6.03 0.59 62.04 607.01 1.23 
30073
9.80 
  Ex-smkrs 2.31 0.41 12.92 16.73 0.41 676.46 
  Unknown 3.10 0.34 28.49 0.00 0.00 . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.51 0.09 2.89 . . . 
  Never 0.48 0.08 3.09 . . . 
  
Ex . . . . . . 
Stroke / Transient Ischemic Attack (TIA) 
No. of subjects for analysis 467 467             
Failures [n (%)] 26 (5.6) 37 (7.9)             
Surv. time in yrs [mean (sd)]  4.6 (3.9) 6.5 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 1.75 0.86 3.56 3.00 0.86 10.49 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 1.00 0.06 15.99 0.59 0.02 15.75 
  25.0 - 29.9 1.14 0.31 4.22 1.11 0.23 5.41 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 0.46 0.10 2.20 0.43 0.04 4.16 
                
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
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  Curr-smkrs 2.05 0.51 8.30 1.00 0.12 8.78 
  Ex-smkrs 3.05 0.85 11.01 2.84 0.43 18.60 
  Unknown 1.47 0.27 8.14 0.00 0.00 . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.13 0.22 5.88 . . . 
  Never 0.79 0.13 4.72 . . . 
  
Ex . . . . . . 
Deep Vein Thrombosis 
No. of subjects for analysis 530 530             
Failures [n (%)] 15 (2.8) 11 (2.1)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.6 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 2.00 0.81 4.96 . . . 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 12.35 0.70 218.26 . . . 
  30.0 - 39.9 . . . . . . 
  40.0 - 55.9 . . . . . . 
  Unknown 2.53 0.25 25.27 . . . 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.72 0.28 10.59 . . . 
  Ex-smkrs 0.96 0.14 6.80 . . . 
  Unknown 4.54 0.28 73.93 . . . 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 0.75 0.17 3.35 . . . 
  Never . . . . . . 
  
Ex . . . . . . 
Pulmonary Embolism 
No. of subjects for analysis 532 532             
Failures [n (%)] 14 (2.6) 1 (0.2)             
Surv. time in yrs [mean (sd)]  4.4 (3.8) 6.7 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 13.00 1.70 99.35 . . . 
                  
Pulmonary Hypertension 
No. of subjects for analysis 559 559             
Failures [n (%)] 7 (1.3) 1 (0.2)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.6 (4.2)             
                
ILD assoc. w/other dis. vs. Non-ILD assoc. w/other dis. . . . . . . 
                  
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
CL=Confidence Limit, L=Lower, U=Upper, RR=Rate ratio 
. = Non-estimable 
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Table 4.5.3.4c ILD-ODIS: Results of proportional hazards regression analyses for an 
incident diagnosis of cancer after index date 













Cancer in Situ Metastasis 
No. of subjects for analysis 454 454             
Failures [n (%)] 53 (11.7) 51 (11.2)             
Surv. time in yrs [mean (sd)]  4.5 (3.8) 6.6 (4.2)             
                
ILD-ODIS (cases) vs. Non-ILD-ODIS (controls) 1.33 0.83 2.14 1.20 0.71 2.02 
            
BMI (kg/m
2
) 18.5 - 24.9 (Ref.) 1.00 -- -- 1.00 -- -- 
  14.0 - 18.4 . . . . . . 
  25.0 - 29.9 0.80 0.37 1.77 0.88 0.37 2.09 
  30.0 - 39.9 0.77 0.23 2.59 1.01 0.27 3.85 
  40.0 - 55.9 . . . . . . 
  Unknown 0.42 0.14 1.30 0.45 0.11 1.75 
          
Smoking status Non-smkrs (Ref.) 1.00 -- -- 1.00 -- -- 
  Curr-smkrs 1.60 0.67 3.84 2.02 0.75 5.49 
  Ex-smkrs 1.55 0.54 4.39 1.32 0.41 4.21 
  Unknown 0.74 0.22 2.49 1.04 0.23 4.77 
          
Alcohol status None (Ref.) 1.00 -- -- 1.00 -- -- 
  Current 1.88 0.67 5.30 0.96 0.22 4.31 
  Never 1.76 0.57 5.42 0.79 0.17 3.75 
  
Ex . . . . . . 
* = Simultaneous adjustment of case-control status, smoking status, BMI, and alcohol consumption status 
CL=Confidence Limit, L=Lower, U=Upper, RR=Rate ratio 
. = Non-estimable 
 
5 Discussion 
Cases with incident ILD diagnoses were identified from the BCDSP-GPRD subset. 
Patients with less than 3 years of ILD-free history in the database prior to a first-time 
recording of an ILD diagnosis were excluded in order to increase the likelihood of 
capturing incident rather than prevalent cases. For this reason and in light of the fact 
that we did not capture existing ILD patients (i.e. those diagnosed prior to 1995 and 
still alive during our study window), the prevalence figures presented here (especially 
for the earlier years under investigation) are likely to be underestimated.  
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Despite implementation of the exclusion criterion mentioned above, we cannot 
guarantee that all prevalent cases were actually excluded from our cohort. Although it 
is unlikely to have played a major role in the present study, having included any 
prevalent cases may have resulted in an overestimation of survival time in our 
models, since prevalent cases are by nature ‘survivors’ and will have contributed 
greater lengths of survival time (as opposed to incident cases). Therefore, the extent 
to which such misclassification is present in our study population may have led to 
some underestimation of incidence and mortality rates. 
A potential weakness in this study could be the validity of ILD diagnoses, as we have 
not validated it directly. However, the validity of a number diagnoses, including death, 
has been tested in the UK GPRD and consistently found to be high [Jick H et al. 
1991, Jick H et al. 1992, Jick SS et al. 2003]. Furthermore, the validity of one type of 
ILD, Cryptogenic Fibrosing Alveolitis, has been assessed and was also found to be 
high [Hubbard R et al. 2003]. Furthermore, it is rather unlikely that GPs would record 
differential ILD diagnoses in their records unless they have been verified by hospital 
and/or specialist referrals [Gribbin J et al. 2006]. Nevertheless, the accuracy of 
diagnoses made by healthcare providers who do not have significant expertise in the 
field of ILD remains a cause of concern. While the clinico-radio-pathologic (CRP) 
consensus approach to ILD diagnosis functions well in the hands of “recognized, 
senior experts” it has been found to work less reliably outside academic specialty 
centers [Flaherty KR et al. 2004]. Therefore, the difficulties encountered by non-ILD 
specialists when applying the ATS/ERS ILD-disease classification guidelines will 
have limited the accuracy of the ILD diagnoses in the database. These factors are 
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unavoidable limitations to the present study, and for that matter, to any retrospective 
epidemiological investigation of ILD.  
Application of the ATS/ERS diagnosis classification in the present study may have 
been problematic. Firstly, it is likely that some UK pulmonologists and ILD specialists 
were late adopters of the ATS/ERS ILD-disease classification guidelines. Secondly, it 
is likely that some patients under study did not undergo a full diagnostic work-up or 
whose ILD diagnoses were not achieved by the CRP consensus approach. Thirdly, 
diagnosis terminology may not be completely in line with diagnosis terminology used 
in the guidelines. For example, the diagnoses of Cryptogenic Fibrosing Alveolitis 
(CFA) and Idiopathic Fibrosing Alveolitis (IFA) have traditionally been used in the UK 
for the past 20-30 years, and although the ATS/ERS consensus statement explicitly 
states that CFA and IPF are synonymous terms, CFA was actually used as an 
umbrella term for a clinical presentation seen commonly in IPF, including some of the 
newly termed IIPs and some cases of EAA.  Furthermore, no READ codes are to be 
found for some of the rarer IIPs such as LIP and LAM. For this reason, and due to the 
fact that the number of patients found with similar diagnosis was quite small, no 
analyses were undertaken for such disease entities. 
For many ILD subgroups an increase in incidence density and prevalence over time 
was observed. We cannot tell whether this finding reflects a real increase, or whether 
such findings are, at least to a certain extent, attributable to secular trends. Firstly, 
during the study window of the present epidemiologic investigation, major political 
changes in the NHS occurred, including more than a doubling in funding. Secondly, a 
certain proportion of incident cases in this time period may have been due to 
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increased recognition of ILD via the increased use of high resolution computer 
tomography (HRCT). Thirdly, following release of the ATS/ERS consensus 
statements around 2001-2002, a greater appreciation of the value of precise 
diagnosis according to such criteria will likely have occurred, not to mention 
increased patient expectations. For the above reasons, an increase in case 
ascertainment may have played a role in the observed increase in incidence rates for 
some ILD subgroups. Furthermore, with an increase in case ascertainment comes 
the increased likelihood of having captured some patients with earlier-staged (and/or 
milder forms of) disease. The degree to which this bias is present in our investigation 
could have contributed to both an increase in incidence density and survival time. 
Despite the potential limitations mentioned above, this study made use of data from 
the general population of a large, defined geographic region. Therefore, the potential 
for underestimation of prevalence and incidence is greatly reduced. Furthermore, the 
UK NHS provides universal health coverage for all UK residents, and as such, no 
segment of the population (e.g. elderly, based on socioeconomic status or type of 




Epidemiologic data on ILD in the general population are limited. It is estimated that 
approximately two-thirds of ILD cases have no reported aetiology (i.e. the IIPs), while 
the remaining one-third results from a variety of exposures including infections, 
drugs, radiation, connective tissue disease  and environmental/occupational 
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exposures [Raghu G et al. 2004]. Recently, population-based data in the UK have 
been used to identify potential risk factors for IPF, one of the most common IIPs. In a 
case-control study using general practice medical records, researchers observed that 
IPF patients more frequently had a history of gastro-oesophageal reflux disease 
(GERD) and use of ulcer drugs [Gribbin J et al. 2009]. The same researchers also 
found associations between both having had a diagnosis of diabetes mellitus (DM) 
and using insulin with an increased likelihood of developing IPF. The authors 
speculate that having a chronic disease such as DM or GERD could possibly be 
associated with greater likelihood of ascertaining a diagnosis of IPF. An argument 
against this theory, however, is found in their observation that IPF was not associated 
with having other chronic diseases such as gout or hyperlipidaemia, and therefore a 
conclusion was drawn that ascertainment bias is not a likely explanation of the 
observed associations. Nevertheless, it cannot be ignored that both DM and GERD 
are associated with other respiratory/pulmonary complications, and it is possible that 
such patients might be more frequently referred to pulmonary specialist centers. 
5.1.2 Disease frequency 
 
Historically, it has been difficult to arrive at precise estimates of incidence and 
prevalence of ILD in the general population. Most published studies have relied on 
data from disease registries and hospital clinics, where case ascertainment and 
selection biases have most likely led to an underestimation of the true prevalence 
and incidence of ILD in the general population. Nevertheless, in 1994, Coultas et al. 
published a landmark epidemiologic study on ILD using data from a dedicated, 
University of Basel  Page 119 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
population-based ILD registry in the defined region of Bernalillo County, New Mexico, 
USA, where multiple methods of case ascertainment and systematic medical chart-
review were used.6 In that study, the overall prevalence and incidence of non-
differential ILD were estimated to be 74.1 cases per 100’000 and 28.8 
cases/105/year, respectively, with approximately one-third of the incident cases 
classified as IPF [Coultas DB et al. 1994]. Both incidence and prevalence were 
higher in men than women. 
Published population-based data on the incidence and prevalence of ILD from other 
countries are scant. Where available, most reports are specific to IPF rather than to 
ILD as a whole. Nevertheless, these published reports suggest national differences in 
the prevalence of IPF and may also be indicative of the comparative prevalence 
estimates of other ILDs. In the Japanese Hokkaido registry, prevalence of IPF was 
estimated at approximately 4 cases / 105 [Munakata M et al. 1994], while in a national 
Finnish registry, estimates ranged from 16-18 cases / 105 [Hodgson U et al. 2002]. In 
two regions of the Czech Republic, prevalence estimates of IPF rose from 7 to 12 
cases /105 from 1981 to 1990 [Kolek V 2009]. With respect to the incidence rates of 
ILD, publications on population-based data range from approximately 4-5/105/year in 
Southern Spain [Lopez-Campos JL et al. 2004] and in Greece [Karakatsani A et al. 
2009] to approximately 33/105/year in Denmark [Kornum JB et al. 2008]. Some of this 
7-8-fold difference may be explained by different case ascertainment methodologies. 
In a publication from 2001, a Working Group of the ERS concluded that there is little 
good epidemiological data on ILD, with many questions remaining unanswered 
[Demedts M et al. 2001] More recent reports continue to express this sentiment and 
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cite the need for more epidemiologic research in the full spectrum of ILD (not only in 
IPF) using population-based data where selection and case ascertainment biases are 
greatly reduced [Olson AL et al. 2008, Wells AU 2008]. 
Existing published data from registries and surveys suggest Sarcoidosis and IPF as 
the most common ILDs, followed by CTD-associated ILD (CTD-ILD) and HP. Among 
the seven subcategories of IIP however, IPF is the most common followed by NSIP. 
5.1.3 Natural history 
 
Most ILDs are insidious in onset, with dyspnea and non-productive cough being the 
predominant symptoms. Very little published data are available describing the natural 
histories (e.g. incident co-morbidity and complications post ILD diagnosis) of non-IPF 
ILDs. The clinical course of non-IPF ILDs ranges from complete remission for COP 
and RBILD to the rapidly progressive fatal course commonly seen in AIP [Katzenstein 
AL & Meyers JL 1998, Noth I & Martinez FJ 2007]. 
A diagnosis of IPF, the most frequent of the IIPs, is associated with a prognosis 
worse than most ILDs [ATS/ERS 2002, Katzenstein AL & Meyers JL 1998, Noth I & 
Martinez FJ 2007]. In many studies conducted after development of the ATS/ERS 
guidelines, median survival of IPF patients ranged from 2 to 4 years after diagnosis 
with only 20 to 40% of patients reaching 5-year survival [Kim DS et al 2006]. 
Historically, the natural history of IPF has been described as one of relentless decline 
in respiratory function. However, observations made during recent clinical studies 
indicate that rather small decreases in the diffusing capacity for carbon monoxide 
(DLCO) and forced vital capacity (FVC) may occur over long periods of time, as well 
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as variability in clinical course [Kim DS et al 2006]. Some patients exhibit slow 
progression over longer periods of time while others experience periods of relative 
stability punctuated by episodes of acute deterioration. Such acute episodes are 
described as abrupt, unexpected deteriorations in the underlying lung disease not 
attributable to (but perhaps secondary to undiagnosed) infections, pulmonary 
embolism, or heart failure; they are recognized as common, highly morbid clinical 
events (now termed Acute Exacerbations of IPF) and as such have received 
increasing attention during recent years [Behr J & Thannickal VL 2009, Karakatsani A 
et al. 2009, Kim DS et al 2006]. Acute exacerbations have also been reported in HP 
and may be a feature common to other fibrosing ILDs [Behr J & Thannickal VL 2009, 
Olson AL et al. 2008]. Several hypotheses on the etiology of acute exacerbations of 
IPF have been put forth such as occult viral infections (e.g. herpes virus), lung injury 
as a result of drug toxicity, and adverse effects from pharmacologic agents commonly 
used in the treatment of the underlying ILD [Collard HR et al 2007, Olson AL et al. 
2008]. More research is necessary in order to characterize incident co-morbidity and 
clinical complications in the full spectrum of ILD. 
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7.1 Incidence of the pneumoconioses in the United Kingdom general 
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Incidence of the pneumoconioses in the UK is primarily estimated using 
occupational-based registries and disability pension schemes. These sources 
indicate a downward trend in incidence of the pneumoconioses from 1995 onwards. 
There are no previously published general population-based observational studies 
quantifying the incidence of the pneumococinoses in the UK. 
Objectives 
The aim of this study was to investigate the incidence of the pneumoconioses in the 
UK general population between 1997-2008 using data from the GPRD. 
Methods 
Data from the UK-based General Practice Research Database was used to estimate 
the incidence of pneumoconioses over a 12-year period (1997-2008).  Crude 
incidence rates for asbestosis and non-asbestos-related pneumoconioses were 
stratified by gender, age group, and calendar period, and rate ratios were adjusted 
using Poisson regression.  
Results 
The majority of cases was diagnosed with asbestosis, and the overall, crude 
incidence density for this pneumoconiosis during the 12-year study period was 2.7 
(95% CI: 2.5 to 2.9) per 100,000 person-years. Incidence increased progressively 
during the period 1997-2005 and then decreased slightly during the period 2006-
2008, even after controlling for the strong effect of an ageing UK population. The 
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non-asbestos pneumoconioses, in contrast to asbestosis, showed a progressive 
reduction in incidence from 2003 onwards. 
Conclusions 
This study demonstrates that the pneumoconioses remain an important public health 
issue and furthermore, documents an overall increase in asbestosis incidence in the 
UK between 1997 and 2008. 
7.1.2 Introduction 
 
The pneumoconioses are a group of interstitial lung diseases caused by inhalation 
and retention of inorganic dusts. These diseases typically evolve over decades of 
occupational exposure to mineral dusts and are characterized by the formation of 
nodular, fibrotic changes to the lung parenchyma [1]. The relatively long time lag 
between occupational exposure and disease onset is reflected in the fact that the 
majority of incident cases is detected in retired workers [2]. 
The primary data sources used to investigate incidence and prevalence of the 
pneumoconioses in the United Kingdom (UK) are the Department for Work and 
Pensions (DWP) Industrial Injuries and Disablement Benefit (IIDB) scheme and The 
Health and Occupation Reporting (THOR) network.  During the period 1998-2008 the 
number of new cases of pneumoconiosis reported by chest and occupational 
physicians within the THOR network fluctuated between 108 and 321 cases per year 
[3]. Trends in incidence of the pneumoconioses from both sources are difficult to 
interpret due to varying definitions of disease states and changing eligibility criteria 
for compensation benefits over time. Additionally, it is known that case numbers have 
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been affected by fluctuations in the numbers and reporting habits of participating 
health care practitioners over time [3]. Data from THOR and the IIDB scheme 
suggest a downward trend in the annual number of new pneumoconiosis cases from 
2005 onward [3,4]. However, as is the case when using data from disease registries, 
measures of disease frequency from both of these sources may be underestimated 
due to case ascertainment and selection biases.  
The UK General Practice Research Database (GPRD) contains anonymised 
electronic patient records collected from routine general practice. The geographic, 
age, and gender distributions of the GPRD population have been shown to be 
representative of the U.K. general population [5]. The aim of this study was to 
investigate the incidence of the pneumoconioses in the UK general population 
between 1997-2008 using data from the GPRD. 
7.1.3 Materials and methods 
 
Data source 
The GPRD has been described elsewhere in detail [5], but briefly, it is a large and 
well-validated U.K.-based database that was established in June 1987. The GPRD 
encompasses nearly five million patients who are or were enrolled with selected 
general practitioners (GPs) throughout the U.K., covering approximately 50 million 
patient-years of follow-up. The participating GPs have been trained to record medical 
information in a standard manner and to provide anonymized records to the GPRD 
Group within the Medicines and Healthcare products Regulatory Agency (MHRA), the 
UK's medicines and devices regulator. The recorded data include demographic 
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information, medical diagnoses, and drug prescriptions. The Boston Collaborative 
Drug Surveillance Program (BCDSP) and its associated researchers at the Basel 
Pharmacoepidemiology Unit (University of Basel) use a large subset of data from the 
GPRD; data from general practices that have failed to report consistent numbers of 
drug prescriptions and diagnostic codes over time have been removed from the 
BCDSP GPRD [6]. Data from the GPRD have been used in previous studies 
involving interstitial lung disease and use of the data for respiratory epidemiology has 
been validated [7,8]. The GPRD is managed by the Medicines and Healthcare 
products Regulatory Agency (MHRA), and the present study protocol was approved 
by the Independent Scientific Advisory Committee (ISAC) for MHRA database 
research.  
Study population 
We identified in the GPRD all patients with a first-time diagnosis of a pneumoconiosis 
between January 1, 1997 and December 31, 2008. Diagnoses in the GPRD are 
coded using the Read coding system, and our list of pneumoconiosis diagnoses 
included any Read code explicitly mentioning pneumoconiosis, silicosis, silica/silicate 
pneumoconiosis, silicotic fibrosis, talc pneumoconiosis, siderosis, berylliosis, 
stannosis, asbestosis, , and coal workers pneumoconiosis.  Read codes without 
explicit mention of a pneumoconiosis such as “Pneumopathy due to inhalation of 
other dust NOS” were not used. In order to increase the likelihood of capturing 
incident rather than prevalent cases, we excluded patients with less than 3 years of 
active recording history prior to the date of the first pneumoconiosis diagnosis.  
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Person-time denominators for the calculations of incidence density were derived from 
the GPRD. For each calendar period, only those patients in the GPRD who were 
alive, actively registered, and had at least 3 years of recorded history contributed 
person-time to the denominators. Incident cases were grouped into four age groups 
(<60, 60-69, 70-79, and ≥80 years) and calendar time was divided into four 3-year 
periods (1997-1999, 2000-2002, 2003-2005, and 2006-2008). Crude incidence rates 
were calculated for the asbestos-related pneumoconiosis (i.e. asbestosis), and for 
non-asbestos-related pneumoconioses separately. The crude rates were stratified by 
gender, age group, and calendar period, with exact 95% confidence intervals being 
calculated from the Poisson distribution. In order to model disease incidence and 
estimate incidence rate ratios, fixed-effects Poisson multivariate regression was 
used. We accounted for overdispersion in all regression models using the quasi-
likelihood approach, that is, by fixing the scaled deviance at unity and introducing a 
dispersion parameter into the model which adjusted the standard errors of the 
parameter estimates.  All analyses were performed with the statistical software SAS 
(release 9.2, SAS Institute, Inc., Cary, NC, USA). 
7.1.4 Results 
A total of 1070 patients with an incident diagnosis of any type of pneumoconiosis 
were identified during the period 1997-2008, which included 840 (87.5%) cases of 
asbestosis and 230 cases of non-asbestos-related pneumoconioses. The frequency 
distribution of incident diagnoses is shown in Table 1.  
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Results: non-asbestos-related pneumoconiosis 
The mean age (SD) at diagnosis was 70 (13.9) years and 217 (94%) cases were 
male. Females were younger than males at the time of first diagnosis (57.8 years (SD 
21.8) vs. 71.1 years (SD 13.0), respectively), and the majority of diagnosed cases 
was 70 years of age and over.  
Between 1997 and 2008 the overall incidence density rate of the non-asbestos-
related pneumonconioses was 0.74 (95% CI: 0.65 to 0.84) per 100,000 person-years, 
and the rate in males was approximately 16-fold that of the rate in females. The 
incidence density increased during the period 1997-2002 (from 0.82 [95% CI: 0.62 to 
1.07] during 1997-1999 to 1.09 [95% CI: 0.87 to 1.35] during 2000-2002 per 100,000 
person-years), and decreased progressively thereafter from 2003-2008. Crude 
incidence rates by calendar period for the non-asbestos-related pneumoconioses are 
shown in Table 2. Poisson regression modelling of incidence rates for the non-
asbestos-related pneumoconioses yielded no statistically significant heterogeneity of 
rates over time (p for trend = 0.1017) (see results in Table 2) 
Results: asbestosis 
The mean age (SD) at diagnosis was 69 (11.4) years and 784 (93%) cases were 
male. Females were younger than males at the time of first diagnosis (61.8 years (SD 
22.1) vs. 70.0 years (SD 10.0), respectively), and the majority of cases was 
diagnosed in the age group 60-79 years. The age distribution of cases is shown in 
Figure 1. 
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Between 1997 and 2008 the overall incidence density rate of asbestosis was 2.7 
(95% CI: 2.5 to 2.9) per 100,000 person-years, and the rate in males was 
approximately 18-fold that of the rate in females. The analysis of crude incidence 
density for asbestosis yielded progressively increasing rates during the period 1997-
2005 (from 1.6 [95% CI: 1.4 to 2.0] during the period 1997-1999 to 3.2 [95% CI: 2.9 
to 3.6] per 100’000 person-years), with a slight downward blip during the period 
2006-2008. Crude incidence rates by calendar period for asbestosis are shown in 
Table 3. 
In the asbestosis cohort there was evidence of statistically significant heterogeneity 
of incidence rate ratios over time (p=0.024), after adjusting for the effects of age and 
gender. The incidence density increased from the period 1997-1999 to 2000-2002 by 
a factor of 1.5. Using the same baseline period, the incidence nearly doubled during 
the period 2003-2005 (IRR=1.9).  Incidence rate ratios for asbestosis are shown in 
Table 4. 
To provide an additional estimate of the average annual increase in the incidence of 
asbestosis we repeated our analyses fitting year as a continuous variable. After 
controlling for the effects of age and gender, we estimated the average annual 
increase in the incidence of abestosis to be 6% during the 12-year study period (IRR 
1.064, 95% CI: 1.04 to 1.09, p<0.0001). 
7.1.5 Discussion 
 
In this large, general-population-based cohort of pneumoconiosis patients, the overall 
incidence rates for asbestos- and non-asbestos-related pneumoconioses were 
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approximately 3 and 1 per 100’000 UK population per year, respectively, suggesting 
that each year during the period 1997-2008 there were ~ 1’800 new cases of 
asbestosis and 600 new cases of non-asbestos-related pneumoconiosis in the UK. 
The incidence of asbestosis increased progressively during the period 1997-2005 
and then decreased slightly during the period 2006-2008, while the incidence of non-
asbestos-related pneumoconiosis showed progressive decline from 2003 to 2008. 
Incidence rates were substantially higher in men than in women, likely reflecting the 
industrial-occupational nature of the disease etiology.  
The majority of cases in our cohort (~80%) was diagnosed with asbestosis, and the 
observed increase in incidence during the study period would seem to be in line with 
the estimation that peak global incidence of asbestos-related disease is expected to 
occur 30 to 40 years after the period of peak asbestos usage (i.e., the 1960s and 
1970s) [9]. This is further reflected in a report by the U.K. Health and Safety 
Executive (HSE) which predicts increasing rates of mesothelioma-related mortality 
until around 2015, after which rates are expected to decline [10,11]. Therefore, the 
projected, overall annual estimate of ~ 1’800 new cases of asbestosis will probably 
not continue far into the future. From the analysis of non-asbestos related 
pneumoconiosis, it can be seen that incidence of pneumoconiosis due to causes 
other than asbestos has declined over time, except for a relative rise in incidence 
noted during the period 2000-2002. 
A potential weakness of the present study could be the validity of pneumoconiosis 
diagnoses, as we have not tested these directly. However, the validity of many 
disease diagnoses has been assessed in the UK GPRD and consistently found to be 
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high [6,12,13]. Furthermore, other researchers have reported a high validity of the 
diagnosis of idiopathic pulmonary fibrosis, another interstitial lung disease, in the 
GPRD [14]. Moreover, it is unlikely that general practitioners would record a 
pneumoconiosis diagnosis without confirmation by specialist referral. Therefore, we 
expect the diagnoses used for the present study to have high specificity.  
On the other hand, the authors are aware that the sensitivity of the diagnoses used 
may not be as high as the specificity. Two main reasons for this are the potential for 
misclassification of true pneumoconiosis cases into less specific disease diagnosis 
categories and the possibility of having missed less severe cases. For instance, we 
did not use less specific respiratory-related diagnosis codes such as “lung disease 
due to other external agents NOS” or “other external agent causing respiratory 
condition” in our case selection algorithm. Overall there were 649 cases with such an 
unspecific diagnosis which we subsequently reviewed in more detail. Only 10 of them 
(1.5%) had some evidence of a pneumoconiosis diagnosis at a later point in time in 
their patient record, which makes substantial misclassification unlikely. It is also 
possible that less severe cases have escaped detection by general practitioners and 
specialists. Thus it is possible that we did not have available for analysis all true 
pneumoconiosis cases from the given sampling frame, which means that we may 
have underestimated the true incidence density of the pneumoconioses in the UK. 
Furthermore, we cannot be certain that all newly identified cases were indeed 
incident cases. However, we excluded cases with less than 3 years of recorded 
medical history in order to minimize the possibility of including prevalent cases in our 
incidence numerators, so we expect the occurrence of such error to be minimal. To 
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the extent that this error occurred it will have resulted in a small overestimation of the 
incidence density rates. Moreover, the percentage of cases disregarded due to the 
above exclusion criterion was 11% of the total number of cases identified during the 
defined study window (2’071 vs. 1’843), and the percentages of cases excluded 
across the study time periods remained relatively stable at 10-12%. This would 
support the conclusion that the results presented here are not influenced by 
fluctuations in the frequency of recorded diagnoses of pneumoconiosis.  
Despite the potential limitations mentioned above, this study determined the best 
current estimates of incidence density for inorganic dust pneumoconioses in the UK 
general population. We have been unable to find any other general population-based 
cohort analyses in the U.K. with which to compare our results. Also, comparison of 
our incidence estimates to those published from the Surveillance of work-related and 
Occupational Respiratory Disease (SWORD) -- as part of the THOR network -- is 
difficult. Recent analyses of SWORD data yielded an average annual decline in 
pneumoconiosis incidence of -0.8% (95% CI: -4.8% to +3.3%) over the period 1999-
2006 [15]. However, with respect to age and gender demography, some similarities 
can be noted; nearly all cases were males (>97%) with a mean age between 66 and 
70 years, and approximately 55% of all cases were observed in the 60-75 year age 
range. Finally, it is acknowledged by the Health Safety Executive (HSE) – the 
national independent watchdog for work-related health, safety, and illness in Great 
Britain – that incidence figures may be substantially underestimated by THOR “since 
the scheme will only include those cases that are serious enough to be seen by a 
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chest consultant, or that occur in individuals with access to occupational physicians” 
[3].  
The observed upward trend in asbestosis incidence in the present study should be 
interpreted with caution. We cannot tell whether this finding reflects a real increase, 
or whether it is, at least to a certain extent, attributable to secular trends. Firstly, 
during the study window major political changes in the NHS occurred, including more 
than a doubling in funding under the auspices of the New Deal [16]. This investment 
in national health care was in part used to boost capacity of NHS services and to 
modernize facilities, thus potentially increasing the likelihood of detecting new cases 
of pneumoconioses. Secondly, a certain proportion of incident cases in this time 
period may have been due to increased recognition of interstitial lung diseases in 
general via the increased use of high resolution computed tomography (HRCT). 
Thirdly, following publication of both the British Thoracic Society’s guideline on 
diagnosis and care of diffuse parenchymal lung disease in 1999 [17] and the 
ATS/ERS consensus statements on idiopathic interstitial pneumonia in 2002 [18], a 
greater appreciation of the value of precise diagnosis according to defined criteria will 
likely have occurred, not to mention increased patient expectations. Finally, the 
observed increase in non-asbestos related pneumoconiosis from 1997-1999 to 2000-
2002 could be partly attributable to a publicity campaign by the DWP around 2002 
inviting people whose claims had been wrongly disallowed between 1994 and 1999 
to re-claim [3]. For the above reasons, an increase in case ascertainment may have 
played a role in the observed increase in incidence density of asbestosis. However, 
the observed numeric decline in incidence of the non-asbestos pneumoconioses from 
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2003 onwards would argue against increased case ascertainment being responsible 
for the progressive upward trend in incidence of asbestosis until the end of 2005. 
Conclusions 
This study makes use of data from a well-validated database which has consistently 
been found to be representative of the UK general population. To our knowledge this 
is the first general population-based observational study quantifying incidence rates 
of pneumoconioses in the UK. Further research using data sources such as the UK 
GPRD is needed to assess future trends in pneumoconiosis incidence and to confirm 
the assumption that asbestos-related diseases are truly beginning to decline in 
incidence as a consequence of health and safety measures enacted at the end of the 
last century. 
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7.1.6 Tables and figures 
 
Table 1. Frequency of incident pneumoconiosis diagnoses 
(N=1070). 
Diagnosis codes Frequency Percent 
Asbestos-related (Total) 840 100.00% 
Asbestosis 826 98.33% 
Asbestosis NOS 14 1.67% 
   Non-Asbestos-related (Total) 230 100.00% 
Pneumoconioses NOS 173 75.22% 
Coal workers pneumoconiosis 17 7.39% 
Silica and silicate pneumoconiosis 7 3.04% 
Talc pneumoconiosis 1 0.43% 
Simple silicosis 5 2.17% 
Massive silicotic fibrosis 1 0.43% 
Silica pneumoconiosis NOS 6 2.61% 
Pneumoconiosis due to other inorganic dust 1 0.43% 
Chronic beryllium disease 1 0.43% 
Siderosis 8 3.48% 
Stannosis 1 0.43% 
Pneumoconiosis due to inorganic dust NOS 9 3.91% 
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95% CI  
(exact 
Poisson) 
      
OVERALL  230 31,165,672.41 0.74  0.65 to 0.84 
      
Gender      
 Female 13 16,421,082 0.08 0.42 to 1.35 
 Male 217 14,744,590 1.47 1.28 to 1.68 
      
Age Groups      
 <60 39 23,309,579.76 0.17 0.12 to 0.23 
 60 - 69 50 3,474,347.44 1.44 1.07 to 1.90 
 70 - 79 78 2,689,162.52 2.90 2.29 to 3.62 
 80+ 63 1,692,582.69 3.72 2.86 to 4.76 
      
Calendar 
period      
 1997 - 1999 55 6,696,773.29 0.82 0.62 to 1.07 
 2000 - 2002 83 7,646,978.15 1.09 0.87 to 1.35 
 2003 - 2005 57 8,232,635.23 0.69 0.52 to 0.90 
 2006 - 2008 35 8,589,285.74 0.41 0.28 to 0.57 
*IR = Incidence rate (density) per 100’000 person-years, CI = Confidence interval 
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Table 3. Poisson regression modelling of incidence for the non-asbestos-related 








95% CI (exact 
Poisson) 
      
OVERALL  840 31,165,672.41 2.70 2.52 to 2.88 
      
Gender      
 Female 56 16,421,082 0.34 0.26 to 0.44 
 Male 784 14,744,590 5.32 4.95 to 5.70 
      
Age Groups      
 <60 108 23,309,579.76 0.46 0.38 to 0.56 
 60 - 69 280 3,474,347.44 8.06 7.14 to 9.06 
 70 - 79 321 2,689,162.52 11.94 10.67 to 13.32 
 80+ 131 1,692,582.69 7.74 6.47 to 9.18 
      
Calendar 
period      
 1997 - 1999 110 6,696,773.29 1.64 1.35 to 1.98 
 2000 - 2002 195 7,646,978.15 2.55 2.20 to 2.93 
 2003 - 2005 266 8,232,635.23 3.23 2.85 to 3.64 
 2006 - 2008 269 8,589,285.74 3.13 2.77 to 3.53 
*IR = Incidence rate (density) per 100’000 person-years, CI = Confidence interval 
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Table 4. Poisson regression modelling of incidence for asbestosis (N=840)  
 
  IRR 95% CI  LRT p-value 
     
Gender    
< 0.0001 
 Female (Ref.)  ------- 
 Male 17.87 11.36 to 28.09 
     
Age Groups    
< 0.0001* 
 <60 (Ref.) 1.00 ------- 
 60 - 69 17.56 12.13 to 25.42 
 70 - 79 28.14 19.57 to 40.48 
 80+ 22.58 14.77 to 34.55 
     
Calendar period    
  
0.0238* 
 1997 – 1999 (Ref.) 1.00 ------- 
 2000 - 2002 1.54 1.04 to 2.27 
 2003 - 2005 1.91 1.32 to 2.76 
 2006 - 2008 1.76 1.22 to2.55 
*IR = Incidence rate (density) per 100’000 person-years, CI = Confidence interval 
University of Basel  Page 143 






1. Roggli VL, Buttnor KJ: Pneumoconioses. In Practical Pulmonary Pathology; A 
diagnostic Approach.  Edited by Leslie KO, Wick MR. Philadelphia: Churchill-
Livingstone; 2005:303-333 
2. Fishwick D. Pneumoconiosis. Medicine 2008; 36(5): 258-260 
3. Pneumoconiosis and Silicosis, Health and Safety Executive (HSE)    
[http://www.hse.gov.uk/statistics/causdis/pneumoconiosis] 
4. McNamee R, Carder M, Chen Y, Agius R: Measurement of trends in incidence of 
work-related skin and respiratory diseases, UK 1996-2005. Occup Environ Med 2008 
Dec; 65(12):808-14. Epub 2008 Apr 16. 
5. Garcia Rodriquez L, Perez Gutthann S: Use of the UK General Practice Research 
Database for Pharmacoepidemiology. Br J Clin Pharmacol 1998. 45(5): 419-25 
6. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodríguez LA, Ruigómez A, Meier 
CR, Schlienger RG, Black C, Jick H: Validity of the General Practice Research 
Database. Pharmacotherapy 2003; 23: 686-9. 
7. Gribbin J, Hubbard RB, Jeune IL, Smith CJP, West J, Tata LJ: Incidence and mortality 
of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980-
985 
8. Hansell A, Hollowell J, Nichols T, McNiece R, Strachan D: Use of the General Practice 
Research Database (GPRD) for respiratory epidemiology: a comparison with the 
4th Morbidity Survey in General Practice (MSGP4). Thorax 1999 May; 54(5):413-9 
9. O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ. Asbestos-related lung disease. 
Am Fam Physician  2007 Mar 1; 75(5): 683-8. 
10. Mesothelioma mortality in Great Britain: estimating the future burden. A report by 
the Health and Safety Executive (HSE), 
[http://www.hse.gov.uk/statistics/causdis/pneumoconiosis] 
11. Grellier L and Astoul P. Mesothelioma and Asbestos-Related Pleural Diseases. 
Respiration 2008; 76:1-15 
12. Jick H, Jick SS, Derby LE: Validation of information recorded on general practitioner 
based computerised data resource in the United Kingdom. BMJ 1991; 302(6779): 
766-8. 
13. Jick H, Terris BZ, Derby LE, Jick SS: Further validation of information recorded on a 
general practitioner based computerized data resource in the United Kingdom 
Pharmacoepidemiol Drug Saf 1992; 1: 347-9. 
University of Basel  Page 144 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
14. Hubbard R, Venn A, Lewis S, Britton J: Lung cancer and cryptogenic fibrosing 
alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161 
(1): 5-8. 
15. Turner S, McNamee R, Carder M, Aguis R: Trends in pneumoconiosis and other lung 
diseases, as reported to a UK-based surveillance scheme for work-related ill-
health. 2009 J. Phys.: Conf. Ser. 151 012009 
16. The NHS plan. A plan for investment. A plan for reform. London: Stationery Office, 
London 2000. [www.nhs.uk/nhsplan] 
17. British Thoracic Society and Standards of Care Committee. The diagnosis, 
assessment and treatment of diffuse parenchymal lung disease in Adults. Thorax 
1999; 54 (Suppl 1): S1-S28 
18. American Thoracic Society / European Respiratory Society International 
Multidisciplinary Consensus Classification of the Idiopathic Interstitial 
Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304 
 
University of Basel  Page 145 




7.2 Drug-/radiation-induced interstitial lung disease in the United 
Kingdom general population: Incidence, all-cause mortality, and 
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Radiotherapy and an increasing number of substances are implicated in the 
pathogenesis of interstitial lung disease (ILD). Whilst the frequency of published data 
on more common ILD entities such as the idiopathic interstitial pneumonias (IIPs) has 
increased in recent years, less attention has been given to relatively rarely occurring 
forms such as drug-/radiation-induced ILD. 
Methods 
Data from the UK-based GPRD was used to estimate the incidence of drug-
/radiation-induced ILD over a 12-year period (1997-2008). Crude incidence rates 
were stratified by gender, age group, and calendar period, and rate ratios were 
adjusted using Poisson regression. All-cause mortality was modelled using Cox 
regression, and characteristics at diagnosis were compared to a random sample of 
matched, non-ILD controls using conditional logistic regression. 
Results 
A total of 128 patients with an incident diagnosis of drug-/radiation-induced ILD were 
identified, and the overall incidence density during the study period was 4.1 (95% CI: 
3.4 to 4.9) per million person-years. Incidence rates increased during the time period 
1997-2005 and decreased thereafter. The adjusted all-cause mortality was > 4 times 
higher in cases compared to controls. 
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This UK population-based study characterizes patients diagnosed with drug-
/radiation-induced ILD, and quantifies incidence and all-cause mortality during 1997-
2008. No statistically significant time-trend in incidence was found, despite having 
observed numeric increases in incidence rates during the study window. Future 
research using the GPRD and other data sources is required to better understand the 
disposition of patients diagnosed with drug-/radiation-induced ILD, and to investigate 
potential trends incidence and mortality over time. 
7.2.2 Introduction 
 
An increasing number of prescription drugs and novel biologics such as monoclonal 
antibodies, anti-Tumor Necrosis Factor (TNFα), interferons, and immunoglobulins are 
implicated in the pathogenesis of infiltrative and/or parenchymal lung disease [1-3]. 
Additionally, certain herbal remedies, dietary supplements, chemotherapeutics, and 
irradiation are also known to induce interstitial lung disease (ILD) [4-7]. During the 
1990’s, data from European ILD registries indicated that drug-induced ILD cases 
represented between 1.9-3.3% of all ILD cases reported [8]. Whilst the amount of 
published epidemiologic data on more commonly-occurring types of ILD (e.g. the 
idiopathic interstitial pneumonias and sarcoidosis) has increased in the recent past, 
less attention is devoted to the epidemiology of less frequently occurring subgroups 
such as drug- and radiation-induced ILD. Moreover, published data on the frequency 
and on mortality of patients with drug- and radiation-induced ILD cases in the UK 
general population are -- to the best of our knowledge -- non-existent. To better 
understand the epidemiology of this ILD subgroup and to predict demand on health 
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care resources, there is a need to describe and quantify drug- and radiation-induced 
ILD in the UK general population. We used the UK General Practice Research 
Database (GPRD) to characterize patients diagnosed with ILD induced by drugs or 
radiation, and to examine the incidence and all-cause mortality of these ILD 





The GPRD has been described elsewhere in detail [9]. In summary, it is a large and 
well-validated UK-based database that was established in June 1987. It contains 
anonymized electronic patient records collected from routine general practice, and 
the geographic, age, and gender distributions of the GPRD population have been 
shown to be representative of the U.K. general population [9].  The GPRD 
encompasses some 9 million patients who are or were enrolled with selected general 
practitioners (GPs) throughout the U.K., covering approximately 50 million patient-
years of follow-up.  The participating GPs have been trained to record medical 
information in a standard manner and to provide anonymized records to the GPRD 
Group within the Medicines and Healthcare products Regulatory Agency (MHRA), the 
UK's medicines and devices regulator. The recorded data include demographic 
information, medical diagnoses, and drug prescriptions. Data from the GPRD have 
been used in previous studies involving interstitial lung disease and use of the data 
for respiratory epidemiology has been validated [10, 11]. The GPRD is managed by 
the Medicines and Healthcare products Regulatory Agency (MHRA), and the present 
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study protocol was approved by the Independent Scientific Advisory Committee 
(ISAC) for MHRA database research.  
Cohort study population 
We identified in the GPRD all patients with a first-time diagnosis of drug- or radiation-
induced ILD between January 1, 1997 and December 31, 2008. Diagnoses in the 
GPRD are coded using the Read coding system, and our list of diagnoses included 
any Read code explicitly mentioning drug- or radiation-related lung disease: acute 
pulmonary radiation disease, acute radiation pneumonitis, chronic pulmonary 
radiation disease, chronic pulmonary fibrosis following radiation, drug-induced 
interstitial lung disorders, acute drug-induced interstitial lung disorders, or chronic 
drug-induced interstitial lung disorders.  Read codes without explicit mention of a 
drug- or radiation-related lung disease such as “Lung disease due to external agents 
NOS” were not used. In order to increase the likelihood of capturing incident rather 
than prevalent cases, we excluded patients with less than 3 years of active recording 
history prior to the date of the first drug-/radiation-ILD diagnosis. In addition, we 
identified at random from the GPRD control subjects without diagnosis of drug-
/radiation-ILD , matched 1:1 on age (same year of birth), sex, general practice, and 
calendar time (i.e. by using the date of the first ILD diagnosis of the case). We 
applied the same exclusion criteria to the control group as to the case patients. 
Within this study population we assessed and compared demography, prescription 
drug use, comorbidities, and other characteristics of cases and controls at or prior to 
the date of incident diagnosis. 
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An initial descriptive analysis was conducted to summarize demographics and other 
baseline characteristics of cases and their matched controls. Comparisons between 
cases and controls were then analyzed using conditional logistic regression. With 
respect to differences in comorbidities and prescription drug use at or prior to incident 
diagnosis, an a priori decision was taken to present and further adjust those ORs that 
reached a conventional level of statistical significance (i.e., p ≤ 0.05). 
Person-time denominators for the calculations of incidence density were derived from 
the GPRD. For each calendar period, only those patients in the GPRD who were 
alive, actively registered, and had at least 3 years of recorded history contributed 
person-time to the denominators. Incident cases were grouped into 10-year age 
bands, and calendar time was divided into four 3-year periods (1997-1999, 2000-
2002, 2003-2005, 2006-2008). Crude incidence rates were calculated for the group of 
drug-/radiation-ILD as a whole and stratified by gender, age group, and calendar 
period, with exact 95% confidence intervals calculated from the Poisson distribution. 
In order to model disease incidence and estimate incidence rate ratios, fixed-effects 
Poisson multivariate regression was used. The above methods were repeated for 
cases diagnosed with drug-induced and radiation-induced ILD separately. 
Initially, the comparison of survival between patients with drug-/radiation-induced ILD 
and matched non-ILD controls was summarized using Kaplan-Meier plots. Survival of 
cases and controls was then modelled using stratified Cox proportional hazards 
regression. Covariates included smoking history, body mass index (BMI), and cancer 
as comorbidity.  All statistical analyses were performed with the statistical software 
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SAS (release 9.2, SAS Institute, Inc., Cary, NC, USA). The proportional hazards 





A total of 128 patients with an incident diagnosis of drug-/radiation-induced ILD were 
identified during the period 1997-2008, of which 106 (83 %) cases were diagnosed 
with radiation-induced lung disease. The frequency distribution of incident diagnoses 
is shown in Table 1. The mean age (SD) at diagnosis was 67 (11.9) years, and 73 
(57%) cases were female. Males and females were of similar mean age at the time of 
first diagnosis (67 years [±SD 12.1] vs. 66 years [±SD 11.8], respectively), and the 
majority of cases was diagnosed in the age group 60-79 years. The age distribution 
of cases is shown in Figure 1. Compared to their matched general-population 
controls, cases were more likely to be ex- or current smokers than non-smokers, 
more likely to have a BMI ≥ 25 than < 25 kg/m2, and less likely to consume alcohol, 
however, none of these characteristics reached statistical significance. With respect 
to healthcare resource utilization, cases (as opposed to their matched controls) were 
almost 8 times more likely to have had  ≥ 20 vs. < 20 practice visits and were greater 
than 3 time more likely to have had  ≥ 25 vs. < 25 drug prescriptions during 1 year 
prior to incident diagnosis (Table 2). Likewise, cases were ≥ 1.8 times more likely 
than their matched general-population controls to have a range of both comorbid 
diagnoses and prescription drug use at or prior to diagnosis; the highest odds ratios 
(ORs) were observed for having a diagnosis of cancer (in situ metastasis) (OR=43.5, 
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95% CI 10.7 – 177.0) and use of immunosuppressives (OR=11.0, 95% CI 1.42 – 
85.20), respectively. After adjusting for cancer diagnosis, elevated ORs achieving 
statistical significance were noted for diagnoses of RA, constipation, IHD, and CHF 
as well as for prescription drug use of immunosuppressives, corticosteroids, 
antiarrhythmics, NSAIDs, and diuretics. Results of comorbidities and prescription 
drug use can be found in Table 3, in which the data for each category is sorted in 
descending order according to the magnitude of the crude ORs. 
Between 1997 and 2008 the overall incidence density of drug-/radiation-induced ILD 
was 4.1 (95% CI 3.4 to 4.9) per 1,000,000 (106) person-years, and the rate in females 
was approximately 20% higher than in males. Across age groups, the lowest 
incidence density was observed for those below the age of 60 years (1.2 [95% CI 0.8 
to 1.7] / 106 person-years); the rates in older age groups were approximately 8-12-
fold higher. Crude incidence rates increased progressively during the first three 
periods and then decreased from the period 2003-2005 to 2006-2008 (5.1 [95% CI 
3.7 to 6.9] vs. 4.4 [95% CI 3.1 to 6.1] / 106 person-years, respectively). Crude 
incidence rates for the aggregate group of drug-/radiation-induced ILD are shown in 
Table 4. With respect to each diagnosis category separately (i.e. drug- vs. radiation-
induced ILD), incidence density increased progressively from 1997 to 2005 for drug-
induced ILD, and then dropped by more than 50% between the period 2003-2005 to 
2006-2008. In the radiation-induced ILD category, incidence density remained 
somewhat stable during the first two 3-year periods (1997-2002, range 2.9 to 3.0/106 
/year), and then increased during the following two 3-year periods (2003-2008, 
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approx. 3.8/106/year). Category-specific incidence density by calendar period can be 
found in Table 5. 
After adjusting for the effects of age and gender in the aggregate category of drug-
/radiation-induced ILD, although having observed numeric increases in incidence 
from 1997-2005 and a subsequent decrease from the period 2003-2005 to 2006-
2008, there was no evidence of statistically significant heterogeneity of rate ratios 
over time (p=0.74).  In contrast, after adjusting for gender and calendar period, there 
was evidence of statistically significant heterogeneity of rate ratios across age 
groups. Incidence density rates in the age groups 60-69 and 70-79 were more than 
10 times higher than in those under 60 years of age. Incidence rate ratios for the 
aggregate category of drug-/radiation-induced are shown in Table 6. 
A total of 64 cases died during follow-up, vs. 16 controls. The mean (±sd) survival 
time for cases was 3.1 (±3.1) vs. 4.8 (±3.1) years for general-population controls. 
Over the 12-year follow-up period cases were 7 times more likely to die compared to 
their matched general-population controls (Figure 2) (HR=7.13, 95% CI 3.40 to 
14.93). After allowing for the confounding effect of baseline cancer diagnosis, the 
difference in 12-year survival decreased, yet remained elevated (HR=4.04, 95%CI 
1.56 – 10.56 (Table 7). No evidence was found to suggest a departure from the 
proportional hazards assumption in the final model. 
7.2.5 Discussion 
 
In this general-population-based UK cohort of drug- and radiation-induced ILD 
patients, the overall incidence rate was approximately 4 per million population per 
University of Basel  Page 154 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
year, suggesting that each year in the UK there will be ~ 250 new cases of drug- and 
radiation ILD. Overall, numeric increases were observed in incidence density rates 
during the first 9 years of the study period, followed by a decline during the final 3 
years. This drop in incidence in the aggregate category of drug- and radiation-
induced ILD was clearly attributable to the >50% decrease in incidence observed in 
the subgroup of drug-induced ILD during the same period.  Incidence density of 
radiation-induced ILD remained relatively stable during the first 6 years (range: 2.9 to 
3.0/106 person-years) and then increased to nearly 3.8/106 person-years.  
All-cause mortality adjusted by matching on age, gender, geography (via general 
practice as a proxy), and number of years of recorded medical history was 7 times 
higher in cases compared to general-population controls. After further adjustment by 
both baseline smoking status and cancer diagnosis (i.e. ~ 75% of cases had a 
diagnosis of cancer at/prior to incident drug-/radiation-induced ILD diagnosis), the all-
cause mortality rate for cases remained elevated at > 4.5 times that of general-
population based controls.  The majority of cases (~54%) in our cohort was 
diagnosed with acute radiation pneumonitis (as opposed to ‘classic’ or ‘sporadic’ 
radiation pneumonitis), a condition that is associated with significant symptoms, and 
in some cases, develops into respiratory failure or Acute Respiratory Distress 
Syndrome (ARDS) [12-13]. However, the adjusted all-cause mortality rate would 
suggest that many of these patients suffer progressive disease resulting in premature 
death. Whether or not the cause of death was attributable to radiation-induced ILD, 
non-remissive cancer, or other comorbidities could not be examined since precise 
information on cause of death is not readily available in the GPRD.  
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A potential weakness of the present study could be the validity of the ILD diagnoses. 
However, the validity of many disease diagnoses has been assessed in the GPRD 
and has consistently found to be high [14-16]. Furthermore, other researchers have 
reported a high validity of the diagnosis of idiopathic pulmonary fibrosis, another 
interstitial lung disease, in the GPRD [17]. Moreover, it is highly unlikely that general 
practitioners would record a diagnosis of drug- or radiation-induced ILD without 
confirmation by specialist referral. In order to explore the specificity of the ILD 
diagnoses in our cohort, we examined the medical history in more detail and found 
the following: (1) Of the 106 cases with a diagnosis of radiation-induced ILD, 79 had 
a diagnosis of thoracic-related cancer while the remaining 27 had a diagnosis of 
cancer that was not otherwise specified. (2) Of the 22 cases with a diagnosis of drug-
induced ILD, the last immunosuppressive prescribed for 9 of these cases was either 
leflunomide (n=1) or methotrexate (n=8), while 8 patients, who did not have any 
history immunosuppressive drug prescription (i.e. mutually exclusive of the 9 patients 
previously described), were prescribed amiodarone immediately prior to their ILD 
diagnosis. All aforementioned prescription drugs are known potential inducers of ILD. 
In light of the above reasons and findings, we expect the diagnoses used for the 
present study to have a high specificity.  
On the other hand, we are aware that the sensitivity of the diagnoses used may not 
be as high as the specificity. Two main reasons for this are the potential for 
misclassification of true ILD cases into less specific disease diagnosis categories and 
the possibility of having missed less severe cases. For instance, we did not use less 
specific respiratory-related diagnosis codes such as “lung disease due to other 
University of Basel  Page 156 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
external agents NOS” or “other external agent causing respiratory condition” in our 
case selection algorithm. Overall there were 649 cases with such an unspecific 
diagnosis which we subsequently reviewed in more detail. None of these had 
evidence of a drug- or radiation-induced ILD diagnosis at a later point in time in their 
medical record, which indicates that misclassification is unlikely. It is also possible 
that less severe cases have escaped detection by general practitioners and 
specialists. Thus it is possible that we did not have available for analysis all true 
cases of drug- and radiation-induced ILD from the given sampling frame, which 
means that we may have underestimated the true incidence density of this ILD 
subgroup in the UK. Furthermore, we cannot be certain that all newly identified cases 
were indeed incident cases. However, we excluded cases with less than 3 years of 
recorded medical history in order to minimize the possibility of including prevalent 
cases in our incidence numerators, so we expect the occurrence of such error to be 
minimal. To the extent that this error occurred it will have resulted in a small 
overestimation of the incidence density rates. Despite the potential limitations 
mentioned above, this study determined current estimates of incidence density for 
the aggregate category of drug- and radiation-induced ILD as well as category-
specific rates for drug-induced and radiation-induced ILD separately in the UK 
general population. 
We have been unable to find any other population-based cohort analyses in the U.K. 
with which to compare our incidence or mortality data. However, data from various 
European and U.S. studies show some similarities and differences. One of the first 
ever population-based epidemiological studies of ILD in the late 1980s (in Bernalillo 
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County, New Mexico) reported an incidence of 1.45/105 person-years for drug and 
radiation ILD, which is approximately 3.5 times higher than the rate observed in our 
cohort [18]. One explanation might be the use of a more comprehensive case 
ascertainment which included ILD cases not only diagnosed by pulmonologists and 
general practitioners, but also those cases discovered in hospital discharge reports, 
death certificates, and autopsy reports. From a more recent survey of ILD-special 
interest Pulmonology centers in Greece, Karakatsani et al. reported an incidence rate 
of 0.07/105 person-years for drug-induced ILD, which is nearly identical to our UK 
category-specific incidence rate for drug-induced ILD [19]. Similarly, López-Campos 
et al. reported an incidence of 0.08/105 person-years for drug-induced ILD from an 
ILD registry encompassing nine provinces in Southern Spain; data from the same 
registry reported an incidence rate of 0.00/105 person-years (only 2 cases of the total 
744 ILD cases reported) for radiation-related ILD, which is strikingly different to the 
rate observed in our study [20]. Factors influencing this difference could be the use of 
a different coding system (ICD codes vs. Read codes), misclassification of ILD 
diagnosis, differences in prevalence of thoracic cancers (for which radiotherapy 
would be indicated), and differences in age- and gender distribution.  
In any case, it is acknowledged in the literature that the frequency of drug-induced 
lung disease reported from any data source is likely to underestimate true disease 
frequency [13,21-22]. Many drugs implicated in ILD are primarily prescribed by non-
respiratory physicians, and under-diagnosis is likely. Moreover, subclinical forms of 
drug-induced ILD are likely to escape detection by plain chest radiography as 
opposed to the use of high resolution computed tomography (HRCT), which would 
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take place in close collaboration with a respiratory specialist. In the oncology setting, 
where drug-induced ILD is likely to be common, a diagnosis of drug-induced ILD will 
often remain inconclusive because the patient’s condition precludes further (invasive) 
diagnostic assessment.  
In this study of the aggregate category of drug-/radiation-induced ILD, no clear trend 
in incidence can be seen. This is evident from the lack of heterogeneity found in the 
numerically increasing incidence rates during 1997-2005, followed by a decrease 
during the final calendar period (2006-2008). However, due to the relatively small 
sample size of cases, the study did not have sufficient statistical power to detect a 
trend in incidence, had such a trend truly existed during the study window. 
Furthermore, we cannot tell whether the overall numeric increase reflects a real 
increase, or whether it is, at least to a certain extent, attributable to secular trends. 
Firstly, during the study window major political changes in the NHS occurred, 
including more than a doubling in funding under the auspices of the New Deal. [23] 
This investment in national health care was in part used to boost capacity of NHS 
services and to modernize facilities, thus potentially increasing the likelihood of 
detecting new cases of drug-/radiation-induced ILD. Secondly, a certain proportion of 
incident cases in this time period may have been due to increased recognition of 
interstitial lung diseases in general via the increased use of HRCT. Thirdly, following 
publication of both the British Thoracic Society’s guideline on diagnosis and care of 
diffuse parenchymal lung disease in 1999 [24] and the ATS/ERS consensus 
statements on idiopathic interstitial pneumonia in 2002 [25], a greater appreciation of 
the value of precise diagnosis according to defined criteria will likely have occurred, 
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not to mention increased patient expectations.  For the above reasons, an increase in 
case ascertainment may have played a role in the observed increase in incidence 
density rates. Furthermore, the incidence pattern seen in the drug-induced ILD 
subgroup might also be explained, not solely in terms of better diagnosis, but also by 
earlier diagnosis, which resulted in a transient increase in incidence density, followed 
by a corresponding decline in subsequent years. 
This study makes use of data from a well-validated database which has consistently 
been found to be representative of the UK general population. To our knowledge, this 
is the first general-population-based observational study quantifying incidence and 
mortality rates of diagnosed drug-/radiation-induced ILD in the UK. 
 
7.2.6 Tables and figures 
 
Table 1. Frequency of incident diagnoses of drug-/radiation-induced ILD 
(N=128). 
 
Diagnosis codes Frequency Percent 
Acute pulmonary radiation disease 1 0.78 
Acute radiation pneumonitis 69 53.91 
Chronic pulmonary radiation disease 1 0.78 
Chronic pulmonary fibrosis following radiation 35 27.34 
Drug-induced interstitial lung disorders 18 14.06 
Acute drug-induced interstitial lung disorders 3 2.34 
Chronic drug-induced interstitial lung disorders 1 0.78 
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Table 2. Characteristics of drug-/radiation-induced ILD cases and their 






OR (95% CI) 
   
 
Mean age (years) ± sd 66.6 ±11.9 66.7±11.9 ----    
 




)       
       
< 25 44 (34.4) 45 (35.2) 1.00 (ref.)    
≥ 25 67 (52.3) 56 (43.8) 1.29 (0.70 – 2.37)    
Unknown 17 (13.3) 27 (21.1) 0.60 (0.27 – 1.35)    
 
Smoking status 
       
Non-smokers 52 (40.6) 62 (48.4) 1.00 (ref.)    
Current/Ex-smokers 70 (54.7) 53 (41.4) 1.68 (0.96 - 2.93)    
Unknown 6 (4.7) 13 (10.2) 0.39 (0.10 - 1.46)    
 
No. of cigarettes per day 
       
0 10   (7.8) 13 (10.2) 1.00 (ref.)    
1 - 10 22 (17.2) 14 (10.9) 2.14 (0.75 - 6.15)    
11 + 16 (12.5) 10 (7.8) 2.07 (0.66 – 6.50)    
Unknown 80 (62.5) 91 (71.1) 1.02 (0.41 - 2.54)    
 




       
0  74 (57.8) 72 (56.3) 1.00 (ref.)    
1 - 7 26 (20.3) 27 (21.1) 0.92 (0.46 – 1.84)    
8 + 28 (21.9) 29 (22.7) 0.92 (0.48 – 1.79)    
 
No. of practice visits
2
     
       
0 - 19  33 (25.8) 87 (68.0) 1.00 (ref.)    
20 + 95 (74.2) 41 (32.0) 7.75 (3.71 – 16.18)    
 
No. of drug prescriptions
3
 
       
0 - 24  46 (35.9) 83 (64.8) 1.00 (ref.)    
25 + 82 (64.1) 45 (35.2) 3.47 (1.95 – 6.16)    
 
CI=Confidence Interval; sd=standard deviation 
1 = last recording prior to index date, 2 = based on recordings of diagnoses and prescriptions 
(falling on separate dates) during 1 year prior to incident diagnosis, 3 = during 1 year prior to 
incident diagnosis 
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Table 3. Odds of comorbidities and prescription drug use for drug-/radiation-induced 





[n=128] OR (95% CI) 






Comorbid diagnoses     
Cancer (i.s. metastasis) 97 (75.8) 12   (9.4) 43.5 (10.7 – 177.0) -- 
RA 13 (10.2)   2   (1.6) 6.50 (1.47 – 28.9) 
21.32 (2.46 – 
184.82) 
Constipation 33 (25.8) 10 (12.8) 5.60 (2.16 – 14.5) 6.09 (1.32 – 28.13) 
Hypothyroidism 18 (14.1)   5   (3.9) 4.25 (1.43 - 12.6) 0.14 (0.01 – 2.96) 
Arrhythmia 25 (18.5)   7   (5.5) 4.00 (1.64 – 9.79) Non-estimable* 
COPD 17 (13.3)   5   (3.9) 3.40 (1.25 – 9.22) 2.04 (0.54 – 7.62) 
IHD 30 (23.4) 15 (11.7) 2.50 (1.20 – 5.21) 
22.18 (2.66 – 
184.98) 
CHF 15 (11.7)   6   (4.7) 2.50 (0.97 – 6.44) 6.27 (1.38 – 28.43) 
GERD/Esophag./Dyspep./Gast
r. 40 (31.3) 28 (21.9) 2.00 (1.05 – 3.80) 0.87 (0.34 – 2.19) 
Asthma 26 (20.3) 16 (12.5) 1.83 (0.91 – 3.70) 1.41 (0.49 – 4.10 
     
 
Rx drug use at/prior to Dx 
Immunosuppressives 11   (8.6)   1  (0.08) 11.0 (1.42 – 85.2) 
27.72 (1.91 – 
402.86) 
Corticosteroids (systemic) 67 (52.3) 31 (24.2) 4.00 (2.12 – 7.53) 4.70 (1.70 – 12.98) 
Anticholinergics 24 (18.8)   6   (4.7) 4.00 (1.64 – 9.79) 3.18 (0.96 – 10.58) 
β – Agonists and comb. 62 (48.4) 28 (21.9) 3.62 (1.96 – 6.68) 2.50 (0.99 – 6.33) 
Antiarrhythmics 17 (13.3)   7   (5.5) 2.67 (1.04 – 6.81) 
27.93 (2.88 – 
271.26) 
Thyroid Gland Therapy 20 (15.6)   9   (7.0) 2.57 (1.07 – 6.16) 3.02 (0.77 – 11.95) 
PPIs 54 (42.2) 33 (25.8) 2.31 (1.29 – 4.16) 2.86 (0.88 – 9.32) 
NSAIDs 98 (76.6) 79 (61.7) 2.12 (1.19 – 3.77) 3.09 (1.08 – 8.80) 
H2-Receptor Antagonists 47 (36.7) 31 (24.2) 2.00 (1.10 – 3.64) 2.04 (0.79 – 5.32) 
Corticosteroids (inhaled) 51 (40.0) 34 (26.6) 1.94 (1.10 – 3.43) 1.27 (0.55 – 2.90) 
Diuretics 59 (46.1) 41 (32.0) 1.86 (1.09 – 3.16) 3.00 (1.25 – 7.20) 
a = adjusted by matching for age, gender, geographic location, and  no. of year s of recorded history in database 
b = further adjusted by cancer status at/prior to index date; Rx = prescription; Dx = diagnosis; CI = Confidence Interval; i.s. = in 
situ; RA = Rheumatoid Arthritis; COPD = Chronic Obstructive Pulmonary Disease; IHD = Ischaemic Heart Disease CHF = 
Congestive Heart Failure; GERD = Gastro-Esophageal Reflux Disorder; PPI = Proton-pump Inhibitors; NSAID=Non-steroidal 
Anti-inflammatory Drugs;  H2 = Histamine-2;  *Non-estimable due to 1 or more strata with null counts 
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95% CI (exact 
Poisson) 
      
OVERALL  128 31,165,672.41 4.11  3.43 to 4.88 
      
Gender      
 Female 73 16,421,082.12 4.45  3.48 to 5.59 
 Male 55 14,744,590.29 3.73  2.81 to 4.86 
      
Age Groups      
 <60 28 23,309,579.77 1.20  0.80 to 1.74 
 60 - 69 45 3,474,347.44 12.95  9.45 to 17.30 
 70 - 79 38 2,689,162.52 14.13  10.0 to 19.40 
 80+ 17 1,692,582.70 10.04  5.85 to 16.10 
      
Calendar 
period      
 1997 - 1999 22 6,696,773.29 3.29  2.06 to 4.97 
 2000 - 2002 26 7,646,978.15 3.40  2.22 to 4.98 
 2003 - 2005 42 8,232,635.23 5.10  3.68 to 6.90 
 2006 - 2008 38 8,589,285.74 4.42  3.13 to 6.07 
IR = Incidence rate (density) per 1,000,000 person-years; CI = Confidence interval 
 







95% CI (exact 
Poisson) 
Drug-induced ILD (N=22) 
Calendar 
period      
 1997 - 1999 2 6,696,773.29 0.30  0.04 to 1.08 
 2000 - 2002 4 7,646,978.15 0.52  0.14 to 1.34 
 2003 - 2005 11 8,232,635.23 1.34  0.67 to 2.39 
 2006 - 2008 5 8,589,285.74 0.58  0.19 to 1.36 
Radiation-induced ILD  (106) 
Calendar 
period      
 1997 - 1999 20 6,696,773.29 2.99  1.82 to 4.61 
 2000 - 2002 22 7,646,978.15 2.88  1.80 to 4.36 
 2003 - 2005 31 8,232,635.23 3.77  2.56 to 5.34 
 2006 - 2008 33 8,589,285.74 3.84  2.64 to 5.40 
IR = Incidence rate (density) per million person-years; CI = Confidence interval 
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Table 6. Poisson regression modelling of drug-/radiation-induced incidence (aggregate 
group) 
 
  IRR 95% CI  LRT p-value 
     
Gender    
0.6254 
 Female (Ref.) 1.00 ------- 
 Male 0.91 0.64 to 1.30 
     
Age Groups    
< 0.001* 
 <60 (Ref.) 1.00 ------- 
 60 - 69 10.73 6.69 to 17.20 
 70 - 79 11.76 7.22 to 19.17 
 80+ 8.22 4.49 to 15.04 
     
Calendar period    
  
0.7387* 
 1997 – 1999 (Ref.) 1.00 ------- 
 2000 - 2002 1.04 0.59 to 1.84 
 2003 - 2005 1.56 0.93 to 2.61 
 2006 - 2008 1.31 0.77 to 2.21 
IRR = Incidence rate ratio; CI = Confidence interval; LRT = Likelihood ratio test, *p for trend 
 
 






HR 95% CI  p-value (LRT) 
Crude (adjusted by matching for age, gender, location, no. of years of recorded medical history) 
      
 General-population controls  16 1.00    
 Drug-/radiation-induced ILD cases 64 7.13 3.40 to 14.93  < 0.0001  
      
Further adjusted for baseline smoking status 
      
 General-population controls  16 1.00    
 Drug-/radiation-induced ILD cases 64 8.92  3.71 to 21.45 < 0.0001   
      
Further adjusted for baseline smoking status and baseline cancer diagnosis 
      
 General-population controls  16 1.00    
 Drug-/radiation-induced ILD cases 64 4.64  1.60 to 13.44 < 0.0001   
HR = Hazard Ratio; CI=Confidence Interval 
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Figure 1.  Age at diagnosis of drug-/radiation-induced ILD (N=128) 
 
 
Figure 2. Kaplan-Meier plot comparing survival in cases diagnosed with drug-
/radiation-induced ILD and matched general-population controls 
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7.3 Interstitial lung disease in patients with connective tissue 
disease: A retrospective cohort study of incident cardiovascular 
comorbidity and all-cause mortality using the U.K. General 
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To investigate survivorship and incident cardiovascular outcomes in patients with 
connective tissue diseases, after a diagnosis of interstitial lung disease. 
Methods 
Data from the UK-based GPRD were used to estimate all-cause mortality rates over 
the 12-year study period (1997-2008). All-cause mortality and incident cardiovascular 
outcomes were modelled using Cox proportional hazards regression. 
Results 
A total of 583 CTD-patients with a first-time diagnosis of ILD were identified during 
the study period. The age- and gender-adjusted 12-year mortality rate was 40% 
lower in non-RA CTD-ILD vs. RA-ILD patients, and the risk of incident pulmonary 
hypertension was >8 times higher in non-RA CTD-ILD vs. RA-ILD patients (p < 
0.001). No statistically significant risk differences for incident arrhythmia or ischemic 
heart disease (IHD) were observed between RA-ILD and Other CTD-ILD patients. 
However, adjusting for age and gender, borderline statistical significance was 
observed for the >50% reduced risk of incident congestive heart failure (CHF) in the 
Other CTD-ILD group vs. RA-ILD (p=0.056). 
Conclusions 
This study underscores the poor prognosis for CTD-ILD patients. Among CTD 
diagnostic subtypes, RA-ILD patients have a significantly higher risk of mortality 
within 12 years after their ILD diagnosis as compared to other CTD-ILD patients. 
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Interstitial lung disease (ILD) comprises a diverse group of disorders affecting the 
lung parenchyma, many of which are characterized by varying degrees of 
inflammation and fibrosis. The fibrotic forms of ILD are rarely curable and often lead 
to significant morbidity and mortality [1-3]. ILD may be broadly subdivided into 
idiopathic interstitial pneumonia (IIP) and those secondary to external exposures or 
associated with a systemic connective tissue disease (CTD). CTD represents a 
heterogeneous group of systemic autoimmune disorders affecting a variety of tissues 
and organs, including the lung. Similar to ILD, many CTDs are associated with 
significant comorbidity, including cardiovascular disease, and elevated mortality rates 
[4-7].  
 Several studies have investigated the epidemiology of CTD-ILD; however, few 
have used large-scale, population-based cohorts to investigate incident 
cardiovascular comorbidity and survivorship in these patients. To advance the 
understanding of the epidemiology of CTD-ILD and to provide additional informative 
data on the prognosis for this disease group, we used data from the UK General 
Practice Research Database (GPRD) to examine all-cause mortality and incident 
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The GPRD has been described elsewhere in detail [9]. In summary, it is a large and 
well-validated UK-based database that was established in June 1987. It contains 
anonymized electronic patient records collected from routine general practice, and 
the geographic, age, and gender distributions of the GPRD population have been 
shown to be representative of the U.K. general population [9].  The GPRD 
encompasses approximately 7 million patients who are or were enrolled with selected 
general practitioners (GPs) throughout the U.K., covering approximately 50 million 
patient-years of follow-up.  The participating GPs have been trained to record 
medical information in a standard manner and to provide anonymized records to the 
GPRD Group within the Medicines and Healthcare products Regulatory Agency 
(MHRA), the UK's medicines and devices regulator. The recorded data include 
demographic information, medical diagnoses, and drug prescriptions. Data from the 
GPRD have been used in previous studies involving ILD and CTD, and the use of the 
data for respiratory epidemiology has been validated [10-12]. The GPRD is managed 
by the Medicines and Healthcare products Regulatory Agency (MHRA), and the 
present study protocol was approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA database research.  
Cohort study population 
We identified in the GPRD all patients having been diagnosed with a CTD (i.e. 
rheumatoid arthritis (RA), systemic sclerosis (SSc), systemic lupus erythematosus 
(SLE), Sjögren Syndrome (SS), dermatomyositis/polymyositis (DM/PM), mixed or 
University of Basel  Page 171 
Doctoral dissertation – RKA  Epidemiology of ILD in the UK 
 
 
undifferentiated connective tissue disease (MCTD/UCTD)) prior to (or at the same 
time of) a first-time diagnosis of ILD (hereinafter referred to as ‘index date’) between 
January 1, 1997 and December 31, 2008. Patients with more than one diagnosis of a 
CTD in their medical history were grouped into a category referred to as ‘> 1 CTD 
Dx’. Diagnoses in the GPRD are coded using the Read coding system, and our list of 
ILD diagnoses included any Read code explicitly mentioning an ILD or lung disease 
with a CTD: diffuse pulmonary fibrosis, fibrosing alveolitis, fibrosis of lung present, 
rheumatoid lung, lung disease with CTD.  Read codes with explicit mention of 
sarcoidosis, allergic alveolitis, hypersensitivity pneumonitis (including fibrosis 
following radiotherapy), occupational lung disease (e.g. pneumoconioses), or “lung 
disease due to external agents NOS” were not used. With respect to our RA CTD-
subgroup, patients with a Read diagnosis of “seronegative RA” were excluded from 
the cohort. All patients with less than three years of active history in the database 
prior to the index date were excluded.  
Data analysis 
Initially, a descriptive analysis was performed to summarize demographics and other 
baseline characteristics, by CTD-subgroup. Survival curves were examined using 
Kaplan-Meier estimates, and heterogeneity of the CTD subgroups was assessed 
using log-rank tests. A data-driven decision was taken to collapse the SSc, SLE, SS, 
DM/PM, and >1 CTD Dx populations into one group, hereinafter termed ‘Other CTD.’ 
All-cause mortality was then modelled using Cox proportional hazards regression. 
Similarly, Cox modelling was used for the analysis of incident cardiovascular 
morbidity, however, cases having such diagnoses (i.e. Arrhythmia, CHF, IHD, and 
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PH) at any time in their medical history prior to the index date were excluded from the 
respective analysis population. All statistical analyses were performed with the 
statistical software SAS (release 9.2, SAS Institute, Inc., Cary, NC, USA). The 
proportional hazards assumption was tested for the final models using the 





A total of 583 CTD patients with an incident diagnosis of ILD were identified during 
the period 1997-2008, of which 58 (10 %) cases were diagnosed with more than one 
type of CTD. The frequency distribution of the CTD subgroups is shown in Table 1. 
The mean age at ILD diagnosis was highest for RA (67 [±SD 11.9] years), and lowest 
in SLE patients (52 [± SD 13.5] years). The female-to-male ratio was highest among 
SS (21:1) and lowest in RA patients (213:172). The highest proportions of ex- or 
current smokers and elevated BMI (≥25 kg/m2) among the various CTD subgroups 
were found for RA (51%) and DM/PM (62%), respectively. Further characteristics for 
the individual CTD subgroups can be found in Table 2.  
All-cause mortality 
Of the 583 patients in the cohort, a total of 229 (39%) died during the 12-year follow-
up period. Among the RA-ILD group 179 (46%) of the 385 patients died, whereas in 
the Other CTD-ILD group 50 (25%) of the 198 patients died. Median survival time 
(from ILD diagnosis until death) for in the RA-ILD group compared to the Other CTD-
ILD group was similar (1.9 vs. 2.1 yrs., respectively). The Other CTD-ILD group had 
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significantly better survival rates than the RA-ILD group (see Figure 2; log-rank test 
p<0.0001). The 5- and 10-year survival estimates for the RA-ILD group were 51% 
and 24%, respectively, versus 73% and 51% for the Other CTD-ILD group. Kaplan–
Meier plots of survival probability for individual CTD-ILD groups and for the collapsed 
Other CTD-ILD versus RA-ILD group can be found in Figures 1 and 2, respectively. 
Multivariate Cox regression modelling was performed to evaluate the effect of 
baseline characteristics on all-cause mortality, and to adjust for potential 
confounders. Only age at index date was found to contribute significantly to 
goodness of model fit, however, gender was forced into the final model based on an 
a priori decision to include variables having an effect with p ≤ 0.1. Therefore, the final 
model yielded a 40% decreased risk of all-cause mortality among the Other CTD-ILD 
group vs. the RA-ILD group (HR=0.60 [95% CI:  0.43 to 0.83]), adjusted for age and 
gender at index date (see Table 3). No evidence was found to suggest a departure 
from the proportional hazards assumption in the final model. 
Incident cardiovascular comorbidity during follow-up 
After excluding from the respective analysis populations those patients having had 
diagnoses of the cardiovascular outcomes of interest prior to index date, the crude 
risk of incident CHF after index date was significantly decreased for Other CTD-ILD 
vs. RA-ILD (HR=0.38 [95% CI:  0.18 to 0.79]), with a borderline statistically significant 
reduction in CHF risk of approximately 50% remaining even after controlling for age 
and gender (HR=0.48 [95% CI:  0.22 to 1.02]). An incident diagnosis of PH after 
index date was observed in 8.2% of the Other CTD-ILD group vs. only 1% of the RA-
ILD group. After controlling for age and gender, a greater than 8-fold elevated risk of 
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incident PH was observed for patients in the Other CTD-ILD group versus the RA-ILD 
group (HR=8.32 [95% CI:  2.54 to 27.12]). No statistically significant differences (at 
the 5% level, after controlling for age and gender) were observed for post-index date 
incident arrhythmia or IHD, across CTD groups. No evidence of departure from the 
proportional hazards assumption was detected in the final model. Further details for 
all incident cardiovascular outcomes of interest can be found in Table 4. 
 
7.3.5 Discussion 
This population-based, retrospective cohort study reinforces the poor prognosis 
associated with ILD diagnosed in patients with CTD. Of the 229 (~40%) patients who 
died during the 12-year study period, the median survival time from incident ILD 
diagnosis to death was ~ 2 years. This estimate is similar to (yet somewhat lower 
than) those found in methodologically-similar, population-based studies examining 
mortality in CTD-ILD patients [13,14]. Using a retrospective database design with RA 
patients only, recent analyses presented by Bongartz et al. estimated median survival 
from incident ILD diagnosis to death to be 2.6 years [14], while a GPRD-cohort of 
patients with several types of CTDs during the period 1989-1997 presented by 
Hubbard and Venn reported a median survival time from incident ILD of 2.4 years 
[13]. The former study used data from a limited geographical region in the USA 
(Rochester, MN) and contained a small sample size of RA-ILD patients, while the 
latter only included ILD patients coded with either “idiopathic” or “cryptogenic” 
fibrosing alveolitis (and hence the smaller sample size compared to the present 
GPRD study). While our study also employed use of these codes for identification of 
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incident ILD patients, we further included in our selection algorithm Read codes 
mentioning “diffuse pulmonary fibrosis,” “fibrosis present,” and “lung disease with a 
CTD” (e.g. “lung disease with SLE,” etc.). 
While much of the CTD-ILD outcome research found in the literature draws 
comparisons between CTD-ILD and idiopathic ILD or between CTD-ILD vs. CTD 
alone, our study compares all-cause mortality and cardiovascular outcomes between 
CTD diagnostic subgroups. In terms of overall patient numbers, the predominant 
CTD in this study was RA (66%), followed by SSc (11%) and SLE (6%). The decision 
to group SSc, SLE, SS, DM/PM, and the >1 Dx populations into one category was 
primarily based on the graphical similarity and log-rank testing (vs. RA-ILD) of the 
individual Kaplan-Meier estimates for these populations. Over the 12-year study 
period, we found a statistically significantly increased risk of all-cause mortality for 
RA-ILD vs. the aggregate category of other CTD-ILD. While we are unable to 
contextualize this risk estimate due to a lack of published data comparing risk of all-
cause mortality between individual CTDs associated with ILD, our 5-, and 10-year all-
cause mortality estimates for RA-ILD (51% and 24%, respectively) are similar to 
those reported by other researchers. In the Early Rheumatoid Arthritis Study (ERAS), 
which included 52 RA-ILD patients from nine centres in England between 1986 and 
1998, Koduri et al. report  5- and 10-year survival probabilities of ~40% (95% CI 
~23% to ~54%) and ~25% (95% CI: ~12% to ~39%), respectively [15]. A Kaplan-
Meier plot from the Bongartz et al. publication shows similar 5- and 10-year survival 
estimates of ~40% and ~20% for their RA-ILD cohort, respectively [14]. 
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Among the incident cardiovascular comorbidities investigated in this study, only the 
risk of PH in the aggregate Other CTD-ILD category was significantly elevated vs. 
RA-ILD. This >8-fold increased risk was clearly driven by the SSc-ILD group to which 
13 of the total 16 incident PH cases were attributed. After adjusting for age and 
gender, a borderline statistically significant reduced risk of CHF remained for the 
aggregate Other CTD-ILD group vs. RA-ILD, and no statistically significant 
differences in risk at the 5%- lever were observed for incident diagnoses of 
arrhythmia or IHD. Irrespective of the potential impact of ILD in RA, risk of 
cardiovascular comorbidity in RA patients has been studied extensively, especially in 
relation to its contribution to premature mortality. In a study by Nicola et al. CHF, as 
opposed to IHD, was identified as an important contributor to excess mortality in a 
cohort of RA patients [16]. A further detrimental impact of ILD on cardiovascular 
comorbidity in RA and other CTD patients is however conceivable due to the 
restrictive lung function characteristic of ILD and its potential consequences on 
pulmonary circulation, e.g. pulmonary arterial hypertension and cor pulmonale. 
Our study has a few potential limitations. We did not directly test the validity of 
mortality or diagnosis data. However, previous research has confirmed the 
completeness of death recording and the high validity of many disease diagnoses in 
the GPRD, including cardiovascular and respiratory disease [17-20]. Likewise, 
validity of RA diagnoses in the GPRD appears to be high, based on two previous 
studies [21,22]. Furthermore, Hubbard et al have reported a high validity of idiopathic 
ILD in the GPRD [23]. Moreover, it is highly unlikely that general practitioners would 
record diagnoses of ILD, CTD or cardiovascular disease without confirmation by 
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specialist referral. Therefore, we expect the diagnoses used in the present study to 
have a high specificity. On the other hand, we acknowledge that the sensitivity of the 
diagnoses used may not be as high as the specificity. It is possible that 
misclassification of CTD or ILD diagnoses play a role here, however, the extent to 
which this occurred is expected to be minimal in light of results from the 
aforementioned validation studies. A further reason contributing to potentially 
reduced sensitivity could be that less severe cases escaped detection by general 
practitioners and specialists. Thus, it is possible that we did not have available for 
analysis all true cases of CTD, ILD, and CV disease. However, the extent to which 
this occurred will likely be true for all chronic disease diagnoses in the GPRD such as 
CTD, CVD, and ILD, and therefore this will not have introduced any substantial bias 
on our risk estimates. Also, we cannot be certain that all newly identified ILD cases 
were indeed incident cases. However, we excluded cases with less than 3 years of 
recorded medical history in order to minimize the possibility of including prevalent 
cases, so we expect the occurrence of such error to be minimal. Likewise, for our 
analysis of incident CVD after ILD diagnosis, we excluded from the CVD analysis 
populations patients with any mention of the respective CVD under investigation prior 
to the index date. 
With respect to our survival estimates, it is not clear to what extent lead-time bias and 
drug treatment affected our results. For instance, the extent to which ILD screening in 
CTD patients differs according to CTD subtype will have biased our estimation of 
survival time. We acknowledge the recommendation by published guidelines that 
SSc patients undergo baseline and annual screening for ILD, as this may have 
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contributed to earlier detection of ILD (and hence longer survival time) among our 
SSc-ILD subgroup [24]. Furthermore, questions relating to survival differences based 
on treatment modalities for different CTDs and ILDs were not explored in this study, 
and so we are unable to comment on potential confounding by such factors. 
In summary, this study shows that CTD patients with a subsequent diagnosis of ILD 
have a median survival of ~ 2 years from the time of ILD diagnosis. The mortality rate 
in non-RA CTD-ILD patients is 40% lower than in those with RA-ILD, after adjusting 
for age and gender. This study not only makes use of data from a well-validated 
database which has consistently been found to be representative of the UK general 
population, but also addresses important questions relating to the natural history and 
prognosis of ILD occurring in patients with CTD [25]. 
 
7.3.6 Tables and figures 
Table 1. Frequency of incident CTD-ILD cases by type of CTD (N=583). 
 
Type of CTD diagnosis Frequency Percent 
RA  385 66.05 
SSc  62 10.63 
SLE  35 6.00 
SS  22 3.77 
DM/PM  21 3.60 
MCTD/UCTD  0 0.00 
>1 CTD Dx 58 9.95 
RA=Rheumatoid Arthritis, SSc = Systemic Sclerosis, SLE = Systemic Lupus Erythematosus, SS = Sjögren 
Syndrome, DM/PM=Dermatomyositis/Polymyositis, MCTD/UCTD=Mixed/Undifferentiated Connective Tissue 
Disease, Dx=Diagnosis
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>1 CTD Dx 
[n=58 ] 
n (%) 
        
Age in years [mean (sd)]  69.7(10.1) 57.5(12.7) 52.0(13.5) 69.4(12.9) 63.3(12.3) 63.0(12.2) 
 Min. 39 30 23 40 39 11 
 Max. 93 87 79 88 89 79 
        
Gender Males 172 (44.7) 11 (17.7) 7 (20.0) 1 (4.5) 5 (23.8) 10 (17.2) 
 Females 213 (55.3) 51 (82.3) 28 (80.0) 21 (95.5) 16 (76.2) 48 (82.8) 
        
BMI [kg/m2] < 25 132 (34.3) 28 (45.2) 14 (40.0) 12 (54.5) 7 (33.3) 23 (39.7) 
 >= 25 171 (44.4) 23 (37.1) 11 (31.4) 8 (36.4) 13 (61.9) 31 (53.4) 
 Unknown 82 (21.3) 11 (17.7) 10 (28.6) 2 (9.1) 1 (4.8) 4 (6.9) 
        
Smoking status Non-smokers 155 (40.3) 34 (54.8) 20 (57.1) 13 (59.1) 12 (57.1) 32 (55.2) 
 Current/Ex 198 (51.4) 24 (38.7) 12 (34.3) 8 (36.4) 8 (38.1) 25 (43.1) 
 Unknown 32 (8.3) 4 (6.5) 3 (8.6) 1 (4.5) 1 (4.8) 1 (1.7) 
        
Last alcohol status prior to 
index date None/Never 166 (43.1) 25 (40.3) 15 (42.9) 6 (27.3) 5 (23.8) 22 (37.9) 
 Current/Ex 219 (56.9) 37 (59.7) 20 (57.1) 16 (72.7) 16 (76.2) 36 (62.1) 
RA=Rheumatoid Arthritis, SSc = Systemic Sclerosis, SLE = Systemic Lupus Erythamatosus, SS = Sjögren Syndrome, DM/PM=Dermatomyositis/Polymyositis, CTD=Connective 
Tissue Disease, Dx=Diagnosis 
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HR* 95% CI p-value (LRT) 
Individual CTD groups vs. RA 
RA 385 179 1.000 Reference  
SSc 62 13 0.497 0.282 to 0.879  
SLE 35 8 0.537 0.260 to 1.108  
SS 22 6 0.681 0.301 to 1.543  
DM/PM 21 7 0.621 0.291 to 1.328  
> 1 CTD Dx 58 16 0.586 0.348 to 0.986 0.0314 
      
Other CTD vs. RA 
RA  385 179 1.000 Reference  
Other CTD 198 50 0.600 0.431 to 0.834 0.0024 
RA=Rheumatoid Arthritis, SSc = Systemic Sclerosis, SLE = Systemic Lupus Erythamatosus, SS = Sjögren Syndrome, 
DM/PM=Dermatomyositis/Polymyositis, CTD=Connective Tissue Disease, Dx=Diagnosis, HR = Hazard Ratio, CI=Confidence 
Interval, *=Adjusted for age 
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Table 4. Incident cardiovascular comorbidity after index date (Cox proportional 
hazards regression) 
 




HR* 95% CI p-value (LRT) 
Arrhythmia 
       
 RA  303 28 1.000 Reference  
 Other CTD 176 12 0.802 0.388 to 1.659 0.552 
       
CHF 
       
 RA  314 38 1.000 Reference  
 Other CTD 171 9 0.478 0.224 to 1.020 0.056 
       
IHD       
       
 RA  251 13 1.000 Reference  
 Other CTD 148 3 0.492 0.131 to 1.846 0.293 
       
PH       
       
 RA  382 4 1.000 Reference  
 Other CTD 193 16 8.316 2.549 to 27.124 <0.001 
       
RA=Rheumatoid Arthritis, CTD=Connective Tissue Disease, CHF=Congestive Heart Failure, IHD=Ischemic Heart Disease, 
PH=Pulmonary Hypertension, HR = Hazard Ratio, CI=Confidence Interval, *=Adjusted for age and gender 
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Figure 1.  Kaplan-Meier plots comparing survival across CTD-ILD subgroups, 
adjusted for age at index date and gender (N=583) 
 
 
Figure 2.  Kaplan-Meier plots comparing survival in RA-ILD vs. Other CTD-ILD, 
adjusted for age at index date and gender (N=583) 
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8.1 Appendix 1. Read diagnosis codes 
 
READ Code READ Name 
ILD of known cause or associated with other diseases 
Extrinsic Allergic Alveolitis (EAA) 
H35..00 Extrinsic allergic alveolitis 
H350.00 Farmers' lung 
H351.00 Bagassosis 
H352.00 Bird-fancier's lung 
H352000 Budgerigar-fanciers' lung 
H352100 Pigeon-fanciers' lung 
H352z00 Bird-fancier's lung NOS 
H353.00 Suberosis (cork-handlers' lung ) 
H354.00 Malt workers' lung 
H355.00 Mushroom workers' lung 
H356.00 Maple bark strippers' lung 
H357.00 Ventilation pneumonitis 
H35y.00 Other allergic alveolitis 
H35y000 Cheese-washers' lung 
H35y100 Coffee-workers' lung 
H35y200 Fish-meal workers' lung 
H35y300 Furriers' lung 
H35y400 Grain-handlers' disease 
H35y600 Sequoiosis (red-cedar asthma) 
H35y700 Wood asthma 
H35y800 Air-conditioner and humidifier lung 
H35yz00 Other allergic alveolitis NOS 
H35z.00 Allergic alveolitis and pneumonitis NOS 
H35z000 Allergic extrinsic alveolitis NOS 
H35z100 Hypersensitivity pneumonitis NOS 
H35zz00 Allergic alveolitis and pneumonitis NOS 
Hyu4300 [X]Hypersensitivity pneumonitis due to other organic dusts 
 
Pneumoconioses 
H4...00 Lung disease due to external agents 
H4...11 Pneumoconioses 
H4...12 Occupational lung disease 
H40..00 Coal workers' pneumoconiosis 
H41..00 Asbestosis 
H410.00 Pleural plaque disease due to asbestosis 
1
 
H41z.00 Asbestosis NOS 
H42..00 Silica and silicate pneumoconiosis 
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READ Code READ Name 
H420.00 Talc pneumoconiosis 
H421.00 Simple silicosis 
H422.00 Complicated silicosis 
H423.00 Massive silicotic fibrosis 
H42z.00 Silica pneumoconiosis NOS 
H43..00 Pneumoconiosis due to other inorganic dust 
H430.00 Aluminosis of lung 
H431.00 Bauxite fibrosis of lung 
H432.00 Berylliosis 
H433.00 Graphite fibrosis of lung 
H434.00 Siderosis 
H435.00 Stannosis 
H43z.00 Pneumoconiosis due to inorganic dust NOS 
H44..00 Pneumopathy due to inhalation of other dust 
H440.00 Byssinosis 
H441.00 Cannabinosis 
H442.00 Flax-dressers' disease 
H44z.00 Pneumopathy due to inhalation of other dust NOS 
H45..00 Pneumoconiosis NOS 
H450.00 Pneumoconiosis associated with tuberculosis 
H464200 Chronic pulmonary fibrosis due to chemical fumes 
H46z000 Silo-fillers' disease 
Hyu4000 [X]Pneumoconiosis due to other dust containing silica 
Hyu4100 [X]Pneumoconiosis due to other specified inorganic dusts 
  
Drug / radiation-induced lung disease (DRAD-ILD) 
H4y0.00 Acute pulmonary radiation disease 
H4y0000 Acute radiation pneumonitis 
H4y0z00 Acute pulmonary radiation disease NOS 
H4y1.00 Chronic pulmonary radiation disease 
H4y1000 Chronic pulmonary fibrosis following radiation 
H4y1z00 Chronic pulmonary radiation disease NOS 
H4y2.00 Drug-induced interstitial lung disorders 
H4y2000 Acute drug-induced interstitial lung disorders 
H4y2100 Chronic drug-induced interstitial lung disorders 
Hyu4800 [X]Chronic+other pulmonary manifestations due to radiation 
 
ILD associated with other diseases (ILD-ODIS) 
H55..00 Postinflammatory pulmonary fibrosis 
H57..00 Lung involvement in diseases EC 
H570.00 Rheumatoid lung 
H571.00 Rheumatic pneumonia 
H572.00 Lung disease with systemic sclerosis 
H57y.00 Lung disease with diseases EC 
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READ Code READ Name 
H57y000 Pulmonary amyloidosis 
H57y100 Lung disease with polymyositis 
H57y300 Lung disease with Sjogren's disease 
H57y400 Lung disease with systemic lupus erythematosus 
H57y500 Lung disease with syphilis 
H57yz00 Lung disease with diseases EC NOS 
A789900 HIV disease resulting in lymphoid interstitial pneumonitis 
N04y012 Fibrosing alveolitis associated with Rheumatoid Arthritis 
  
Idiopathic Interstitial Pneumonia (IIP) 
Idiopathic Pulmonary Fibrosis (IPF) 
H563.00 Idiopathic fibrosing alveolitis 
H563.12 Cryptogenic fibrosing alveolitis 
H563z00 Idiopathic fibrosing alveolitis NOS 
 
Other potential IIP diagnoses (not used due to sparse no. of cases found) 
H563.11 Hamman - Rich syndrome 
H563000 Alveolar capillary block 
H564.00 Bronchiolitis obliterans organising pneumonia 
H312300 Bronchiolitis obliterans 
H58y400 Squamous metaplasia of lung 
H560.00 Pulmonary alveolar proteinosis (PAP) 
 
Granulomatous ILD 
H57y200 Pulmonary sarcoidosis 
G754.00 Wegener's granulomatosis 
AD50.00 Sarcoidosis of the lung 
AD53.00 Sarcoidosis of skin 
AD51.00 Sarcoidosis of lymph nodes 
AD52.00 Sarcoidosis of lung with sarcoidosis of lymph nodes 
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